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A B S T R A C T
Background
This updated Cochrane Review of reminiscence therapy (RT) for dementia was first published in 1998, and last updated in 2005. RT
involves the discussion of memories and past experiences with other people using tangible prompts such as photographs or music to
evoke memories and stimulate conversation. RT is implemented widely in a range of settings using a variety of formats.
Objectives
To assess the effects of RT on people living with dementia and their carers, taking into account differences in its implementation,
including setting (care home, community) and modality (group, individual).
Search methods
We searched ALOIS (the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register) on 6 April 2017 using the
search term ’reminiscence.’
Selection criteria
We included all randomised controlled trials of RT for dementia in which the duration of the intervention was at least four weeks
(or six sessions) and that had a ’no treatment’ or passive control group. Outcomes of interest were quality of life (QoL), cognition,
communication, behaviour, mood and carer outcomes.
Data collection and analysis
Two authors (LOP and EF) independently extracted data and assessed risk of bias. Where necessary, we contacted study authors for
additional information. We pooled data from all sufficiently similar studies reporting on each outcome.We undertook subgroup analysis
by setting (community versus care home) and by modality (individual versus group). We used GRADE methods to assess the overall
quality of evidence for each outcome.
Main results
We included 22 studies involving 1972 people with dementia. Meta-analyses included data from 16 studies (1749 participants). Apart
from six studies with risk of selection bias, the overall risk of bias in the studies was low.
Overall, moderate quality evidence indicated RT did not have an important effect on QoL immediately after the intervention period
compared with no treatment (standardised mean difference (SMD) 0.11, 95% confidence interval (CI) -0.12 to 0.33; I2 = 59%; 8
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studies; 1060 participants). Inconsistency between studies mainly related to the study setting. There was probably a slight benefit in
favour of RT in care homes post-treatment (SMD 0.46, 95% CI 0.18 to 0.75; 3 studies; 193 participants), but little or no difference
in QoL in community settings (867 participants from five studies).
For cognitive measures, there was high quality evidence for a very small benefit, of doubtful clinical importance, associated with
reminiscence at the end of treatment (SMD 0.11, 95% CI 0.00 to 0.23; 14 studies; 1219 participants), but little or no difference
at longer-term follow-up. There was a probable slight improvement for individual reminiscence and for care homes when analysed
separately, but little or no difference for community settings or for group studies. Nine studies included the widely used Mini-Mental
State Examination (MMSE) as a cognitive measure, and, on this scale, there was high quality evidence for an improvement at the end
of treatment (mean difference (MD) 1.87 points, 95% CI 0.54 to 3.20; 437 participants). There was a similar effect at longer-term
follow-up, but the quality of evidence for this analysis was low (1.8 points, 95% CI -0.06 to 3.65).
For communication measures, there may have been a benefit of RT at the end of treatment (SMD -0.51 points, 95% CI -0.97 to -0.05;
I2 = 62%; negative scores indicated improvement; 6 studies; 249 participants), but there was inconsistency between studies, related to
the RT modality. At follow-up, there was probably a slight benefit of RT (SMD -0.49 points, 95% CI -0.77 to -0.21; 4 studies; 204
participants). Effects were uncertain for individual RT, with very low quality evidence available. For reminiscence groups, evidence of
moderate quality indicated a probable slight benefit immediately (SMD -0.39, 95% CI -0.71 to -0.06; 4 studies; 153 participants),
and at later follow-up. Community participants probably benefited at end of treatment and follow-up. For care home participants, the
results were inconsistent between studies and, while there may be an improvement at follow-up, at the end of treatment the evidence
quality was very low and effects were uncertain.
Other outcome domains examined for people with dementia included mood, functioning in daily activities, agitation/irritability and
relationship quality. There were no clear effects in these domains. Individual reminiscence was probably associated with a slight benefit
on depression scales, although its clinical importance was uncertain (SMD -0.41, 95% CI -0.76 to -0.06; 4 studies; 131 participants).
We found no evidence of any harmful effects on people with dementia.
We also looked at outcomes for carers, including stress, mood and quality of relationship with the person with dementia (from the
carer’s perspective). We found no evidence of effects on carers other than a potential adverse outcome related to carer anxiety at longer-
term follow-up, based on two studies that had involved the carer jointly in reminiscence groups with people with dementia. The control
group carers were probably slightly less anxious (MD 0.56 points, 95%CI -0.17 to 1.30; 464 participants), but this result is of uncertain
clinical importance, and is also consistent with little or no effect.
Authors’ conclusions
The effects of reminiscence interventions are inconsistent, often small in size and can differ considerably across settings and modalities.
RT has some positive effects on people with dementia in the domains of QoL, cognition, communication and mood. Care home
studies show the widest range of benefits, including QoL, cognition and communication (at follow-up). Individual RT is associated
with probable benefits for cognition and mood. Group RT and a community setting are associated with probable improvements in
communication. The wide range of RT interventions across studies makes comparisons and evaluation of relative benefits difficult.
Treatment protocols are not described in sufficient detail in many publications. There have been welcome improvements in the quality
of research on RT since the previous version of this review, although there still remains a need for more randomised controlled trials
following clear, detailed treatment protocols, especially allowing the effects of simple and integrative RT to be compared.
P L A I N L A N G U A G E S U M M A R Y
Reminiscence therapy for dementia
Review question
We wanted to find out what effect reminiscence therapy (RT) has on people with dementia. In particular, we were interested in effects
on quality of life, communication, cognition (the general ability to think and remember), mood, daily activities and relationships. We
were also interested in any effects on carers.
Background
RT involves discussing events and experiences from the past. It aims to evoke memories, stimulate mental activity and improve well-
being. Reminiscence is often assisted by props such as videos, pictures and objects. It can take place in a group or be done with a person
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on their own, when it often results in some form of life-story book being created. RT helps older people with depression. It may be
suitable for people with dementia both because depression is common in dementia and because people with dementia typically have a
better memory for the distant past than for recent events.
Methods
We searched for randomised, controlled trials in which RT was compared with no treatment or with a non-specific activity, such as
time spent in general conversation. Our search covered all trials available up to April 2017.
Results
We found 22 trials with 1972 participants to include in the review. All the participants had dementia, mostly of mild or moderate
severity. Some of the participants were living at home and some were in care homes. The length of the trials varied from four weeks to
two years, and the overall amount of time spent on therapy varied from three to 39 hours. Overall, we thought most of the trials were
well conducted.
Looking at all the trials together, there did not seem to be an effect of RT on the quality of life reported by the participants. However,
there was probably a slight benefit of treatment in the trials done in care homes, which was not seen in the trials done in the community.
People having RT scored slightly better than the control group on tests of cognition immediately after the course of treatment, but
not weeks to months later. It was not clear that the effect was large enough to be important. The effect was most evident in care home
studies, which used individual RT, but not in community studies, which used group RT.
We found that group RT and RT in community settings may have a positive effect on the communication and interaction of the person
with dementia immediately after the end of treatment, and probably also weeks to months later, although the effect was small.
Apart from a probable slight benefit of individual RT on scales measuring depressed mood, we found no evidence for effects of RT
on other outcomes, such as agitation, ability to carry out daily activities or relationships with other people. We found no evidence of
harmful effects of RT for the people with dementia themselves.
We found no effect of RT on family carers other than a suggestion that it made carers slightly more anxious in two large studies of
joint reminiscence work. In this type of RT, the carers and the people with dementia were both directly involved in the reminiscence
sessions.
Conclusions
We were encouraged to find that the amount and quality of research on RT for dementia has increased considerably since the last
version of this review. We concluded that the effects of RT vary, depending on the way it is given and whether it takes place in care
homes or the community. However, there is some evidence that RT can improve quality of life, cognition, communication and possibly
mood in people with dementia in some circumstances, although all the benefits were small. More research is needed to understand
these differences and to find out who is likely to benefit most from what type of RT.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Reminiscence Therapy compared to no treatment for people living with dementia
Patient or population: people living with dementia
Setting: Care home and community sett ings
Intervention: Reminiscence Therapy
Comparison: no treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no treatment Risk with Reminis-
cence Therapy
Quality of Life (self -re-
port) at end of treat-
ment
assessed with: QOL-
AD, SRQoL
follow up: range 1 days
to 6 weeks
SMD 0.11 higher
(0.12 lower to 0.33
higher)
- 1060
(8 RCTs)
⊕⊕⊕©
MODERATE 1
A higher score is indica-
t ive of improved quality
of lif e. Subgroup analy-
sis by sett ing likley ex-
plains the variat ion in
ef fect size across the
studies
Cognit ion at end of
treatment
assessed with: MMSE,
AMI-PSS, AMI(E)-PSS,
ADAS-COG
follow up: range 1 days
to 6 weeks
SMD 0.11 higher
(0 to 0.23 higher)
- 1219
(14 RCTs)
⊕⊕⊕⊕
HIGH
A higher score is indica-
t ive of improved cogni-
t ion
Communicat ion and In-
teract ion at end of treat-
ment
assessed with: So-
cial Engagement Scale,
Communicat ion Obser-
vat ion Scale, MOSES
SMD 0.51 lower
(0.97 lower to 0.05
lower)
- 249
(6 RCTs)
⊕⊕©©
LOW 12
A lower score is indica-
t ive of improved com-
municat ion
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Withdrawal sub-scale,
Holden Communicat ion
Scale
follow up: range 1 days
to 2 weeks
Funct ional behaviour at
end of treatment
assessed with: MDS-
ADL, FIM, ADL, BADLS,
ADCS-ADL, DAD
follow up: range 1 days
to 6 weeks
SMD 0.24 lower
(0.69 higher to 0.21
higher)
- 1030
(6 RCTs)
⊕©©©
VERY LOW 34
A lower score is indica-
t ive of improved func-
t ional behaviour
Agitat ion/ irritability at
end of treatment
assessed with: CMAI,
MOSES (irritability sub-
scale)
follow up: range 1 days
to 6 weeks
SMD 0.03 higher
(0.17 lower to 0.24
higher)
- 359
(3 RCTs)
⊕⊕⊕©
MODERATE 2
A lower score is indica-
t ive of improved agita-
t ion/ irritability
Depressed mood at end
of treatment
assessed with: CSDD,
GDS, GDS-SF,MOSES
(depression subscale),
HADS (depression sub-
scale), MADRS
follow up: range 1 days
to 6 weeks
SMD 0.03 lower
(0.15 lower to 0.1
higher)
- 973
(10 RCTs)
⊕⊕⊕⊕
HIGH
A lower score is indica-
t ive of improved mood
Stress related to caring
(caregiver)
assessed with: ZBI-SF,
RSS, NPI, Modif ied ZBI,
ZBI
follow up: range 1 days
SMD 0.03 SD higher
(0.21 lower to 0.14
higher)
- 1155
(7 RCTs)
⊕⊕⊕©
MODERATE 5
A lower score is indica-
t ive of less caregiver
stress
5
R
e
m
in
isc
e
n
c
e
th
e
ra
p
y
fo
r
d
e
m
e
n
tia
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
to 6 weeks
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one point for inconsistency due to substant ial heterogeneity
2 Downgraded one point for imprecision due to small sample size (<400 part icipants)
3 Downgraded one point for imprecision as the conf idence interval contains null ef fect and the lower lim it passes -0.5
4 Downgraded two points for inconsistency due to considerable heterogeneity
5 Downgraded one point for inconsistency due to moderate heterogeneity
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B A C K G R O U N D
Reminiscence therapy (RT)was introduced to dementia care in the
late 1970s (Kiernat 1979; Norris 1986), and has taken a variety of
forms. At its most basic, it involves the discussion of past activities,
events and experiences, usually with the aid of tangible prompts
(e.g. photographs, household and other familiar items from the
past, music and archive sound recordings). More recently, digital
storage and presentation of photographs, music and video clips
have become widely used (Subramaniam 2010).
The development of reminiscence work is usually traced to Butler
1963’s early work on “Life Review.” Butler described Life Review
as a naturally occurring process where the person looks back on
his/her life and reflects on past experiences, including unresolved
difficulties and conflicts. This concept was incorporated in psy-
chotherapy for older people, which emphasises that life review can
be helpful in promoting a sense of integrity and adjustment. But-
ler’s seminal work contributed to the change in professional per-
spectives on reminiscence. Rather than being viewed as a problem,
with the older person ’living in the past,’ reminiscence was sees
as a dynamic process of adjustment. This fitted well with Erikson
1950’s late-life stage of development, where the person is seen as
reflecting on life, seeking to make sense and find meaning in a life
lived.
Around the same time, increasing interest in oral history meant
that the reminiscences of older people were valued more greatly.
In the UK, the development of the ’Recall’ tape-slide package (
Help the Aged 1981)meant that reminiscence triggers were widely
available in day care centres, care homes and hospitals, leading
many staff to establish some formof reminiscence work, of variable
quality. There was also interest in using reminiscence to guide
environmental design on the basis that, for example, a lounge of
a care home which resembled a living room from earlier in the
person’s life would seem more familiar and might lead to better
maintenance of independence.
It is evident that reminiscence work may take a number of dif-
ferent forms, from psychotherapy through to environmental re-
design. There is an extensive literature on the various functions
of reminiscence, with numerous classification systems proposed
(e.g. Romaniuk 1981). Differences have emerged between remi-
niscence functions in their association with mental health, with
seeking identity having a positive association and a focus on bit-
terness, boredom reduction and loss being associated with worse
mental health (Ros 2016). In one general systematic review of
reminiscence work, across a variety of populations, drawing from
over 100 studies, Pinquart 2012 categorised the type of ’therapeu-
tic work’ undertaken into three broad categories: ’simple reminis-
cence,’ involving the recall and sharing of selected personal and
sharedmemories and stories; ’life review,’ seen as a structured, eval-
uative process, usually conducted individually, covering the whole
life story chronologically, seeking to integrate negative and posi-
tive memories; and ’life review therapy,’ typically aimed at people
with depression or other mental health difficulties where the aim
is to re-evaluate negative memories, promoting a more positive
view of life. ’Life story work’ is becoming increasingly used to de-
scribe aspects of reminiscence work, such as life review, where the
emphasis is on developing a narrative biography, drawing together
past, present and future. Life story books are common tangible
outcomes from such work, but other media have also been used,
such as a display box, portraying key elements of the person’s life.
Life story work has been employed with children and young peo-
ple, people with learning disabilities and people with depression
(Woods 2016). The type of reminiscence work undertaken has
important implications for the training, supervision and support
needed by those acting as facilitators or therapists.
Reminiscence work, including life review, has consistently been
helpful for older people with depressed mood (Bohlmeijer 2003;
Pinquart 2007). The effects are comparable to both medication
and other psychosocial approaches. Life reviewmay also be helpful
in preventing depression in older adults (Pot 2010), and in im-
proving life satisfaction and quality of life (QoL) in older adults in
general (Bohlmeijer 2007). The effects are also seen in older peo-
ple with depressed mood living in long-term care environments
(Zhang 2015). Given that depressed mood is more common in
people with dementia, reminiscence work may be helpful in de-
mentia in relation to improving mood.
In the context of dementia, reminiscence work can also be seen
to have a cognitive rationale. People with dementia often appear
able to recall events from their childhood, but not from more re-
cent times, even earlier the same day. Drawing on the apparently
preserved store of remote memories appears a sensible strategy,
when dementia is typically accompanied by great difficulty in new
learning. By linking with the person’s cognitive strengths in this
way, communication might be enhanced, allowing the person to
talk confidently of their earlier life and experiences. In fact, stud-
ies of remote memory suggest that recall for specific events is not
relatively preserved; performance across the lifespan is impaired
but people with dementia, like all older people, have an ’autobi-
ographical memory bump,’ recalling more memories from youth
and adolescence (Morris 1994). Some of the memories represent
well-rehearsed, much practised items or anecdotes. The almost
complete absence of autobiographical memories from the person’s
middle years could lead to a disconnection of past and present,
which could contribute to the person’s difficulty in retaining a
clear sense of personal identity. From a cognitive standpoint, au-
tobiographical memory and level of communication appear key
outcomes.
Since the first study on reminiscencework thatwas conductedwith
a group of older people with dementia was reported by Kiernat
1979, the approach has continued to be implemented widely, in
a variety of forms. However, the research literature has developed
more slowly. The 2005 version of this review included only four
studies, and several of them were of low quality. In a more recent
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review, Cotelli 2012 also highlighted the absence of high quality
studies. Subramaniam 2012 focused on individual reminiscence
work in their systematic review, identifying five randomised con-
trolled trials (RCT), mainly with small sample sizes. The distinc-
tion between ’simple’ reminiscence and ’life review,’ often leading
to the production of a life story book, appeared salient in these
reviews. Simple reminiscence may be on an individual or a group
basis, whereas life review is typically conducted individually. The
involvement of family carers in reminiscence groups jointly with
people with dementia is a further development, using simple rem-
iniscence but potentially having an effect on pre-existing relation-
ships (Bruce 1998; Thorgrimsen 2002).
The implications of this background for the current review are as
follows.
• The type of reminiscence work and its aims needs to be
clearly defined. In considering reminiscence work with people
with dementia, the key distinction is between ’simple’
reminiscence work that has a focus on the individual making
sense of their own life story, which is described as having an
integrative function. This has implications for whether the work
is carried out individually or in a group; life review/life story
reminiscence is almost always individual, whereas simple
reminiscence can be sustained in one-to-one settings or in a
group. Life story work usually requires memory triggers specific
to the person, whereas more general triggers may be sufficient to
trigger a broad range of stories and memories, in simple
reminiscence.
• Different outcome measures may be appropriate according
to the type of reminiscence work and its aims. The range of
potential aims include: to enhance communication; to increase a
sense of personal identity; to have an enjoyable activity in
company with others; to improve mood and QoL; to stimulate
memories; to increase the individualisation of care; or a
combination of these. This list suggests that improvements in
general cognition and behaviour might not be the most
prominent of the changes expected, except as an indirect
consequence of mood change perhaps.
• The impact on others, in addition to the person with
dementia, may also be important, particularly where family
carers are involved in the reminiscence work. For example,
Baines 1987 examined staff knowledge of those attending group
sessions; this increased in reminiscence groups compared with no
treatment. Knowledge regarding the person with dementia is of
course a prerequisite for individualised care.
• Memories from the person’s earlier life will not all be
sources of pleasure and happiness; indeed some may be
distressing or traumatic. Evaluation of any negative impact of
this approach is required to monitor whether the recall of such
memories occurs, and, if it does, whether these can be managed
safely within the particular therapeutic context.
O B J E C T I V E S
To assess the effects of RT on people living with dementia and
their carers, taking into account differences in its implementation,
including setting (care home, community) and modality (group,
individual).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies had to meet the following criteria.
• RCTs including cluster randomised trials and cross-over
trials that used RT of any type as an intervention for people
living with dementia.
• Control activity was no treatment, treatment as usual or a
passive treatment such as basic social contact.
• Study was written in English and published in a peer-
reviewed journal.
Trials that did not publish (or later supply) adequate information
about study design and results were included in the review but
not in the meta-analysis. Details are noted in Characteristics of
included studies.
Types of participants
We included:
• participants were people with a diagnosis of dementia,
preferably a formal diagnosis according to the Diagnostic and
Statistical Manual of Mental Disorders - fourth edition
(DSM-IV), but other diagnostic criteria were considered and
included if appropriate. There were no age limits. The main
diagnostic categories were Alzheimer’s disease (AD) and vascular
dementia (VD). These were combined in the analysis;
• all levels of severity. Severity of dementia was determined by
group mean scores or score ranges on standardised scales such as
the Clinical Dementia Rating (CDR) (Hughes 1982) or Mini-
Mental State Examination (MMSE) (Folstein 1975);
• family or professional carers where studies recruited dyads
(person with dementia and their carer together);
• trials that investigated the effects of RT on different
dementia diagnoses by allocating specific control groups for each
diagnosis were analysed as separate studies.
We excluded:
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• participants with mild cognitive impairment (MCI) where
the degree of cognitive impairment did not warrant a diagnosis
of dementia.
Types of interventions
• Studies were considered for this review if they described a
reminiscence intervention (including life story work) targeting
people living with dementia in any of the outcomes of interest.
Outcomes of interest are described under Types of outcome
measures.
• Studies were included if the planned duration of the
intervention was four weeks or longer or if at least six sessions
were offered over a shorter time frame. There was no restriction
on the maximum number of RT sessions.
• Studies were included if a comparison was made to ’no
treatment,’ ’treatment as usual’ or a basic passive control
treatment. Passive treatments could consist of, for example, an
equivalent number of sessions in which general conversation
with participants took place. Comparisons with other activities
or therapies such as music therapy were not considered in this
review. ’Treatment as usual’ was taken to mean standard health
care, or activities in accordance with health or social care services’
usual provision.
Types of outcome measures
• Studies included assessments of any of the outcomes of
interest, provided they used standardised measures, rating scales
or questionnaires. Studies could have presented data on both
outcomes for the person with dementia and carer outcomes.
• Outcomes that measured post-treatment (typically
immediately after, or within one month after the intervention),
and at follow-up (typically one to six months’ post-intervention).
• Maintaining the effects of the intervention over time was
anticipated to be an issue for studies involving people with
dementia, therefore, it was expected that post-treatment data
would be captured as close to the final session as possible, to
identify immediate outcomes or changes that may have been lost
to longer-term follow-up.
• Attrition and the reasons for participants dropping out were
noted.
Outcomes for the person with dementia
Primary outcome
• Quality of life.
Secondary outcomes
• Cognition.
• Communication and interaction.
• Quality of relationship with carer
• Behaviour, including agitation and activities of daily living
(ADL).
• Mood-related outcomes, including apathy, anxiety and
depression.
Outcomes of interest for the person with dementia were measured
using standardised instruments to determine if changes in these
outcomes were observed following the intervention. This included
self-reported ratings, clinical ratings or carer ratings of the out-
come.
Outcomes for the carer
’Carer’ in these contexts refers to family carers and professional
carers, although they were considered separately in the review.
• Mood.
• Stress/stain related to caring.
• Quality of life.
• Outcomes relating to the dyadic relationship.
Adverse outcomes
There is a potential risk that the process of recalling memories
from the past may bring about difficult or emotional (or both)
memories, which should be anticipated and managed sensitively
by facilitators. The potential for adverse outcomes was monitored
by observing negative responses on the outcome measures. Family
carers or care staff hold their own perceptions of the intervention
and its effect on the participant, as well as on themselves, which
will be reflected in their carer-rated outcome measures.
Search methods for identification of studies
Electronic searches
We searched ALOIS (
www.medicine.ox.ac.uk/alois), the Cochrane Dementia and Cog-
nitive Improvement Group’s Specialized Register on 6 April 2017.
The search term used was ’reminiscence.’
ALOIS was created in part thanks to a grant from the American
Alzheimer’s Association and ismaintained by the Information Spe-
cialists of the Cochrane Dementia and Cognitive Improvement
Group. It contains studies in the areas of dementia prevention,
dementia treatment and cognitive enhancement in healthy older
populations. The studies are identified from:
• monthly searches of major healthcare databases:
MEDLINE, Embase, CINAHL, PsycINFO and LILACS;
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• monthly searches of trial registers: ISRCTN; UMIN
(Japan’s Trial Register); the World Health Organization (WHO)
portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese
Clinical Trials Register; the German Clinical Trials Register; the
Iranian Registry of Clinical Trials and the Netherlands National
Trials Register, plus others);
• quarterly search of Central Register of Controlled Trials
(CENTRAL);
• six-monthly searches grey literature sources: ISI Web of
Knowledge Conference Proceedings; Index to Theses;
Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website.
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL and conference
proceedings can be viewed in the ’methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
Additional searches (6 April 2017) were performed in many of the
sources listed above to cover the timeframe from the last searches
performed for ALOIS to ensure that the search for the review was
as up-to-date and comprehensive as possible. See Appendix 1 for
search strategies.
Searching other resources
• The Alzheimer’s Society library.
• Letters published in BPS Division of Clinical Psychology
Faculty of Psychology of Older People and the BPS (British
Psychological Society) magazines, requesting information on any
controlled trials that may not have been easily discovered (e.g.
unpublished papers).
• Personal contact with specialists in the field.
Additionally, we searched the reference lists of all papers for fur-
ther references, and review authors searched personal holdings of
references to reports and trials. We sent letters/e-mails to all au-
thors of included RCTs asking for essential information, where
this was not available in the publication (e.g. statistics or details of
randomisation, or both).
Data collection and analysis
Selection of studies
Following deduplication, two review authors (LOP and EF) inde-
pendently reviewed the abstracts and, if necessary, themanuscripts
of potential studies identified by the search. These review authors
were not involved in any of the studies produced by the searches.
We excluded obviously irrelevant studies. We obtained the full
text of remaining studies and excluded studies that did not meet
the inclusion criteria with reasons outlined in the Characteristics
of excluded studies table. If authors disagreed about the inclusion
of a particular study, this was referred to another review author
(BW or AS) for clarification. We collated multiple reports of the
same study, so that each study, rather than each report, was the
unit of interest in the review. We recorded the selection process in
sufficient detail to complete a PRISMA flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
Two review authors (EF and LOP) independently extracted de-
scriptive characteristics, study methodology data and study results
from the included studies, recorded themon a data collection form
and entered them into Review Manager 5 (RevMan 2014). The
form was piloted on ten studies. We compared the data to ensure
accuracy. Where data did not match, one review author (LOP)
checked the data of both authors and made changes if necessary
with the agreement of another review author (EF).
For each outcome measure, the authors sought to obtain data on
every participant randomised irrespective of whether the partici-
pant was excluded or dropped out of the intervention or research
(i.e. data from an intention to treat (ITT) analysis). If these data
were not available in the published studies, the review authors
sought the data of those who completed the trials.
Where necessary, we sent emails to trial authors requesting addi-
tional information. If this was unsuccessful, we contacted authors
through ResearchGate.
Assessment of risk of bias in included studies
Two review authors (LOP and EF) independently assessed the
risk of bias of each trial using the Cochrane ’Risk of bias’ tool
(Higgins 2011). We attempted to obtain additional information
from study authors when we required further information. Based
on the methods detailed in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011), we classified each category
of bias as ’low risk of bias,’ ’high risk of bias’ or ’unclear risk of bias.’
An outline of this can be seen in Table 1 below. The meta-analysis
included only trials with a low or unclear risk of bias, except in
the case of random sequence generation where only trials with a
low risk of bias were included. Any disagreements regarding risk
of bias ratings were referred to an independent review author (AS)
for clarification. Overall ratings were assigned with respect to each
study’s methodological quality and are described in the ’Risk of
bias’ table, Figure 2; and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
13Reminiscence therapy for dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Table 1. Risk of bias assessment table
Domain Risk of bias judgement
Selection bias Low High Unclear
Random sequence generation Assigned if simple randomisa-
tion was used (e.g. computer-
generated random sequence,
coin tossing)
Assigned if study reported
an inadequate randomisation
method (e.g. using date of birth
or odd/even numbers)
Assigned if there was insuffi-
cient detail to judge the risk of
bias as low or high
Assigned if restricted randomi-
sation was used (e.g. block
randomisation, provided that
within groups randomisation
was not affected)
Allocation Concealment Assigned if there was evi-
dence of concealed allocation
sequence in which allocations
could not have been foreseen
in advance of, or during, enrol-
ment
Assigned if those enrolling par-
ticipants were aware of the
group (or period in a cross-over
trial) to which the next enrolled
participant would be allocated
Assigned if there was insuffi-
cient detail to judge the risk of
bias as low or high
Detection bias Low High Unclear
Blinding of outcome assessors
(blinding of participants and fa-
cilitators is not possible in psy-
chosocial interventions)
Assigned if outcome assessors
were blind to treatment alloca-
tion
Assigned if the outcome asses-
sors were aware of treatment
allocation (e.g. if the reminis-
cence facilitator was also an out-
come assessor)
Assigned if there was insuffi-
cient detail to judge the risk of
bias as low or high
Attrition bias Low High Unclear
Incomplete outcome data Assigned if the study reported
levels of attrition, reasons for
attrition and how missing data
were dealt with. Assigned if the
impact of missing data was not
believed to alter the conclusions
and there were acceptable rea-
sons for the missing data
Assigned if there was inad-
equate information regarding
the level of attrition in each
group, reasons for attrition and
ifmissingdatawere not handled
correctly
Assigned if there was insuffi-
cient detail to judge the risk of
bias as low or high
Reporting bias Low High Unclear
Selective reporting Assigned if study reported re-
sults of all outcome measures
that were detailed in the meth-
Assigned if study did not report
results of all outcome measures
that were detailed in the meth-
Assigned if there was insuffi-
cient detail to judge the risk of
bias as low or high
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(Continued)
ods section. If a study protocol
was available, low risk of bias
was assigned if the outcome as-
sessments reported in the trial
papermatched those detailed in
the protocol
ods section. Assigned if all out-
come measures detailed in the
protocol (if available) were not
reported in the study
Other bias Low High Unclear
Availability of training and su-
pervision
Assigned if RT sessions were fa-
cilitated by people who had re-
ceived some form of training to
ensure the necessary principles
of RTwere adhered to. The def-
inition of training was inclusive
and could range fromabrief ses-
sion to a longer, more intensive
course. This also applied to in-
terventions delivered by trained
family carers. The opportunity
for facilitators to access appro-
priate supervision was also de-
sirable
Assigned if there was no evi-
dence of facilitator training or
supervision
Assigned if there was insuffi-
cient detail to judge the risk of
bias as low or high
Availability of manual, struc-
ture or protocol
Assigned if there was evidence
of a documented intervention
protocol, structure or manual
outlining the content of each
session to ensure the principles
of RT were adhered to
Assigned if there was no evi-
dence of a treatment protocol,
structure or manual for facilita-
tors to follow
Assigned if there was insuffi-
cient detail to judge the risk of
bias as low or high
RT: reminiscence therapy.
Measures of treatment effect
Data from all included studies were continuous. This type of data
required the mean change scores from baseline, the standard devi-
ation of the mean change and the number of participants for each
treatment group at each assessment. Themajority of study authors
did not report change scores from baseline. The baseline assess-
ment was defined as the latest available assessment prior to ran-
domisation, but no longer than two months prior. Where change
scores were not reported, the review authors extracted the mean,
standard deviation and number of participants for each treatment
group at each time point and calculated the required summary
statistics manually. In this case, a zero correlation between the
measurements at baseline and assessment time was assumed. This
method overestimates the standard deviation of the change from
baseline, but this conservative approach is considered to be prefer-
able in a meta-analysis.
The meta-analyses included the combination of data from trials
that may not have used the same rating scale to measure a particu-
lar outcome. For example, cognition may have been measured by
the MMSE in one study and the Autobiographical Memory In-
terview (AMI) in another. In this situation, the standardised mean
difference (SMD; the absolute mean difference (MD) divided by
the standard deviation) was used to measure the treatment dif-
ference. Where pooled trials used the same rating scale or test to
measure an outcome, the MD was used.
To allow comparisons with other scales assessing similar outcomes,
it was necessary to reverse the change scores on certain scales.
For example, on measures of depression where a low score was
indicative of a positive outcome on one scale and a high score was
indicative of a positive outcome on another.
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Unit of analysis issues
In studies using a cross-over design, only data from the first treat-
ment phase after randomisation were eligible for inclusion.
Where studies used cluster randomisation and were large, one re-
view author (LOP) extracted the mean size of each cluster, the
mean and standard deviation summary statistics, and the estimated
intraclass correlation coefficient (ICC) in order to reduce the size
of the trial to its effective sample size. This was carried out fol-
lowing Cochrane guidelines set out in the Cochrane Handbook for
Systematic Reviews of Interventions. Where studies were not large
enough, this could not be carried out.
Cluster trials were also assessed for additional biases associated
with clustering, including recruitment bias; baseline imbalance;
loss of clusters and comparability with individually randomised
trials.
Dealing with missing data
Where possible, review authors extracted data on all participants
randomised. Data from ITT analyses were preferred to per proto-
col or compliance analyses.
Assessment of heterogeneity
Assessments of heterogeneity were performed using both the Chi2
and I2 statistic. Review authors followed guidance in theCochrane
Handbook for Systematic Reviews of Interventions to interpret het-
erogeneity percentages (i.e. 0% to 40% might not be important;
30% to 60% may represent moderate heterogeneity, 50% to 90%
may represent substantial heterogeneity; and 75% to 100% is con-
siderable heterogeneity).
Assessment of reporting biases
If there were enough studies available, authors created a funnel
plot to assess the risk of publication bias.
Data synthesis
The meta-analyses presented overall estimates of the treatment
difference using a fixed-effect model. Where there was evidence of
high heterogeneity of the treatment effect between trials, we used
a random-effects model (which results in broader CIs than a fixed-
effect model).
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were performed where possible to assess for
any important differences related to environmental context or the
type/modality of the reminiscence intervention. Assessments of
heterogeneity were performed using both the Chi2 test and I2
statistic. Where heterogeneity was high, we used a random-effects
model (rather than a fixed-effect model).
Sensitivity analysis
Where necessary, sensitivity analyses were carried out. For exam-
ple, when meta-analysing carer scores on the Zarit Burden Inter-
view (ZBI), a sensitivity analysis was carried out depending on the
level of carer involvement in the intervention.
Presentation of results and ’Summary of findings’
tables
We used GRADE methods to rate the quality of evidence (high,
moderate, low or very low) behind each effect estimate in the re-
view (Guyatt 2011). This rating referred to our level of confidence
that the estimate reflected the true effect, taking account of the
risk of bias in the included studies, inconsistency between studies,
imprecision in the effect estimate, indirectness in addressing our
review question and the risk of publication bias. We produced
’Summary of findings’ tables for RT compared to no treatment
to show the effect estimate and the quantity and quality of the
supporting evidence for the following outcomes:
1. self-reported QoL,
2. communication and interaction
3. cognition
4. functional behaviour
5. agitation
6. depressed mood
7. carer stress
We produced additional tables to summarise the effects on QoL,
communication and interaction, and cognition for the two differ-
ent settings for reminiscence work included in this review (com-
munity and care home settings) and for the two major modality
types (individual reminiscence work and reminiscence groups).
We prepared the ’Summary of findings’ tables using the GRADE-
pro GDT 2015 (gradepro.org).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; and Characteristics of ongoing studies tables.
Results of the search
Systematic searches conducted since the previous review up to
October 2014 identified 102 potentially eligible trials, of which 11
were included. A further search conducted inApril 2015 identified
21 potential trials. One of these met the inclusion criteria, but was
only available as a conference paper (Dwolatzky 2014). Later, in
April 2016 another search returned 25 records, with three eligible
for inclusion. A final search in April 2017 yielded 37 results, of
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which two were eligible for inclusion. This gave a total of 21 trials
that met the inclusion criteria. Two trials by the same authors were
identified (Tadaka 2004; Tadaka 2007), and further examination
showed that the same data set and outcome measures were used
in both papers. As the data from the earlier paper were not in
usable form, the more recent paper, which presented the results as
a comparison of AD and VDwas included (Tadaka 2007), and the
earlier paper (Tadaka 2004) was excluded. Because Tadaka 2007
analysed the two participant groups separately, with a different
control group for each disease type, we entered this study into the
meta-analysis as two separate RCTs (Tadaka 2007 (AD); Tadaka
2007 (VD)), bringing the number of included studies to 22. More
information can be found in the study flow diagram (Figure 1).
Included studies
The review included 22 studies, with 1972 participants: 1001 par-
ticipants were randomised to treatment conditions and 971 par-
ticipants to control conditions. In addition to the five studies in
our previous 2005 review (Baines 1987; Goldwasser 1987; Lai
2004; Morgan 2012; Thorgrimsen 2002) (of which the Morgan
2012 study is now a published article rather than a doctoral the-
sis), 17 new studies met the inclusion criteria (Akanuma 2011;
Amieva 2016; Azcurra 2012; Charlesworth 2016; Gonzalez 2015;
Haight 2006; Hsieh 2010; Ito 2007; Melendez 2015; O’Shea
2014; Särkämö 2013; Subramaniam 2013; Tadaka 2007 (AD);
Tadaka 2007 (VD); Woods 2012a; Yamagami 2012; Van Bogaert
2016).
We excluded six of the included studies from the meta-analyses
(Akanuma 2011; Baines 1987; Goldwasser 1987; Gonzalez 2015;
Hsieh 2010; Yamagami 2012). All six studies were at unclear risk
of selection bias due to inadequate information about random
sequence generation and allocation concealment. This was the
main reason they were excluded, although all six were also rated at
unclear risk of bias in at least one other domain. The risk of bias
details for each study are summarised in theRisk of bias in included
studies tables while Figure 2 depicts the risk of bias summary.
Considering that the Baines 1987 and Goldwasser 1987 studies
dated from the 1980s, we did not attempt to contact the study
authors. Furthermore, in the previous versions of this review, we
were unable to get in touch with the authors of the Goldwasser
1987 study. We attempted to contact the authors of the Akanuma
2011; Gonzalez 2015; Hsieh 2010; and Yamagami 2012 studies
for more information, but there was no response.
Full details of included studies are presented in the Characteristics
of included studies table and reasons for exclusion of studies in
the Characteristics of excluded studies table.
Design
All studies were described by their authors as RCTs, although,
as noted above, six studies did not provide enough information
on the randomisation methods for us to be sure that the risk of
selection bias was low. One study was a cross-over trial (Baines
1987). There were three cluster randomised trials (Gonzalez 2015;
Melendez 2015; O’Shea 2014).
Diagnosis
All studies recruited participantswith a diagnosis of dementia.One
study recruited both participants with MCI and dementia due to
AD, but we extracted only data from participants with dementia
(Melendez 2015). Four studies did not specify which diagnostic
criteria were used (Baines 1987; Goldwasser 1987; Thorgrimsen
2002; Yamagami 2012). Twelve studies specified a diagnosis of
dementia according the DSM-IV (Azcurra 2012; Charlesworth
2016; Gonzalez 2015; Hsieh 2010; Lai 2004; Melendez 2015;
O’Shea 2014; Subramaniam 2013; Tadaka 2007 (AD); Tadaka
2007 (VD); Van Bogaert 2016;Woods 2012a). Of these, four also
used the CDR to support a diagnosis of dementia (Charlesworth
2016; Tadaka 2007 (AD); Tadaka 2007 (VD); Woods 2012a).
One study enrolled participants with a diagnosis of AD based on
the criteria of the National Institute of Neurological and Com-
municative Disorders and Stroke-Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRD) (Amieva 2016). One
study reported that participants had undergone assessment and
diagnosis at the neurology department of the General Hospital
of Valencia and met the study inclusion criteria (Gonzalez 2015).
Two studies recruited participants if they fulfilled the diagnostic
criteria of ischaemic vascular disease with reference to computed
tomography or magnetic resonance imaging (or both) findings,
and if they scored between 10 and 24 on the MMSE (Akanuma
2011; Ito 2007). One study recruited care home staff volunteered
residents who had a diagnosis of dementia (Haight 2006). In one
study, staff members selected participants and then completed
the Clifton Assessment Procedures for the Elderly (CAPE) scale
(Baines 1987).
Dementia type
Six studies recruited participants with a specific type of dementia
diagnosis. Four studies only recruited participants with a diagnosis
of AD (Amieva 2016; Azcurra 2012; Gonzalez 2015; Melendez
2015), although Melendez 2015 also recruited a separate group
of participants with amnesic MCI, and two studies sought only
participants with a diagnosis of VD (Akanuma 2011; Ito 2007).
Tadaka 2007 recruited both participants with AD and VD, but
analysed the two groups separately, with a different control group
for each disease type.
Dementia severity
The majority of included studies sought to recruit participants
in the mild to moderate stages of dementia. However, Gonzalez
2015 and Melendez 2015 only included people with mild AD as
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measured by a score of 3 or 4 on the Geriatric Depression Scale
(GDS; i.e. mild dementia was themaximum level). Five studies did
not specify a particular level of severity in their inclusion/exclusion
criteria (Goldwasser 1987; Haight 2006; Lai 2004; Thorgrimsen
2002; Yamagami 2012).
Six studies used the CDR as a screening measure to assess if par-
ticipants met the inclusion criteria. Five studies required a score
of between 1 and 2 (mild to moderate dementia) to participate
(Morgan 2012; Subramaniam 2013; Tadaka 2007 (AD); Tadaka
2007 (VD); Woods 2012a), while potential participants in one
study needed to score between0.5 and2 (questionable tomoderate
dementia) (Särkämö 2013). Nine studies reported baseline CDR
scores. Azcurra 2012 reported amean score of 1 and Särkämö 2013
reported a mean score of 1.35, indicating that participants had
mild-to-moderate dementia. Seven studies reported (or sent the re-
view authors) the number of participants who achieved each score.
Across five studies, approximately 65% of participants obtained a
score of 1 on the CDR indicating that they had mild dementia,
while 35% scored 2 indicating moderate dementia (Hsieh 2010;
Morgan 2012; Subramaniam 2013; Tadaka 2007 (AD); Tadaka
2007 (VD)).One study used theCDR sumof boxes as an outcome
measure and baseline CDR scores indicated that nine participants
had ’questionable dementia’, 24 had mild dementia, 17 had mod-
erate dementia and four had severe dementia (Yamagami 2012).
Woods 2012a indicated that 6.2% of his participants scored 0.5,
67.4% scored 1 and 26.5% scored 2.
Sixteen studies reported MMSE scores at baseline. This included
one study that used the Hasegawa Dementia Scale-Revised (the
authors reported this was similar to the MMSE) (Yamagami
2012). One study used the Cantonese version of the MMSE (Lai
2004), while two studies used the Spanish version (Gonzalez 2015;
Melendez 2015). Although published cut-off points on theMMSE
should be interpreted cautiously, a widely cited study classified an
MMSE score of less than 10 as severe impairment, 10 to 20 as
moderate impairment and 20 to 25 as mild impairment (Folstein
1975). In 13 studies, the mean MMSE score fell within the mod-
erate range (Azcurra 2012; Charlesworth 2016; Goldwasser 1987;
Gonzalez 2015; Haight 2006; Ito 2007; Melendez 2015; O’Shea
2014; Särkämö 2013; Tadaka 2007 (AD); Tadaka 2007 (VD);
Thorgrimsen 2002; Van Bogaert 2016; Yamagami 2012), and in
one study the mean MMSE score fell within the severe range (Lai
2004).
Recruitment setting
Included studies recruited participants from a range of settings in-
cluding residential care facilities, local hospitals, day hospital facil-
ities and outpatient clinics. Fourteen studies recruited participants
from residential/hospital care settings, while eight recruited com-
munity-dwelling participants (Amieva 2016; Charlesworth 2016;
Melendez 2015; Särkämö 2013; Tadaka 2007 (AD); Tadaka 2007
(VD); Thorgrimsen 2002;Woods 2012a). The interventions took
place in the care homes where participants resided or community
locations such as day centres.
Participant age
Themean age of participants was over 80 years, with the exception
of participants in three studies where reported mean ages were 78
years (Akanuma 2011), 77 years (Särkämö 2013), and 78 years
(Woods 2012a). One study reported age range of 60 to 99 years
(Haight 2006), and one study reported themedian participant age
and interquartile range (IQR) as 84 years (78 to 90 years) (Van
Bogaert 2016).
Length and duration of interventions
The length of reminiscence interventions ranged from four weeks
(the minimum number for inclusion in the review) to 24 months.
For studies that reported a range of time for each session (e.g. 60
to 90 minutes), we took the median time to calculate exposure
time and session length.
The intervention delivered at the highest frequency each week
was 30 minutes a day, five days a week, for four weeks (Baines
1987). Six other studies reported session frequencies of more than
once a week (Azcurra 2012; Goldwasser 1987; Melendez 2015;
O’Shea 2014; Van Bogaert 2016; Yamagami 2012). The great-
est possible reminiscence exposure time was 39 hours (Amieva
2016). Participants received 90 minutes of reminiscence a week
for 12 weeks, followed by six-weekly maintenance sessions for the
next 21 months. Two studies had a possible exposure time of 38
hours (Charlesworth 2016; Woods 2012a). In both studies, par-
ticipants received weekly two-hour reminiscence sessions for 12
weeks, followed by monthly reminiscence maintenance sessions
for seven months, giving a total of 38 potential hours of RT. In the
Charlesworth 2016 study, the family carers met separately from
the main group for 45 minutes for four sessions, with the aim of
developing listening and communication skills, and considering
how the activities and strategies in the sessions could continue
at home. The least intensive intervention was weekly 30-minute
sessions for six weeks, totalling three hours of possible exposure
to reminiscence (Lai 2004). All other studies delivered the inter-
vention once a week for varying lengths of time. For two studies,
the length of reminiscence sessions, and, therefore, potential rem-
iniscence exposure time was unclear (O’Shea 2014; Thorgrimsen
2002). Across the remaining included studies, the median inter-
vention exposure time was 11.5 hours. The median individual
session length was approximately 53 minutes with a range of 30
minutes to two hours per session.
Reminiscence therapy activities
Sixteen trials used simple reminiscence (Akanuma 2011; Amieva
2016; Baines 1987; Charlesworth 2016; Gonzalez 2015;
Goldwasser 1987; Hsieh 2010; Ito 2007; Melendez 2015; O’Shea
19Reminiscence therapy for dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2014; Särkämö 2013; Tadaka 2007 (AD); Tadaka 2007 (VD);
Thorgrimsen 2002; Woods 2012a; Yamagami 2012), which is
a form of unstructured autobiographical story telling (Gerben
2010). It involved discussions around specific themes of the past,
such as school days, holidays, food and drink, and work, and was
carried out in small groups. Five trials used the more structured
approach of life review (Azcurra 2012; Haight 2006; Lai 2004;
Morgan 2012; Subramaniam 2013), which aimed to reconstruct
the participant’s life in a sequential manner on a one-to-one basis
(Haber 2006). One trial used a standardised reminiscence inter-
vention based on the SolCos Model (Van Bogaert 2016).
One study trained staff across several care homes to deliver the in-
terventions in small groups and gave data about their knowledge of
the residents they cared for (O’Shea 2014). Three studies carried
out reminiscence jointly with participants and their family carers
living in the community (Charlesworth 2016; Thorgrimsen 2002;
Woods 2012a). One study had a music listening group in which
participants listened to songs from their past, and were encour-
aged to join in and share their memories of that period, such as
“remembering the childhood through children’s songs” (Särkämö
2013).
Control group activities
Participants in control conditions were either assigned to a ’treat-
ment as usual’ condition or a social contact group involving gen-
eral unstructured conversion.
Some trials included additional conditions as well as a no-treat-
ment control condition. However, we used only the no-treatment
control in our analyses. For example, one study had an additional
’music singing group’ (Särkämö 2013), while another study had
included a counselling condition (Azcurra 2012). One study used
a factorial design with four conditions, but we included only data
from the RT only and treatment as usual groups (Charlesworth
2016). Similarly, another study had four conditions, but we ex-
tracted data only from the reminiscence and control conditions
(Amieva 2016).
One study had a ’gift’ condition whereby a family member of par-
ticipants in the control group made a life story book for them
without their knowledge. We included data from the first follow-
up time point (i.e. before the life story books were given to par-
ticipants) in the review, as the ’gift’ condition was effectively a no
treatment control condition until the participants received their
life story books (Subramaniam 2013).
Excluded studies
In preparing this up-dated review, we excluded 63 studies that
did not meet all necessary inclusion criteria (see Characteristics of
excluded studies table).
Reasons for the exclusion of studies varied. The most common
reasons were no or inadequate randomisation (meaning the study
was not anRCT), interventionwas not reminiscence or studies did
not specifically recruit participants with a diagnosis of dementia.
Risk of bias in included studies
Specific details of the risk of bias for each study are outlined in the
’Risk of bias’ table and are summarised in Figure 2 and Figure 3.
Allocation
13 studies were at low risk of selection bias, while nine were rated as
unclear. Most studies reported randomisation methods although
allocation concealment was rarely reported in detail. Where neces-
sary, we contacted authors for clarification. Replies generally stated
that adequate concealment of treatment allocation had been ap-
plied, without detailing the method. In these cases, good practice
has been assumed, though it was regrettable that further details
were not available. Three studies used an accredited trials unit
to randomise and allocate participants to their respective condi-
tions (Charlesworth 2016; Subramaniam 2013; Woods 2012a).
Three studies used cluster randomisation. One large scale study
used cluster randomisation stratified by public or private residen-
tial units (O’Shea 2014). Two studies recruited participants in two
nursing homes and then randomly allocated the nursing homes to
the treatment and control conditions (Gonzalez 2015; Melendez
2015).
Blinding
Performance bias
Participants cannot be blinded to the experience of taking part in
an intervention and likewise, control participants will be aware
that they have entered a research trial, but are not receiving any
treatment. The person’s expectations of potential benefits, or oth-
erwise, may well influence outcome measures, which is difficult to
control for.
Detection bias
Eight studies were at unclear risk of detection bias (Goldwasser
1987; Gonzalez 2015; Haight 2006; Hsieh 2010; Morgan 2012;
Tadaka 2007 (AD); Tadaka 2007 (VD); Yamagami 2012). How-
ever, fourteen studies took adequate measures to blind outcome
assessors and were at low risk of detection bias. Two studies asked
assessors to record their prediction of which arm of the trial each
participant belonged to, and their confidence in that prediction
(Charlesworth 2016; Woods 2012a). In the Woods 2012a study,
in 44% of cases, interviewers felt participants could equally have
been assigned to control or treatment group, with 23% making
a correct definite judgement. The proportion of correct definite
20Reminiscence therapy for dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
judgements remained low at follow-up, at about 25%, which re-
flected the considerable degree of uncertainty around treatment al-
location. Charlesworth 2016 reported a similar prediction pattern.
Measures of behaviour, functioning and carer-rated outcomes of
mood and QoL were typically completed by a person who knew
the participant and could reliably comment.
Incomplete outcome data
Eighteen studies were at low risk of attrition bias, while four were
at an unclear risk. Data extracted from several studies were from
ITT analyses (Amieva 2016; Azcurra 2012; Charlesworth 2016;
Lai 2004; Melendez 2015; O’Shea 2014; Woods 2012a). Eight
studies used a per protocol analysis where the analysis was com-
pleted without data from participants who dropped out (Hsieh
2010; Ito 2007; Särkämö 2013; Subramaniam 2013; Tadaka 2007
(AD); Tadaka 2007 (VD); Van Bogaert 2016; Yamagami 2012).
In the Ito 2007 study, both a per protocol and ITT analysis were
completed, but we could only extract data from the per proto-
col analysis. Four studies reported zero withdrawals (Baines 1987;
Haight 2006; Morgan 2012; Thorgrimsen 2002). In one study,
one participant dropped out, so the authors randomly excluded
one participant from each of the two other groups (Goldwasser
1987). All trials, apart from Gonzalez 2015, reported attrition
rates.
The largest care home study, which was based in residential care
homes across Ireland, reported 25/153 withdrawals (16%) in the
intervention group and 27/151 (18%) in the control group, with
withdrawals predominantly due to hospitalisation, transfer to a
different residential home or the death of the participant (O’Shea
2014). The largest community-based study reported a slightly
higher attrition rate with 137 total withdrawals from the trial
(23% from the treatment group and 34% from the control group)
(Woods 2012a). Reasons cited were wide ranging and included
death or illness of participant or carer, not enough time, or no
explanation given. A total of 79/291 participants (27%) were lost
over the duration of the Charlesworth 2016 study, for varying rea-
sons including carer in poor health and loss to contact.
Selective reporting
There was no evidence of selective outcome reporting for any
study. All studies reported the same outcomemeasures in themeth-
ods and results sections of papers. Four studies had a protocol
and the outcome measures detailed in the protocol were reported
in the completed papers (Charlesworth 2016; O’Shea 2014; Van
Bogaert 2016; Woods 2012a).
Other potential sources of bias
Treatment protocol
The previous version of this review recommended that future tri-
als should follow a clear treatment protocol, so that it is possible
to define precisely the key elements of the different approaches to
reminiscence work. The presence of a treatment protocol, or at
least evidence of a session plan, is imperative to ensure that the in-
tervention is delivered correctly, and to prevent intervention ’drift’
(where the theme of the session may drift off-topic), or introduce
unintentional bias. Seventeen studies were at a low risk of bias re-
lating to the presence of a treatment protocol, while five were at an
unclear risk. Seven studies used a standardised reminiscence for-
mat. Three of these used the Haight 1992 Life Review Model and
Life Review Experience Form, which provides a structured for-
mat for obtaining relevant information from participants (Haight
2006; Morgan 2012; Subramaniam 2013). The Woods 2012a,
Charlesworth 2016 and Thorgrimsen 2002 studies followed ’Re-
membering Yesterday, Caring Today’ (RYCT; Schweitzer 2008),
which is a large group-based approach, bringing people with de-
mentia and family carers together with a focus on active reminis-
cence.The Van Bogaert 2016 study based their reminiscence in-
tervention on the SolCos model (Soltys 1994).
Facilitator training and supervision
We considered the knowledge of staff delivering the interventions,
total training hours and availability of supervision. All studies
were at a low risk of bias in relation to facilitator training and
supervision. Eleven studies did not specify training (Akanuma
2011; Goldwasser 1987; Gonzalez 2015; Hsieh 2010; Ito 2007;
Melendez 2015; Morgan 2012; Särkämö 2013; Subramaniam
2013; Tadaka 2007 (AD); Tadaka 2007 (VD)), but all were re-
ported to have been delivered by appropriate facilitators such as
psychologists or gerontologists. Further details are available in
the ’Risk of bias’ table. The other studies provided four hours
(Yamagami 2012), six hours (Baines 1987), 10 hoursHaight 2006,
19.3 hours (Lai 2004), 22 hours (Thorgrimsen 2002), 30.4 hours
(Azcurra 2012), one day (Charlesworth 2016), two and a half days
(Woods 2012a), and three days (Amieva 2016; O’Shea 2014) of
training. Facilitators in the Van Bogaert 2016 study received a
training programme though the total number of hours was not
specified.
Contamination
The main risk of contamination arose from trials located in care
homes, in which control and intervention participants resided and
socialised together. Two studies that included residential care par-
ticipants seemed to use at least one member of staff or research
team to carry out the interventionwhilst alsoworking in the home,
potentially meaning that themes of reminiscence could be car-
ried over into daily care and contaminate any control conditions
(Goldwasser 1987; Haight 2006). However, correct adherence to
the trial protocol would have minimised this risk.
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Outcome measures
Where more than one measure of a single outcome domain was
used in a study, data from the most common or themost extensive
measure were included in the meta-analysis. This was to avoid
including data from the same participants more than once in each
outcome analysis.
Most studies collected outcomes up to two weeks after the final
session, but for some larger studies this may have been up to four
weeks (Charlesworth 2016; Woods 2012a). For purposes of this
review, the primary end points of the Amieva 2016; Charlesworth
2016; andWoods 2012a studies were after the 12 weeks of weekly
reminiscence sessions (three months post-baseline) while the later
follow-up time point was following completion of the monthly
maintenance sessions.
Quality of life
Ten studies measured self-reported QoL at the end of treatment
time point, while six measured it at follow-up. Two were excluded
from the meta-analysis for risk of selection bias (Baines 1987;
Gonzalez 2015), while the Subramaniam 2013 follow-up data
were also not included because the control group condition had
changed by then (participants had been given a life story book as
a gift). In the meta-analysis, all studies used the Quality of Life
in Alzheimer’s Disease (QoL-AD), except for the Azcurra 2012
study, which used the Self-Report Quality of Life (SR-QoL) scale.
Seven studies measured proxy-rated QoL. The Baines 1987 and
Goldwasser 1987 studies were excluded from themeta-analysis for
risk of selection bias. All used the proxy scale on the QoL-AD.
Three studies went on to measure it at follow-up.
Two studies measured observed QoL using the Well-being/Ill-
being (WIB) scale at both end of treatment and follow-up (Azcurra
2012; Lai 2004).
Cognition
Nineteen studies measured cognition at end of treatment. Five
studies at unclear risk of selection bias (Akanuma 2011; Baines
1987; Goldwasser 1987; Gonzalez 2015; Yamagami 2012), and
follow-up data from Subramaniam 2013 were excluded. Eight
studies were included in the meta-analysis at follow-up. The most
commonly used measures in the meta-analysis were the MMSE
(nine studies) and the Autobiographical Memory Interview Ex-
tended Version (AMI-E) (four studies).
Communication and Interaction
Eight studies measured communication and interaction at end of
treatment with four assessing it at a later follow-up time point.
Two studies were excluded from the meta-analysis for risk of selec-
tion bias (Baines 1987; Yamagami 2012). The meta-analysis in-
cluded data from four outcome measures; the Holden Communi-
cation Scale (Thorgrimsen 2002), Social Engagement Scale (SES)
(Azcurra 2012; Lai 2004), Multidimensional Observation Scale
for Elderly Subjects (MOSES) withdrawal subscale (Tadaka 2007
(AD); Tadaka 2007 (VD)), and the Communication Observation
Scale for Cognitive Impaired (Haight 2006). The follow-up meta-
analysis was comprised of data from the SES (Azcurra 2012; Lai
2004) and MOSES (Tadaka 2007 (AD); Tadaka 2007 (VD))
Quality of caring relationship
Three studies evaluated the quality of the relationship between
the carer and the person with dementia (as rated by the person
with dementia) at the end of treatment (Charlesworth 2016;
Subramaniam 2013; Woods 2012a). All three used the Quality of
Carer and Patient Relationship (QCPR), which has two subscales:
warmth and absence of conflict. The Charlesworth 2016 and
Woods 2012a studies measured this again at a follow-up time
point.
Behaviour
We divided measures of behaviour into measures of function (i.e.
daily living skills) and measures of agitation/irritability. Four stud-
ies used scales which assess both of these domains (MBS, CAPE,
Behavior Rating Scale for the Elderly (BRSE)) (Akanuma 2011;
Baines 1987; Haight 2006; Thorgrimsen 2002). As the authors
were unable to extract scores for each, data from these two out-
come measures were not included in the meta-analysis.
Behaviour: function
Seven studies measured functional behaviour at end of treatment
and at follow-up (Amieva 2016; Azcurra 2012; Charlesworth
2016; Goldwasser 1987; Haight 2006; Lai 2004; Woods 2012a)
except for the O’Shea 2014 study. The Goldwasser 1987 study
was excluded from the meta-analysis for risk of selection bias. The
most common outcomemeasure was the Activities of Daily Living
Scale, though all studies used various ADL measures.
Behaviour: agitation/irritability
Four studies measured agitation/irritability (O’Shea 2014; Tadaka
2007 (AD); Tadaka 2007 (VD); Yamagami 2012), though one
was excluded from the meta-analysis as there was a high risk of
selection bias (Yamagami 2012). The Tadaka 2007 (AD) and
Tadaka 2007 (VD) studies used the irritability subscale of the
MOSES at endof treatment and follow-up,while theO’Shea 2014
study used the Cohen Mansfield Agitation Inventory (CMAI) at
end of treatment only. The Ito 2007 study alsomeasured agitation/
irritability using theMOSESbut did not report the scores obtained
on each subscale. Therefore, the MOSES data from this study
could not be included in this meta-analysis.
Mood-related outcomes (person with dementia)
Depression
Fifteen studies measured depression at end of treatment with
ten contributing data to the meta-analysis (Akanuma 2011;
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Amieva 2016; Charlesworth 2016; Goldwasser 1987; Gonzalez
2015; Haight 2006; Hsieh 2010; Morgan 2012; O’Shea 2014;
Subramaniam 2013; Tadaka 2007 (AD); Tadaka 2007 (VD); Van
Bogaert 2016; Woods 2012a; Yamagami 2012). Four used the
Cornell Scale for Depression inDementia (CSDD), whichwas the
most common measure (Haight 2006; O’Shea 2014; Van Bogaert
2016; Woods 2012a). Other measures utilised were the Mont-
gomery-Åsberg Depression Rating Scale (MADRS), MOSES de-
pression subscale, Geriatric Depression Scale - Short Form (GDS-
SF), and 30-question Geriatric Depression Scale (GDS-30). Six
of these studies also measured depression at follow-up time points
(Amieva 2016; Charlesworth 2016; Morgan 2012; Tadaka 2007
(AD); Tadaka 2007 (VD); Woods 2012a).
Anxiety
Two studies measured anxiety at end of treatment and follow-up
using the Hospital Anxiety and Depression Scale (HADS) - Anxi-
ety subscale (Charlesworth 2016) and Rating Anxiety In Demen-
tia (RAID) scale (Woods 2012a).
Apathy
Two studies measured apathy at end of treatment; Amieva 2016
used a carer rated Apathy Index and Hsieh 2010 used the Apathy
Evaluation Scale, but the latter study was excluded from the meta-
analysis for risk of selection bias.
Carer outcomes
Carer outcomes were divided into outcomes measuring stress re-
lated to caring, carer anxiety and depression, carer QoL, and the
quality of the caring relationship.
Stress related to caring
Seven studies measured stress related to caring at end of treat-
ment (Amieva 2016; Azcurra 2012; Charlesworth 2016; O’Shea
2014; Särkämö 2013; Thorgrimsen 2002; Woods 2012a) with
five also measuring it at follow-up (Amieva 2016; Azcurra 2012;
Charlesworth 2016; Särkämö 2013; Woods 2012a). The most
popular measures were the ZBI or Zarit Burden Interview - Short
Form (ZBI-SF).
Carer depression and anxiety
Two studies measured carer depression and anxiety at end of treat-
ment and follow-up (Charlesworth 2016; Woods 2012a). Both
studies used the HADS. These subscales were analysed separately.
Carer well-being and quality of life
Four studies measured carer well-being and QoL at end of treat-
ment (Charlesworth 2016; Särkämö 2013; Thorgrimsen 2002;
Woods 2012a).Only the Thorgrimsen 2002 study did not include
a follow-up measure. The meta-analysis comprised of data from
the 12-item General Health Questionnaire (GHQ-12), 28-item
General Health Questionnaire (GHQ-28) and the 12-item Short
Form (SF-12) Mental component.
Quality of caring relationship
Three studies evaluated the quality of the relationship between
the carer and the person with dementia (as rated by the carer) at
the end of treatment (Charlesworth 2016; Subramaniam 2013;
Woods 2012a). All three used the Quality of Carer and Patient
Relationship (QCPR), which has two subscales: warmth and ab-
sence of conflict. The Charlesworth 2016 andWoods 2012a stud-
ies measured this again at a follow-up time point.
Effects of interventions
See: Summary of findings for the main comparison
Reminiscence Therapy compared to no treatment for people
living with dementia; Summary of findings 2 Reminiscence
therapy compared to no treatment for people living with dementia
(modality); Summary of findings 3 Reminiscence therapy
compared tono treatment for people livingwith dementia (setting)
Effect sizes
Evaluating the clinical meaningfulness of changes on the outcome
measures used in studies of reminiscence interventions is challeng-
ing, as there are no internationally agreed standards to apply in this
context. For SMDs, we have adopted the rule that an SMD of 0.5
or greater reflects an important difference, with SMDs less than
0.10 being negligible. For analyses using the MMSE, we judged a
difference of 1.5 points or more as clinically important. The rate
of decline on this measure has been estimated, in mild tomoderate
dementia, to be between 2 and 4 points per annum (Mohs 2000),
and so 1.5 points is broadly equivalent to preventing six months
of decline in cognition. For other measures, we did not have par-
allel criteria, so have applied the 0.5 of a standard deviation rule,
taking the standard deviation from the baseline evaluations. Thus,
for the QoL-AD, we have taken a difference of 3 points or more
to be clinically meaningful, reflecting approximately half the typ-
ical standard deviation in samples of people with mild to moder-
ate dementia (e.g. Woods 2012a). For the SR-QoL, this translates
to 2.2 points or more (Azcurra 2012); for the WIB, 0.3 points
or more (Azcurra 2012; Lai 2004); for the MOSES Withdrawal
Scale, 3.1 points or more (Tadaka 2007); for the SES, 0.75 points
or more (Azcurra 2012); for the QCPR warmth and absence of
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conflict scales, rated by the person with dementia, 1.8 points; for
the MOSES Irritability Scale, 2.2 points or more (Tadaka 2007);
for the ZBI 3 points or more (Azcurra 2012); for HADS - Anxiety,
2.2 points or more; for HADS - Depression, 1.8 points or more
(Woods 2012a); for the QCPR rated by the carer: warmth 2.7
points or more, absence of conflict 2.2 points or more.
Outcomes for the person with dementia
Quality of life
(See Figure 4.)
Figure 4. Forest plot of comparison: 1 Reminiscence therapy versus no treatment, outcome: 1.1 Self-
reported quality of life post-treatment.
For the overall evaluation of the effects of reminiscence on QoL
at the end of treatment, eight studies reporting a self-report
QoL measure were included in the meta-analysis (Amieva 2016;
Azcurra 2012; Charlesworth 2016; O’Shea 2014; Särkämö 2013;
Subramaniam 2013; Thorgrimsen 2002; Woods 2012a). This in-
cluded 1060 participants living with dementia; 595 received a
reminiscence intervention and 465 received no treatment. Where
studies used more than one measure of QoL, the analysis was con-
ducted on the most common or extensive self-report assessment;
seven studies used the QoL-AD (self-report) and one study used
the SR-QoL. A random-effects analysis resulted in a small overall
effect size (SMD 0.11, 95% CI -0.12 to 0.33; I2 = 59%; moder-
ate quality evidence; Analysis 1.1). This indicated that, across the
eight included studies, reminiscence did not have an important
effect on self-reported QoL.
Five studies (all involving reminiscence groups) went on to mea-
sure the effects of reminiscence on QoL at later follow-up of six
to 21 months (Amieva 2016; Azcurra 2012; Charlesworth 2016;
Särkämö 2013; Woods 2012a). This analysis involved 499 par-
ticipants who received a reminiscence intervention and 375 who
received a control intervention. We could not determine whether
reminiscence was associated with any effect on self-reported QoL
at follow-up. The results were inconsistent between studies and
the result of the meta-analysis was imprecise and compatible with
either an improvement or a small detrimental effect (random-ef-
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fects analysis; SMD 0.35, 95% CI -0.11 to 0.80; I2 = 89%; mod-
erate quality evidence; Analysis 1.17).
At both end of treatment and follow-up there was substantial het-
erogeneity, which appeared to relate to different modalities and
(particularly) contexts of reminiscence work being analysed to-
gether. Analyses were accordingly undertaken for different modal-
ities and contexts separately.
Modality
One small study reported self-reportQoL outcomes for individual
reminiscence interventions at end of treatment (Subramaniam
2013). This involved 23 participants, and indicated life story work
may have improved self-reportedQoL-AD(meandifference (MD)
7.00 points, 95% CI -0.14 to 14.14; low quality evidence).
Of the seven studies that implemented group reminiscence in-
terventions, including 1037 participants, six used the self-report
QoL-AD. There was little or no difference between the reminis-
cence and control groups (random-effects analysis; SMD 0.06,
95% CI -0.15 to 0.28; I2 = 56%; high quality evidence). The
different settings (community versus care home) appeared to be
responsible for the substantial level of inconsistency identified in
this analysis. The findings for reminiscence groups at longer-term
follow-up were detailed in the previous section.
Setting
Three studies including 193 participants living in care home set-
tings were included in themeta-analysis of self-report QoL indices
(Azcurra 2012; O’Shea 2014; Subramaniam 2013). The analysis
suggested that therewas probably an improvement in self-reported
QoL following a reminiscence intervention in care homes, but we
could not be sure that this was large enough to be clinically im-
portant (fixed-effect analysis; SMD 0.46, 95% CI 0.18 to 0.75; I
2 = 0%; moderate quality evidence). The single care-home study
that reported longer-term (six months) follow-up, with 88 par-
ticipants, also showed a probable improvement on the SR-QoL
(9.8 points, 95% CI 7.05 to 12.55; moderate quality evidence)
(Azcurra 2012).
Five studies with 867 participants included only community-res-
ident people with dementia (Amieva 2016; Charlesworth 2016;
Särkämö 2013; Thorgrimsen 2002; Woods 2012a). All used the
self-report QoL-AD. There was little or no difference between the
reminiscence and control groups (fixed-effect analysis; MD -0.57
points, 95% CI -1.37 to 0.22; I2 = 0%; high quality evidence).
Four of these studies measured the effects of reminiscence on QoL
of 786 participants living in the community at follow-up time
points of six to 21 months (Amieva 2016; Charlesworth 2016;
Särkämö 2013; Woods 2012a). There was little or no difference
between the reminiscence and control groups (QoL-AD) (fixed-
effect analysis; MD 0.17 points, 95% CI -0.79 to 1.13; I2 = 0%;
high quality evidence).
Proxy ratings
The above findings on QoL were based on self-report measures.
Five studies of reminiscence groups with 763 participants used
proxy measures, where a family carer or member of care staff rated
the person’s QoL (Charlesworth 2016; O’Shea 2014; Särkämö
2013; Thorgrimsen 2002; Woods 2012a). All used the QoL-AD
proxy version. There was little or no difference in outcomes at the
end of treatment (random-effects analysis; MD 0.35 points, 95%
CI -1.23 to 1.94; I2 = 45%; moderate quality evidence; Analysis
1.2). At longer-term follow-up of six to seven months postinter-
vention, three studies with 505 participants, all community based
and involving reminiscence groups, reported findings on theQoL-
AD proxy version (Charlesworth 2016; Särkämö 2013; Woods
2012a). There was little or no difference between the reminiscence
and control groups (MD -0.15 points, 95% CI -1.14 to 0.83; I2
= 25%; high quality evidence; Analysis 1.18).
Observed quality of life
Two studies used the WIB, an observational measure of QoL,
which was completed during a minimum of six hours’ observation
of the person undertaking their usual activities (Azcurra 2012;
Lai 2004). The studies included 154 care home participants, and
there was probably little or no difference on WIB scores at end
of treatment (MD 0.00 points, 95% CI -0.17 to 0.18; I2 = 0%;
moderate quality evidence). At longer-term follow-up of six to 24
weeks’ postintervention, due to the imprecision of the results and
the development of inconsistency between the studies, we were
unable to determine whether there was any effect of reminiscence
on observedQoL (random-effects analysis;MD -0.40 points, 95%
CI -1.34 to 0.54; I2 = 93%; very low quality evidence; Analysis
1.19).
Cognition
(See Figure 5.)
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Figure 5. Forest plot of comparison: 1 Reminiscence therapy versus no treatment, outcome: 1.5 Cognition
(overall) post-treatment.
For cognition, we analysed data from 14 studies involving 1219
people living with dementia, in which 679 received some form
of reminiscence and 540 were assigned to control groups. Where
studies used more than one measure of cognition, we used the
most common or extensive assessment (for the AMI and AMI-E
this was the Personal Semantic Memory Sub-scale (PSS)). There
was a slight improvement in cognition immediately following a
reminiscence intervention, but the effect was small and of uncer-
tain clinical importance (change scores between reminiscence and
control conditions: SMD 0.11, 95% CI 0.00 to 0.23; I2 = 9%;
high quality evidence; Analysis 1.5).
The MMSE was the most widely used cognitive measure, used
in nine studies involving 437 participants. A fixed-effect analysis
found an improvement following reminiscence compared to the
control group (MD 1.87 points, 95% CI 0.54 to 3.20; I2 = 0%;
high quality evidence).
Nine studies measured the difference in cognition scores between
reminiscence and control groups over a longer follow-up period of
six to 84 weeks postintervention. This involved 983 participants
with 561 in the intervention groups and 422 in the control groups.
Therewas little or nodifference in outcomebetween groups (SMD
0.04, 95% CI -0.09 to 0.17; I2 = 3%; high quality evidence;
Analysis 1.21). For the five studies reporting MMSE, there may
have been an improvement at follow-up of six to 36 weeks (MD
1.8 points, 95% CI -0.06 to 3.65; I2 = 0%; 282 participants;
low quality evidence), with the quality rating reduced due to the
relatively low sample size and imprecision.
Modality
There was a probable slight improvement with individual remi-
niscence compared with the control group in five studies with 196
participants, but we could not be sure that this was large enough
to be clinically important (SMD 0.32, 95% CI 0.04 to 0.61; I2 =
6%; moderate quality evidence). For individual reminiscence, two
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studies (both in care homes) with 83 participants reported results
at six weeks’ follow-up. There may have been some benefit, but
the results were so imprecise that we could not be certain of this,
or whether any effect was large enough to be clinically important
(SMD0.35, 95%CI -0.08 to 0.79; I2 = 0%; lowquality evidence).
For the nine studies with 1023 participants of group reminiscence,
there was little or no difference in cognition at the end of treatment
between reminiscence and control groups (SMD 0.07, 95% CI -
0.05 to 0.20; I2 = 0%; high quality evidence). For the six group
reminiscence studies with 281 participants using theMMSE, there
was a probable improvement in favour of reminiscence (MD 1.81
points, 95%CI 0.17 to 3.46; I2 = 0%; moderate quality evidence).
For group reminiscence (all community-based studies), there was
little or no difference in cognition at longer-term follow-up of six
to 84 weeks (SMD0.01, 95%CI -0.12 to 0.14; I2 = 0%; 7 studies;
900 participants; high quality evidence).
Setting
Six studies in care homes, involving 230 participants, reported
cognitive outcomes at end of treatment (Haight 2006; Ito 2007;
Lai 2004;Morgan 2012; Subramaniam 2013; Van Bogaert 2016).
There was a probable slight improvement in favour of the remi-
niscence intervention, but we could not be sure that this was large
enough to be clinically important (SMD 0.29, 95% CI 0.03 to
0.56; I2 = 0%; moderate quality evidence).
Eight studies with 989 participants were carried out in community
settings. There was little or no difference in cognition apparent
at the end of treatment between reminiscence and control groups
(SMD 0.07, 95% CI -0.05 to 0.20; I2 = 8%; high quality evi-
dence).
All the community studies with long-term follow-up involved a
group intervention and all those in care homes involved an indi-
vidual intervention, and so these results have been detailed under
’Modality’ above, with little or no difference for community/group
studies, and uncertainty about possible benefit in care home/indi-
vidual studies.
Communication and interaction
(See Figure 6.)
Figure 6. Forest plot of comparison: 1 Reminiscence therapy versus no treatment, outcome: 1.7
Communication and interaction post-treatment.
Six studieswith 249participants, using a variety of different indica-
tors of communication and interaction,were included in the endof
treatment analysis (Azcurra 2012; Haight 2006; Lai 2004; Tadaka
2007 (AD); Tadaka 2007 (VD); Thorgrimsen 2002). (Note: in
this analysis, negative scores indicated improved communication.)
There may have been an improvement in communication and in-
teraction following a reminiscence intervention, but, due to in-
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consistency between studies, we could not rule out a small or neg-
ligible effect (random-effects analysis; SMD -0.51 points, 95%CI
-0.97 to -0.05; I2 = 62%; low quality evidence; Analysis 1.7).
Four of the six studies, with 204 participants, also reported data at
six to 24 weeks’ follow-up (Azcurra 2012; Lai 2004; Tadaka 2007
(AD); Tadaka 2007 (VD)). There was probably an improvement
in communication and interaction at longer-term follow-up after
a reminiscence intervention, but we could not be sure that this was
large enough to be clinically important (SMD -0.49 points, 95%
CI -0.77 to -0.21; I2 = 0%; moderate quality evidence; Analysis
1.22).
Modality
Two studies using individual reminiscence reported end of treat-
ment measures of communication and interaction (Haight 2006;
Lai 2004).We could not be certain whether there was an improve-
ment as the quality of the evidence was very low, due to impre-
cision and serious inconsistency (random-effects analysis; SMD -
0.74, 95% CI -2.38 to 0.89; I2 = 91%; very low quality evidence).
Longer-term follow-up data were only available in one study of
individual reminiscence (Lai 2004), with effects uncertain due to
imprecision.
Analysis of the four trials of group reminiscence, including 153
participants, indicated a probable slight improvement for partic-
ipants receiving reminiscence compared with the control group
at end of treatment, although we could not be certain of its clin-
ical importance (SMD -0.39, 95% CI -0.71 to -0.06; I2 = 0%;
moderate quality evidence) (Azcurra 2012; Tadaka 2007 (AD);
Tadaka 2007 (VD); Thorgrimsen 2002). For group reminiscence,
three studies with 138 participants reported data at six months’
follow-up (Azcurra 2012; Tadaka 2007 (AD); Tadaka 2007 (VD)).
There was a probable improvement after this longer-term follow-
up (SMD -0.63, 95% CI -0.97 to -0.29; I2 = 0%; moderate qual-
ity evidence).
Setting
Three studies, with 65 participants, were based in the commu-
nity. There was a probable improvement on communication and
interaction in favour of RT although we could not be certain it
was clinically important (SMD -0.57, 95% CI -1.08 to -0.06; I2
= 0%; moderate quality evidence). At longer-term follow-up, only
two studies, with 50 participants, took place in the community
(Tadaka 2007 (AD); Tadaka 2007 (VD). There was a probable
improvement in favour of RT, although we could not be certain
it was clinically important (MOSES withdrawal subscale: MD -
3.64 points, 95% CI -7.21 to -0.06; I2 = 0%; moderate quality
evidence).
Three studies with 184 participants took place in care homes.
Here, we could not ascertain from our results whether there was
an important effect on communication and interaction due to
imprecision and unexplained variation in results between studies
(random-effects analysis; SMD -0.52, 95% CI -1.29 to 0.24; I2 =
83%; very low quality evidence). The two care home studies, with
154 participants, with longer-term follow-up of six to 24 weeks
used the SES (Azcurra 2012; Lai 2004). There may have been an
improvement; however, imprecision and inconsistency between
the studies means we could not be certain of a clinically important
effect (random-effects analysis; MD -0.93 points, 95% CI -1.77
to -0.09; I2 = 41%; low quality evidence).
Quality of relationship
Three studies, with 528 participants, included ratings by the per-
son with dementia of his/her relationship with his/her family carer
(Charlesworth 2016; Subramaniam 2013;Woods 2012a). All used
the QCPR and reported results separately for its two subscales:
warmth and absence of conflict. On both subscales, there was lit-
tle or no difference between RT and control groups at the end of
treatment (warmth: MD 0.16 points, 95% CI -0.53 to 0.84; I2 =
0%; high quality evidence; absence of conflict: MD -0.40 points,
95% CI -1.09 to 0.29; I2 = 15%; high quality evidence).
Two of the studies, involving 415 participants, both community-
based and using reminiscence groups, reported seven months’ fol-
low-up post-intervention. Due to the imprecision of the results
and inconsistency between the two studies, we were unable to de-
termine whether there was any effect of reminiscence on warmth
at follow-up (random-effects analysis; MD -0.09 points, 95% CI
-1.82 to 1.63; I2 = 62%; low quality evidence). There was little or
no difference in absence of conflict (MD -0.38 points, 95% CI -
1.28 to 0.51; I2 = 11%; high quality evidence).
Behaviour: function
Six studies, involving 1030 participants, assessed changes in the
functional level of the person with dementia at the end of treat-
ment (Amieva 2016; Azcurra 2012; Charlesworth 2016; Haight
2006; Lai 2004; Woods 2012a). In this analysis, a lower score in-
dicated a more positive outcome. Due to imprecision and incon-
sistency between studies, we were uncertain whether RT improved
function at the end of treatment (random-effects analysis; SMD -
0.24, 95% CI -0.69 to 0.21; I2 = 90%; very low quality evidence;
Analysis 1.8). This uncertainty was present at longer-term follow-
up (six to 84 weeks) in an analysis that involved five studies and
941 participants (random-effects analysis; SMD -0.31, 95% CI -
0.66 to 0.03; I2 = 83%; very low quality evidence; Analysis 1.24).
Modality
Two studies, involving 96 participants, examined the effects of
individual reminiscence on level of function (Haight 2006; Lai
2004). There was probably little or no difference in function be-
tween RT and control groups at the end of treatment (SMD -
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0.07, 95% CI -0.33 to 0.47; I2 = 0%; moderate quality evidence).
Only the Lai 2004 study went on to assess participants at later
follow-up time points, with no effect evident at six weeks’ post-
intervention.
Four studies implementing a group reminiscence intervention re-
proted a relevant outcome at end of treatment in 934 participants
and at follow-up in 875 participants (Amieva 2016; Azcurra 2012;
Charlesworth 2016;Woods 2012a). From baseline to end of treat-
ment, the difference in change scores between the RT and control
groups showed a probable slight benefit of RT (random-effects
analysis; SMD -0.40, 95% CI -0.99 to 0.20; I2 = 94%; moder-
ate quality evidence). There was a similar slight improvement at
longer-term follow-up of six to 21 months (random-effects analy-
sis; SMD -0.38, 95% CI -0.78 to 0.03; I2 = 87%; moderate qual-
ity evidence). In both cases, we could not be sure that the im-
provement noted was large enough to be clinically important; the
high inconsistency in each analysis was clearly attributable to the
inclusion of the Azcurra 2012 study, the only one of the four to be
located in a care home setting, and which reported more positive
results in this domain than the community-based group studies.
Setting
Three large group studies, including 846 participants, provided
data on the effects of RT on functioning of community residents
(Amieva 2016; Charlesworth 2016; Woods 2012a). There was
little or no difference in function at the end of treatment between
groups (SMD 0.05, 95% CI -0.09 to 0.18; I2 = 0%; high quality
evidence), with a slight improvement in favour of RT, of uncertain
clinical importance, at longer-term follow-up (SMD -0.12, 95%
CI -0.27 to 0.02; I2 = 0%; high quality evidence).
Due to imprecision and inconsistency, we could not be certain of
the effect of RT in care home settings (three studies with 184 par-
ticipants; Azcurra 2012; Haight 2006; Lai 2004). This was true at
the end of treatment (random-effects analysis; SMD -0.53, 95%
CI -1.87 to 0.80; I2 = 94%; very low quality evidence) and at
longer-term follow-up (two studies with 154 participants; Azcurra
2012; Lai 2004) (random-effects analysis; SMD -0.67, 95% CI -
1.89 to 0.55; I2 = 92%; very low quality evidence). The inconsis-
tency in results within these analyses was attributable to the more
positive results reported by the one care home study using a group
intervention (Azcurra 2012).
Behaviour: agitation/irritability
Three studiesmeasured irritability and agitationusing theMOSES
irritability subscale (O’Shea 2014) andCMAI (Tadaka 2007 (AD);
Tadaka 2007 (VD)). A lower score was indicative of improved
agitation/irritability. The three studies included 359 participants,
with 181 receiving an RT and 178 receiving control conditions,
and all implemented a group reminiscence intervention. There
was probably little or no difference in outcome between groups at
the end of treatment (SMD 0.03, 95% CI -0.17 to 0.24; I2 = 0%;
moderate quality evidence; Analysis 1.9). Two studies measured
changes in behaviour scores again six months’ post-intervention
(Tadaka 2007 (AD); Tadaka 2007 (VD)). There may have been a
slight improvement, although we could not be certain of this, or
of its clinical importance, due to imprecision (MD -1.52 points,
95% CI -4.07 to 1.03; I2 = 0%; low quality evidence; Analysis
1.25).
All the studies were group studies, and in the absence of hetero-
geneity between studies, analyses by setting were not undertaken.
Mood
(See Figure 7.)
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Figure 7. Forest plot of comparison: 1 Reminiscence therapy versus no treatment, outcome: 1.10 Mood-
related outcomes (depression) post-treatment.
Ten studies included amood scale administered at the end of treat-
ment (Amieva 2016; Charlesworth 2016; Haight 2006; Morgan
2012; O’Shea 2014; Subramaniam 2013; Tadaka 2007 (AD);
Tadaka 2007 (VD); Van Bogaert 2016; Woods 2012a). These in-
cluded self-report measures such as the HADS and the GDS, but
four studies using the CSDD, where the researcher integrated re-
ports from the carer and the person with dementia. In these anal-
yses, negative scores indicated improved mood.
For depression, the 10 studies included 973 participants. There
was little or no difference in depression between groups evident
at the end of treatment (SMD -0.03, 95% CI -0.15 to 0.10; I2
= 32%; high quality evidence; Analysis 1.10). At longer-term fol-
low-up (six to 84 weeks), six studies, including 747 participants,
reported measures of depressed mood. We could not be certain of
the effects of RT at follow-up, as the results were consistent with
improvement or with little or no effect, and there was inconsis-
tency between studies attributable to the reminiscence modality
(random-effects analysis; SMD -0.16, 95% CI -0.43 to 0.11; I2 =
55%; moderate quality evidence; Analysis 1.26).
Two large community-based studies of group reminiscence, in-
cluding 436 participants, analysed anxiety (Charlesworth 2016;
Woods 2012a). There was little or no difference in anxiety be-
tween groups at the end of treatment (SMD -0.03, 95% CI -0.22
to 0.16; I2 = 0%; high quality evidence; Analysis 1.11), and there
was probably little or no difference in anxiety at seven months’
follow-up (SMD 0.01, 95% CI -0.20 to 0.21; I2 = 0%; moderate
quality evidence; 391 participants; Analysis 1.27).
One study with 326 participants evaluated apathy, using a carer-
rated Apathy Index (Amieva 2016). There was probably little or
no difference in apathy between groups at the end of treatment
assessment or at 21 months’ follow-up.
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Modality
The four studies using an individual reminiscence approach in-
cluded 131 participants. There was probably a slight effect on de-
pressed mood in favour of individual RT, although we could not
be sure of its clinical importance (SMD -0.41, 95% CI -0.76 to -
0.06; I2 = 0%; moderate quality evidence). The single study with
an individual approach that included a longer-term follow-up (six
weeks) showed a probable benefit, but the sample size (17 partic-
ipants) was very small (Morgan 2012).
Six studies with 842 participants used a group approach. There
was little or no difference between group RT and controls (SMD
0.03, 95% CI -0.10 to 0.17; I2 = 27%; high quality evidence). At
longer-term follow-up of six to 21 months, five studies of group
RT reportedmeasures of depressedmood, but all were community
based, so the results were confounded with the setting. There was
little or no difference related to the RT (SMD -0.04, 95% CI -
0.19 to 0.11; I2 = 0%; high quality evidence; 730 participants).
Setting
Five studies with 187 participants were based in care homes. There
was probably a small benefit of RT, but we could not rule out little
or no effect and could not be sure of the clinical importance of any
effect (SMD -0.19, 95% CI -0.48 to 0.10; I2 = 30%; moderate
quality evidence).
The five community-based studies, all involving group interven-
tions, included 786 participants and showed little or no effect of
RT (SMD 0.01, 95% CI -0.13 to 0.16; I2 = 31%; high quality
evidence).
The results for longer-term follow-up were discussed in the
’Modality’ section above, with all the community studies being
group studies, and the single care home study followed up involv-
ing individual reminiscence.
Outcomes for the carer
For all carer outcomes, lower scores indicated a more positive out-
come.
Stress related to caring
Seven studies used measures such as the Relative Stress Scale (RSS)
andZBI that evaluated the carer’s stress directly related to aspects of
caring (Amieva 2016; Azcurra 2012; Charlesworth 2016; O’Shea
2014; Särkämö 2013; Thorgrimsen 2002; Woods 2012a). In six
of the studies, the carer was a family member or friend, but in the
O’Shea 2014 study, the carer was a healthcare assistant or nurse.
At end of treatment, these studies involved 1155 participants.
Overall, there was probably little or no difference in carer stress
related to the reminiscence intervention (random-effects analysis;
SMD -0.03, 95% CI -0.21 to 0.14; I2 = 43%; moderate quality
evidence; Analysis 1.12). There appeared to be some inconsistency
between studies, related to the different settings. Excluding the
O’Shea 2014 study, so that the 965 participants were all family or
friend carers made little difference to the overall results (random-
effects analysis; SMD -0.08, 95% CI -0.32 to 0.16; I2 = 59%;
high quality evidence). The inclusion of a single care home study,
which reported much more positive findings, was responsible for
the observed inconsistency (Azcurra 2012).
Five studies, involving 895 participants, went on to measure carer
stress at follow-up of six to 21 months (Amieva 2016; Azcurra
2012; Charlesworth 2016; Särkämö 2013; Woods 2012a). The
results were again inconsistent between studies (due to the inclu-
sion of the single care home study) and the result of the meta-
analysis was imprecise being compatible with either improvement
or a small or no effect (random-effects analysis; SMD -0.19, 95%
CI -0.54 to 0.16; I2 = 82%; moderate quality evidence; Analysis
1.28).
Modality
All the seven studies that measured stress related to caring involved
group reminiscence (Amieva 2016; Azcurra 2012; Charlesworth
2016; O’Shea 2014; Särkämö 2013; Thorgrimsen 2002; Woods
2012a). However, an additional aspect of modality that should
be considered in relation to carer outcomes relates to whether the
family carer was actively involved in the reminiscence group. This
joint reminiscence was a key feature of the Charlesworth 2016;
Särkämö 2013; Thorgrimsen 2002 and Woods 2012a studies,
which included 551 participants. There was little or no difference
in carer stress between the reminiscence intervention and control
conditions at end of treatment in these studies (SMD 0.04, 95%
CI -0.13 to 0.21; I2 = 16%; high quality evidence) or at longer-
term follow-up of six to seven months (SMD -0.04, 95% CI -
0.22 to 0.15; I2 = 0%; high quality evidence; 3 studies; 481 par-
ticipants). In contrast, only one study including 88 participants
evaluated family carer stress when family carers were not exten-
sively involved in the RT (Azcurra 2012). The study used the ZBI
and found that there was probably a benefit to carers at the end
of treatment (MD -4.90 points, 95% CI -8.20 to -1.60; moderate
quality evidence) and at six months’ follow-up (MD -7.90 points,
95% CI -10.97 to -4.83; moderate quality evidence).
Setting
Five studies, including 877 participants, were community-based
(Amieva 2016; Charlesworth 2016; Särkämö 2013; Thorgrimsen
2002; Woods 2012a). There was little or no difference in carer
stress between groups at end of treatment (SMD 0.05, 95% CI -
0.08 to 0.19; I2 = 0%; high quality evidence) or at longer-term
follow-up of six to 21 months (SMD 0.02, 95% CI -0.12 to 0.16;
I2 = 0%; high quality evidence; 4 studies; 807 participants).
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There were two care home studies, both using the ZBI (Azcurra
2012; O’Shea 2014). The Azcurra 2012 study, which involved
family carers, reported probable benefit at both end of treatment
and longer-term follow-up, but, when combined with the O’Shea
2014 study, end of treatment data on staff carers, we could not be
certain of any benefits due to inconsistency between the studies
and imprecision (random-effects analysis; MD -1.48 points, 95%
CI -5.43 to 2.47; I2 = 70%; very low quality evidence; 278 par-
ticipants).
Mood: depression and anxiety
Two large community-based joint reminiscence group studies with
517 participants used the HADS to evaluate changes in anxiety
and depressed mood following carers’ participation in joint remi-
niscence groups with people with dementia (Charlesworth 2016;
Woods 2012a). There was little or no difference between groups
on the HADS Anxiety subscale at the end of treatment (MD 0.06
points, 95% CI -0.54 to 0.66; I2 = 0%; high quality evidence;
Analysis 1.14). At seven months’ follow-up, there was probably a
slight advantage for the control participants, but we could not be
certain of the clinical implications of this result, which was also
consistent with little or no difference (MD 0.56 points, 95% CI
-0.17 to 1.30; I2 = 0%; moderate quality evidence; 464 partici-
pants; Analysis 1.30). There was little or no difference between
reminiscence and control conditions for the HADS Depression
subscale at the end of treatment (MD -0.08 points, 95% CI -
0.59 to 0.44; I2 = 0%; high quality evidence; Analysis 1.13) and
at seven months’ follow-up (MD -0.05 points, 95% CI -0.71 to
0.60; I2 = 0%; high quality evidence; Analysis 1.29).
Well-being and quality of life
Four community-based joint reminiscence group studies, includ-
ing 530 participants, evaluated aspects of carer psychological well-
being (Charlesworth 2016; Särkämö 2013; Thorgrimsen 2002;
Woods 2012a). Outcome scales included the GHQ-12, GHQ-28
and SF-12Mental component. There was little or no difference in
carer well-being between groups at end of treatment (SMD -0.04,
95% CI -0.22 to 0.13; I2 = 1%; high quality evidence; Analysis
1.15). Three studies provided longer-term follow-up data after six
to sevenmonths, and there was little or no difference in carer well-
being (SMD 0.01, 95% CI -0.18 to 0.19; I2 = 0%; high quality
evidence; 467 participants; Analysis 1.31) (Charlesworth 2016;
Särkämö 2013; Woods 2012a).
Quality of caring relationship
Three studies, including up to 528 participants, evaluated the
quality of the relationship between the carer and the person with
dementia (as rated by the carer), all using the QCPR with two
subscales: warmth and absence of conflict (Charlesworth 2016;
Subramaniam 2013; Woods 2012a). There was little or no differ-
ence related to RT on the warmth subscale at the end of treatment
(MD -0.01 points, 95% CI -0.77 to 0.76; I2 = 0%; high quality
evidence) or (for the Charlesworth 2016 and Woods 2012a stud-
ies) after seven months’ follow-up (MD -0.66 points, 95% CI -
1.59 to 0.27; I2 = 0%; high quality evidence). Similarly, there was
little or no difference on the absence of conflict subscale at end
of treatment (MD -0.26 points, 95% CI -1.01 to 0.48; I2 = 0%;
high quality evidence) or after longer-term follow-up (MD -0.37
points, 95% CI -1.23 to 0.50; I2 = 0%; high quality evidence).
Adverse outcomes
The only outcome identified that probably favoured control par-
ticipants was carer anxiety at seven months’ follow-up, from an
analysis involving two large community studies that involved fam-
ily carers along with people with dementia in reminiscence groups.
The estimated MD was small enough to be of uncertain clini-
cal importance and the evidence was of moderate quality, down-
graded due to imprecision. These two studies also reported a few
incidences of specific adverse outcomes. The Charlesworth 2016
study recorded 159 ’serious adverse events’ during the trial, with
three of these attributable to the RYCT intervention. Specific de-
tails were not given, though it reported that none of these three
events led to withdrawal. The Woods 2012a study recorded one
adverse event linked to participation in the trial. One participant
became upset in one of the intervention sessions relating to mar-
riage. There was a detailed protocol for dealing with distressing
events that was implemented.While adverse events are regrettable,
it is important to view them in context of the total number of
participants and intervention sessions.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Reminiscence therapy compared to no treatment for people living with dementia (modality)
Patient or population: people living with dementia (modality)
Setting: care home and community sett ings
Intervention: reminiscence therapy
Comparison: no treatment
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no treatment Risk with reminiscence
therapy
Individual: quality of
life (self- reported) at
end of treatment
assessed with: QoL-AD
Scale f rom: 13 to 52
follow-up: range 1 to 7
days
- MD 7.00 points higher
(0.14 lower to 14.14
higher)
- 23
(1 RCT)
⊕⊕©©
Low1
Higher score on qual-
ity of lif e measures in-
dicated a more posit ive
outcome. 3.0 points
may be the minimum
clinically important dif -
ference
Individual: cognition at
end of treatment
assessed with: MMSE,
AMI-PSS
follow-up: range 1 day
to 2 weeks
- SMD 0.32 higher
(0.04 higher to 0.61
higher)
- 196
(5 RCTs)
⊕⊕⊕©
Moderate2
Higher score on cog-
nit ive measures indi-
cated a more posit ive
outcome
Individual: communi-
cation at end of treat-
ment
assessed with: SES,
COS
follow-up: range 1 day
to 2 weeks
- SMD 0.74 lower
(2.38 lower to 0.89
higher)
- 96
(2 RCTs)
⊕©©©
Very low3,4
Lower score on commu-
nicat ion measures indi-
cated a more posit ive
outcome
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Group: quality of life
(self- reported) at end
of treatment
assessed with: QoL-AD,
SR-QoL
follow-up: range 1 day
to 6 weeks
- SMD 0.06 higher
(0.15 lower to 0.28
higher)
- 1037
(7 RCTs)
⊕⊕⊕⊕
High
Higher score on qual-
ity of lif e measures in-
dicated a more posit ive
outcome
Group: cognition at end
of treatment
assessed with: MMSE,
AMI-PSS, ADAS-Cog
follow-up: range 1 day
to 6 weeks
- SMD 0.07 higher
(0.05 lower to 0.20
higher)
- 1023
(9 RCTs)
⊕⊕⊕⊕
High
Higher score on cog-
nit ive measures indi-
cated a more posit ive
outcome
Group: communication
at end of treatment
assessed with: SES,
COS, MOSES With-
drawal subscale
follow-up: range 1 day
to 1 weeks
- SMD 0.39 lower
(0.71 lower to 0.06
lower)
- 153
(4 RCTs)
⊕⊕⊕©
Moderate2
Lower score on commu-
nicat ion measures indi-
cated a more posit ive
outcome
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ADAS-Cog: Alzheimer’s Disease Assessment Scale Cognit ive subscale; AMI-PSS: Autobiographical Memory Interview - Perceived Stress Scale; CI: conf idence interval;
Communicat ion Observat ion Scale; MD: mean dif ference; MMSE: Mini-Mental State Examinat ion; MOSES: Mult idimensional Observat ion Scale for Elderly Subjects; QoL-AD:
Quality of Life in Alzheimer’s Disease; RCT: randomised controlled trial; SES: Social Engagement Scale; SMD: standardised mean dif ference; SR-QoL: Self -Report Quality of
Life.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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1Downgraded 2 levels for imprecision due to small sample size (< 400 part icipants) and including both null ef fect and an
upper lim it greater than 0.3.
2Downgraded 1 level for imprecision due to small sample size (< 400 part icipants).
3Downgraded 2 levels for inconsistency due to considerable unexplained heterogeneity.
4Downgraded 2 levels for imprecision due to small sample size (< 400 part icipants) and both conf idence interval lim its
crossing 0.5.
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Reminiscence therapy compared to no treatment for people living with dementia (setting)
Patient or population: people living with dementia (sett ing)
Setting: community and care home sett ings
Intervention: reminiscence therapy
Comparison: no treatment
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no treatment Risk with reminiscence
therapy
Care home: quality of
life (self- reported) at
end of treatment
assessed with: QoL-AD,
SR-QoL
follow-up: range 1 day
to 6 weeks
- SMD 0.46 higher
(0.18 higher to 0.75
higher)
- 193
(3 RCTs)
⊕⊕⊕©
Moderate1
Higher score on qual-
ity of lif e measures in-
dicated a more posit ive
outcome
Care home: cognition
at end of treatment
assessed with: MMSE,
AMI-PSS
follow-up: range 1 day
to 2 weeks
- SMD 0.29 higher
(0.03 higher to 0.56
higher)
- 230
(6 RCTs)
⊕⊕⊕©
Moderate1
Higher score on cog-
nit ive measures indi-
cated a more posit ive
outcome
Care home: communi-
cation at end of treat-
ment
assessed with: SES,
Communicat ion Scale
for Cognit ively Im-
paired
follow-up: range 1 day
to 2 weeks
- SMD 0.52 lower
(1.29 lower to 0.24
higher)
- 184
(3 RCTs)
⊕©©©
Very low2,3
Lower score on commu-
nicat ion measures indi-
cated a more posit ive
outcome
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Community: quality of
life (self- reported) at
end of treatment
assessed with: QoL-AD
(self -report)
Scale f rom: 13 to 52
follow-up: range 1 day
to 6 weeks
- MD 0.57 points lower
(1.37 lower to 0.22
higher)
- 867
(5 RCTs)
⊕⊕⊕⊕
High
Higher score on qual-
ity of lif e measures in-
dicated a more posit ive
outcome. 3.0 points
may be the minimum
clinically important dif -
ference
Community: cognition
at end of treatment
assessed with: MMSE,
AMI-PSS, AMI-E-PSS,
ADAS-Cog
follow-up: range 1 day
to 6 weeks
- SMD 0.07 higher
(0.05 lower to 0.20
higher)
- 989
(8 RCTs)
⊕⊕⊕⊕
High
Higher score on cog-
nit ive measures indi-
cated a more posit ive
outcome
Community: communi-
cation and interaction
at end of treatment
assessed with: Holden
Communicat ion Scale
and MOSES (with-
drawal subscale)
follow-up: range 1 day
to 7 days
- SMD 0.57 lower
(1.08 lower to 0.06
lower)
- 65
(3 RCTs)
⊕⊕⊕©
Moderate1
Lower score on commu-
nicat ion measures indi-
cated a more posit ive
outcome
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
ADAS-Cog: Alzheimer’s Disease Assessment Scale Cognit ive subscale; AMI-PSS: Autobiographical Memory Interview - Perceived Stress Scale; AMI-E-PSS: Autobiographical
Memory Interview - Extended Version - Perceived Stress Scale; MD: mean dif ference; MMSE: Mini-Mental State Examinat ion; MOSES: Mult idimensional Observat ion Scale for
Elderly Subjects; QoL-AD: Quality of Life in Alzheimer’s Disease; RCT: randomised controlled trial; SES: Social Engagement Scale; SMD: standardised mean dif ference; SR-
QoL: Self -Report Quality of Life.
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded 1 level for imprecision because of small sample size (< 400 part icipants).
2Downgraded 2 levels for imprecision because of small sample size (< 400) and the conf idence interval including a null ef fect
and a lower lim it crossing -0.5.
3Downgraded 2 levels for inconsistency due to considerable unexplained heterogeneity.
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D I S C U S S I O N
Summary of main results
There has been a welcome increase in the volume of research on
reminiscence in dementia care (and an improvement in its qual-
ity) since this review was last updated. It has now been possible to
include large-scale multicentre RCTs, using clearly defined inter-
ventions and protocols. It has also been possible to exclude studies
where the risk of bias was rated as too high, without detracting
greatly from the volume of research considered. For several out-
comes, meta-analyses included 800 or more participants. For the
first time, it was possible to undertake analyses taking into account
different modalities of reminiscence work and different contexts.
Individual and group reminiscence work can now be considered
separately for several outcomes, and community studies distin-
guished from those carried out in care homes.
The primary finding of the review was that reminiscence work was
not associated consistently with improved well-being and QoL for
people with dementia assigned to receive it in research studies.
Although its clinical importance was uncertain, in care homes,
but not in community settings, there was a probable benefit on
QoL measures immediately following the reminiscence interven-
tion. This finding arose from ameta-analysis of three studies, from
different countries, involving 193 people with dementia. Notably,
in four of the five community studies in this analysis (and none
of the care home studies), the intervention involved joint group
sessions, where people with dementia and their family carers par-
ticipated together.
The extent to which reminiscence work would be predicted to
improve cognitive functioning is debatable, but this review pro-
vides evidence (across 14 studies involving 1219 people with de-
mentia) of a small benefit on cognitive tests evident immediately
following the reminiscence work, but not sustained after a longer
follow-up period. The analyses separating individual and group
reminiscence work indicated probable slight benefits in cognition
related to individual work. There was a probable slight benefit
to cognition in care homes but not the community. The overall
effect size for cognition at the end of treatment (SMD) was 0.11
(95% CI 0.00 to 0.23); the comparable SMD from the Cochrane
Review of cognitive stimulation (Woods 2012b) was 0.41 (95%
CI 0.25 to 0.57). However, a direct comparison of the subset of
studies using the MMSE in the two reviews indicated an MD of
1.74 points (95% CI 1.13 to 2.36), from 10 studies of cognitive
stimulation involving 600 participants, compared with an MD of
1.87 points (95% CI 0.54 to 3.20) for nine studies of RT involv-
ing 437 participants. This suggests the effects may be comparable
on the MMSE between the two types of interventions, but with a
wider CI for the reminiscence result.
The quality of evidence relating to the communication and in-
teraction outcome was lower, but there was probably a benefit of
RT at longer-term follow-up, albeit of uncertain clinical impor-
tance. The number of studies including a relevant outcome mea-
sure was smaller (six at end of treatment, four at follow-up, with
200 or more participants in each case), and the large studies of
joint (with carer) reminiscence work were among those without
a relevant outcome measure in this domain. Here, a probable ef-
fect was evident for community-based studies at end of treatment
and follow-up, but was even less certain in the care home context.
Group reminiscence was associated with a probable slight benefit
in communication immediately and a benefit within the clinically
important range at follow-up, whereas (in smaller studies) there
was considerable uncertainty in the results for individual reminis-
cence work.
Despite a body of evidence for the effects of reminiscence on de-
pressed mood in older people without dementia (e.g. Bohlmeijer
2003; Pinquart 2007), only individual reminiscence work was as-
sociated with a probable improvement in mood for people with
dementia in this review, and the size of the effect (SMD -0.41)
was relatively small and of uncertain clinical importance. There
were no indications of benefits associated with reminiscence work
in relation to the other outcomes examined for the person with
dementia. These included the person’s level of function, extent of
irritability and agitation, and their own rating of the quality of
relationship with their family carer. Despite the inclusion of sev-
eral large studies of joint reminiscence work, where family carers
were fully involved in the reminiscence sessions, we identified no
benefits for family carers in relation to reduced stress related to
caring, well-being and QoL, carer mood or the carer’s rating of the
quality of their relationship with the person with dementia. The
only exception to this was a single care home study, with 88 par-
ticipants, in which family carers probably experienced less stress
after their relative had been involved in reminiscence groups, both
immediately after treatment and at six months’ follow-up. Inter-
estingly, this was the only study to examine family carer outcomes
that did not have a focus on joint reminiscence work. There were
some suggestions from the REMCARE (REMiniscence groups for
people with dementia and their family CAREgivers) trial (Woods
2012a) of negative effects on carer anxiety, and this was evident
to an extent in the analyses combining data from several studies
of joint reminiscence work, where there was slightly higher carer
anxiety (a difference of uncertain clinical importance) at the seven
months’ follow-up assessment. One qualitative study explored po-
tential factors in increased anxiety among carers taking part in
joint reminiscence groups (Melunsky 2015). It identified issues
such as the carer feeling disappointed when improvements in the
group setting were not evident at home; the carer seeing people
withmore advanced dementia, resulting in increased fears for what
the future might hold; and increased guilt from not being able to
put into practice skills learned in the groups. These negative as-
pects were in the context of many positive experiences that carers
reported from participation in the groups for themselves and the
person with dementia.
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Overall completeness and applicability of
evidence
Although there is now a sufficient body of evidence to enable us
to draw conclusions regarding reminiscence work in general, it
remains difficult to consider fully different types of reminiscence
work. For example, studies of individual reminiscence work have
tended to be small-scale and carried out in care homes, so we could
not be certain of any difference in outcomes between individual
and group approaches. Related to this, we were unable to draw a
distinction in our analyses between simple and integrative remi-
niscence work. Although some studies have followed a very clear,
published treatment protocol, reporting of details of interventions
in other studies has been less complete, with even the distinction
between individual and group reminiscence not always immedi-
ately apparent.
Little evidence has emerged regarding the characteristics of people
with dementia thatmight be associatedwith better outcomes, with
the exception of the suggestion that reminiscence has a stronger
effect on QoL in a care home context, as opposed to community
settings. There clearly are differences between studies in the ex-
tent (and direction of changes) demonstrated by the high levels of
heterogeneity evident in several analyses. However, many of these
differences are yet to be explained. Some studies included only
people with AD; others only recruited people with VD; others
included any form of dementia. No clear differences in outcomes
related to dementia type emerged from the analyses undertaken,
and similarly there were few indications of the effects of dementia
severity.
It is unlikely that there is a simple ’dose’ related effect, in that
the studies offering the greatest exposure to reminiscence activ-
ities were among those with the least positive findings (Amieva
2016; Charlesworth 2016; Woods 2012a). However, within stud-
ies a ’dose’ effect may have operated. It is clear that in community
settings, a significant proportion of people randomised to receive
a reminiscence intervention did not engage with the groups. For
example, in Woods 2012a, 11% of participants did not attend a
single reminiscence session, with over 25% attending three ses-
sions or fewer. An even larger proportion of participants in the
Charlesworth 2016 study (43%) did not attend any reminiscence
sessions. In line with our protocol, we included the ITT results
in our analyses in this review. While it is important to know that
these groups may not, for a variety of reasons, be taken up by all
people with dementia and their carers, their results must under-
estimate any actual direct effects of reminiscence. For example,
in a compliance analysis, Woods 2012a showed an improvement
in cognitive function (AMI-E PSS) at the end of treatment and
improved QoL (European Quality of Life 5 Dimensions; EQ-
5D) and quality of relationship (QCPR) at longer-term follow-up,
but accompanied by an increase in carer stress (RSS). In contrast,
Charlesworth 2016 reported no relationship between attendance
and outcomes.
Quality of the evidence
There has been an overall significant improvement in the quality
of included studies since the previous version of this review was
undertaken. We are now able to include large-scale studies, over-
seen by accredited clinical trials units, with quality assurance pro-
cedures and well-developed remote randomisation procedures.
However,more generally, under-reporting of details of trialsmeant
that a number of authors had to be contacted for additional in-
formation regarding, for example, randomisation and allocation,
and several studies were excluded because of their risk of bias.
Some risks of bias arise from the nature of psychosocial interven-
tions such as RT. Participants and carers will be aware of the in-
tervention being received, and, in general single-blinding is the
aim, with assessors being blind to treatment allocation. However,
ratings completed by, for example, staff in care homes, may not
be blinded, and the blinding of assessors may be compromised
by participants and carers providing indications a treatment in-
tervention has been received. Studies such as Woods 2012a asked
assessors to indicate which group the participant was in, and their
degree of certainty of their judgement so that the extent of bias
could be estimated. Expectations of benefit from participation or
resentment at not being allocated to the active treatment may oc-
cur, and may produce some additional bias. Treatment expecta-
tions may be seen in the context of a pragmatic trial as part of the
overall ’treatment package,’ of course.
Potential biases in the review process
Our search strategy was as comprehensive as possible, and we
consulted with experts in the field to identify any further stud-
ies. Two review authors (LOP and EF) independently conducted
selection of studies, data extraction and risk of bias assessments,
and disagreements resolved by contacting authors and consulta-
tion with other members of the review author team. The present
review included all outcomes detailed in the protocol, irrespective
of whether or not the results identified improvements. It must be
acknowledged that the included studies could represent a biased
sample of the studies undertaken worldwide on RT. It may be the
case that trials that are not ’successful’ (i.e. do not produce the
expected positive findings) are less likely to be published. This
may be especially the case with smaller trials. The welcome trend
to preregistration of trials, and the publication of trial protocols,
makes this less likely to occur in the future in relation to larger,
well-funded trials. The meta-analyses here have been influenced
strongly by larger trials, several of which did not report any pos-
itive findings (e.g. Charlesworth 2016; Woods 2012a), but these
were both of a group approach, in community settings. Our care
home and individual reminiscence findings could perhaps have
been more influenced by publication bias. A funnel plot of cogni-
tion at the end of treatment showed some asymmetry (Figure 8),
but this was largely driven by smaller/lower quality community
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studies having positive findings, with care home studies showing a
symmetrical pattern. For most of our outcomes, there are too few
included studies for meaningful funnel plots to be plotted.
Figure 8. Funnel plot of comparison: 1 Reminiscence therapy versus no treatment, outcome: 1.5 Cognition
(overall) post-treatment.ADAS-Cog: Alzheimer’s Disease Assessment Scale for Cognition; AMI-PSS:
Autobiographical Memory Interview - Perceived Stress Scale; AMI-E-PSS: Autobiographical Memory
Interview Extended Version - Perceived Stress Scale; MMSE: Mini-Mental State Examination.
Agreements and disagreements with other
studies or reviews
We identified five reviews that overlap with this one.
Cotelli 2012 included seven RCTs, with 218 participants, three of
which were included in the current review. They identified some
benefits for mood and cognitive function but pointed out that the
number of trials ’remains very small and their quality is often poor’
(two were excluded from this review on the basis of risk of bias).
This review appeared to have predated the recent improvement in
quality and size of trials.
Subramaniam 2012 focused on individual reminiscence work,
identifying five RCTs, three of which were included in the current
review. They concluded that there was a consistent pattern emerg-
ing, with those studies offering ’individual reminiscence work that
includes a life review process, uses specific memory triggers and
results in the production of a life story book’ having positive psy-
chosocial outcomes for people with dementia. In contrast, where
reminiscence was more general, evidence for efficacy was not ap-
parent. Unfortunately, there are still insufficient studies of inte-
grative reminiscence work to confirm this early conclusion.
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Kwon 2013 reported a meta-analysis including 10 studies. The
studies included are not referenced, so comparisons were difficult.
They conclude that reminiscence had a positive effect on cogni-
tion, depression and QoL, all with large effect sizes, but not on
problem behaviour.
Testad 2014 reported a broader review relating to people with de-
mentia in care homes, with RT included as one of several psy-
chosocial interventions. They included six studies involving RT,
most of which did not meet the inclusion criteria for the current
review (e.g. three were not RCTs). The authors concluded that
reminiscence was associated with improved mood, but there was
no consistent evidence regarding other outcomes.
Huang 2015 included 12 studies, with 1325 participants. Cogni-
tion and depressed mood were the main outcomes studied, with
nine studies contributing to meta-analyses in each case. As with
the current review, they identified a small effect size for cognition
(SMD 0.18, 95% CI 0.05 to 0.30) but unlike the current review,
there was amoderate-sized effect for depressedmood (SMD -0.48,
95% CI -0.70 to -0.28). There was evidence that the effect on
mood was greater in care home settings than in the community,
which is in accordance with our results. Notably the community
studies included in the Huang 2015 review were all included in
this review, but there were differences in the care home studies
included, partly due to different exclusion criteria, but also be-
cause they were able to include studies published in Chinese. In
general, the current review has adopted stricter quality standards
than other reviews, and identified considerably more studies for
inclusion, across different modalities and settings.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Whilst this updated review has shown that reminiscence therapy
(RT) can improve outcomes for people with dementia, its effects
are inconsistent, often small in size and can differ considerably
across settings and modalities. The outcomes for which some ben-
efit has been identified are cognitive function, communication/in-
teraction, quality of life (QoL) and mood. However, the effects are
not consistent across different types of reminiscence work (group
or individual, with or without family carer involvement), or across
different contexts (care home or community), particularly where
QoL is the outcome. The evidence relating toQoL ismost promis-
ing in care homes; that relating to mood is most promising for
individual RT.
RT can now be viewed alongside cognitive stimulation as an
ecopsychosocial intervention with a credible evidence-base. Indi-
vidual and group approaches have some support, although the
two large, well-conducted UK studies of joint reminiscence group
work involving family members alongside people with dementia
have been the studies showing the smallest effects. Individual work
has the potential benefit of resulting in some form of life story
book, which provides a platform to enhance person-centred care.
However, to date it has not proven clearly superior to group work,
which may have added value in terms of enhancing interaction
and communication.
The lack of participation in the two UK studies of joint reminis-
cence work suggests that consideration should be given to offer-
ing it as one of a number of approaches, as participation does not
appear to be valued by a significant number of people with de-
mentia and carers. Where it is offered, benefits beyond the ’in the
moment’ enjoyment of a shared social group experience, should
not be anticipated as general outcomes.
The diversity of approaches to reminiscence seen in the various
studies suggests that there is a need for manuals and training to
be developed so that approaches can be more readily shared, and
common approaches developed, for both individual and group
work. It is essential that the different functions of reminiscence
and the different types of reminiscence work are recognised, to
aid sharing of good practice and understanding of the training,
support and resources needed for implementation.
Implications for research
The research agenda in relation to reminiscence work now needs
to address some of the discrepancies and uncertainties highlighted
by this review, and more fully reflect and identify the differences
in function and types of reminiscence work. A large scale ran-
domised controlled trial (RCT) of individual, integrative reminis-
cence work, producing a conventional or digital life story book,
would demonstrate whether the promising results from small stud-
ies could be replicated on a larger platform, with greater attention
to the detail of randomisation and allocation concealment. Such a
study should include enough people living with dementia in care
home and community settings, and with a range of severities of
impairment, so that more fine-grained conclusions may be drawn.
Research is also needed on the extent to which reminiscence work
can drive person-centred care, so that the person’s biography be-
comes a rich resource for planning and action.
There has been increasing interest in digital reminiscence work
(e.g. Subramaniam 2010; Subramaniam 2016), but to date there
have been no studies meeting the criteria for inclusion in the cur-
rent review. This is clearly an area where more research is justified,
in developing the intervention and then delineating its effects.
The research to date has emphasised changes beyond the group,
on measures carried out before and after a set number of rem-
iniscence sessions. More emphasis on the experience of people
with dementia (and carers) within the reminiscence session may
be helpful. Is each session an enjoyable experience in itself, even if
the lasting benefits are more elusive? Brooker 2000 used an obser-
vational method, Dementia Care Mapping, to demonstrate that
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people with dementia showed greater well-being when participat-
ing in simple reminiscence groups than when undertaking other
activities, and it would be helpful to take this ’in the moment’
evaluation approach further.
Finally, in view of the significant number of people not taking
up reminiscence interventions, research would be helpful delin-
eating who does take it up and why, and what type of approach
is beneficial for which people, so there can be better tailoring of
interventions to individuals.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akanuma 2011
Methods RCT.
Participants 24 care home residents with ischaemic VD according to ADDTC criteria with reference
to CT and MRI, scoring 10-24 on the MMSE. Care home situated in a rural area in
northern Japan
Mean age: 78.25 years.
Interventions Intervention: group RT.
Control: treatment as usual.
Outcomes Cognitive: MMSE.
Behavioural: BRSE.
Mood-related outcomes: GDS.
Length and frequency of intervention 1 hour per week for 3 months.
Time points measured Paper stated, “before and after the interventions.”
Number of participants who did not com-
plete study
0.
Notes Authors also measured PET and metabolic outcomes, voxel by voxel analysis, and ROI
analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Paper stated participants randomly assigned to 2 arms but did
not specify how
Allocation concealment (selection bias) Unclear risk Not specified, though paper reported the allocator was blind
when performing allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “the assessment of cognitive function and behavioral activities
was conducted by well-trained neuropsychologists who were
blinded to the assignment. Nursing staff engaged in daily care,
and who were blinded to the study protocol, assessed the pa-
tients’ behavioral activities.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk None.
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Akanuma 2011 (Continued)
Selective reporting (reporting bias) Low risk All outcomes listed in methods section were reported and there
was no evidence of selective outcome reporting
Other bias Low risk
Availability of training and supervision
Objective outcome measures
Unclear risk 3 specialists were part of each group (a psychologist, speech
therapist, and occupational therapist)
Availability of manual or protocol for in-
tervention
All outcomes
Low risk The facilitators followed a clear protocol detailed in Akanuma
2006.
Amieva 2016
Methods Multicentre RCT.
Participants 653 community-dwelling people who attended day centres or memory clinics in France,
diagnosed with AD, 16-26 on MMSE, 2-5 on GDS, and with an identified family carer
326 participants were in groups relevant to this review.
Mean age: 78.75 years
Interventions Intervention 1: group RT.
Control: treatment as usual.
Intervention 2: cognitive training (not included in the current review).
Intervention 3: individual cognitive rehabilitation (not included in the current review).
Outcomes Quality of life: QoL-AD.
Cognitive: MMSE, ADAS-Cog.
Behavioural: DAD, AGGIR.
Mood-related outcomes: Apathy Inventory, MADRS.
Carer outcomes: ZBI.
Length and frequency of intervention 1 × 90-minute session per week for the first 3 months, and once every 6 weeks for next
21 months
Time points measured Baseline, 3 months’ postbaseline (i.e. after the weekly sessions) and 24 months’ post-
baseline (i.e. after 6 weekly sessions)
(MMSE and GDS measures only taken/reported at 24 months).
Number of participants who did not com-
plete study
56/326 (17.18%).
Notes Primary outcome was rate of participants alive and without moderately severe to severe
dementia at 2 years. The NPI was also used
Risk of bias
Bias Authors’ judgement Support for judgement
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Amieva 2016 (Continued)
Random sequence generation (selection
bias)
Low risk “The list of randomization was prepared by a statistician using
permuted blocks, stratified by site.”
Allocation concealment (selection bias) Low risk Participants randomised through an independent and remote
telephone randomisation service provided by the clinical trial
unit
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All assessment interviews done by physicians and psychologists
blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 33 dropouts from RT and 23 from control group. Paper dis-
tinguished between participants who died and participants who
withdrew, though specific reasons for these withdrawals were not
reported. Results from a ’Missing Equals Failure’ analysis was
carried out
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a
Availability of training and supervision
Objective outcome measures
Low risk All therapists received a 3-day training session where the therapy
programmes were thoroughly presented. Therapists were given
contact details for the researchers who designed the programmes
so they could contact them if necessary
Availability of manual or protocol for in-
tervention
All outcomes
Low risk “Each therapy program was developed according to current sci-
entific data, standardized by a leader known to have scientific
and clinical expertise in the field. To guarantee homogeneity in
the way interventions were applied, a standardized procedure
was followed.” Therapists were given a manual detailing the in-
tervention
Azcurra 2012
Methods RCT.
Participants 135 participants from privately funded nursing homes in Argentina, with a diagnosis of
AD according to DSM-IV
90 participants were in groups relevant to the current review.
Mean age: 85 years.
Interventions Intervention 1: group RT.
Control: unstructured social contact.
Intervention 2: counselling (not included in the current review).
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Azcurra 2012 (Continued)
Outcomes Quality of life: SR-QoL, WIB.
Communication: SES.
Behavioural: ADL scale.
Carer: ZBI.
Length and frequency of intervention 1 hour twice per week for 12 weeks.
Time points measured Paper stated, “The data were collected at baseline (T0), twelve weeks (T1), and six
months post-intervention (T2).”
Number of participants who did not com-
plete study
5/90 (5.56%).
Notes Some participants were on psychotropic medication and physically restrained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised block design. Participants meeting enrolment cri-
teria were randomly allocated to 1 of 3 groups by the assignment
of a unique kit number using a permuted block design at each
investigational site (block size of 6) (stated by e-mail)
Allocation concealment (selection bias) Low risk Paper reported, “we used an appropriate method of randomisa-
tion with adequate concealment of the participant allocation to
treatment groups.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Independent raters (social workers) completed outcome mea-
sures blinded to group allocation. The facilitators carrying out
the intervention blinded to the outcome measures
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis.
Missing data replaced with the mean value of the outcome vari-
ables for each group
Withdrawals due to death, moving and believing their allocated
condition (control) was “useless.”
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Team trained by principal investigator to deliver the correspond-
ing sessions in a structured manner. Facilitators had 15 training
sessions totalling 30.4 hours
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Azcurra 2012 (Continued)
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Clear protocols developed in the training sessions.
Baines 1987
Methods RCT.
Cross-over design.
Participants 15 people living in a care home with moderate to severe impairment of cognitive func-
tioning, as measured using the CAPE
10 of these participants were in groups that were included in the current review.
Mean age: 81.5 years.
Interventions Intervention 1: group RT.
Control: no treatment.
Intervention 2: reality orientation(not included in the current review).
Outcomes Quality of life: Life Satisfaction Index.
Cognitive: CAPE (information/orientation subscale).
Communication: Holden Communication Scale.
Behavioural: CAPE (behaviour subscale).
Length and frequency of intervention 30 minutes per day, 5 days per week, for 4 weeks.
Time points measured Before and immediately after the 4-week intervention.
Number of participants who did not com-
plete study
0/10 (from groups relevant to the current review).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Paper stated, “participants were randomly assigned to one of
three groups,” but did not report method used
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessments made by an independent psychologist, and staff
who knew the residents well, but were not involved with the
therapy groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk n/a.
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Baines 1987 (Continued)
Selective reporting (reporting bias) Low risk All outcomes listed in themethods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Paper reported, “preliminary training for staff included six
hours of introductory talks, videos, discussions and hand
outs.” Staff training was carried out by a clinical psychologist
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Paper reported, “the reminiscence therapy sessions were
based on the format suggested by Andrew Norris (Norris
1986).”
Charlesworth 2016
Methods Factorial pragmatic RCT.
Participants 291 community-dwelling people in the UK, with a diagnosis of dementia according to
DSM-IV and their family carers
144 participants were in groups relevant to the current review
Mean age: 74.21 years.
Interventions Intervention 1: group reminiscence (RYCT) for people with dementia and their carers
(RYCT program)
Control: treatment as usual
Intervention 2: carer support programme.
Intervention 3: both intervention 1 and intervention 2
The current review used data from participants in the RYCT (only) and treatment as usual
(only) groups.
Outcomes Quality of life: QoL-AD, EQ-5D, DEMQOL.
Behavioural: ADCS-ADL.
Mood-related outcomes: HADS, NPI, QCPR.
Carer: mental component score of the UK Short Form-12 Health Survey (UK SF-
12), EQ-5D, HADS, Emotional Loneliness Scale, NPI-D, PANAS, COPE-PAC, PGI,
QCPR
Length and frequency of intervention 1 session, 2 hours per week, for 12 weeks. After the weekly sessions, monthly sessions
continued for 7 months, giving a possible 19 sessions over 10 months
Time points measured Baseline, 5 months’ postrandomisation and 12 months postrandomisation
Number of participants who did not com-
plete study
50/291 (17%); across all groups, including those not relevant to the current review.
Specific attrition for each group not reported
Notes In group reminiscence sessions, family carers met separately from the main group for
45 minutes during 4 sessions, with the aim of developing listening and communication
skills, and considering how the activities and strategies in the sessions could continue at
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Charlesworth 2016 (Continued)
home
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A 2-stage sequential dynamic algorithm was used to ran-
domise participants. Randomisation was web based and was
developed in collaboration with an accredited trials unit
Allocation concealment (selection bias) Low risk The combination of the 2 randomisation stages resulted in
participant allocation. An (unblinded) administrator then
informed carers of their allocation by letter
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All research interviewers who assessed outcomes were
blinded. After interview, researchers recorded their percep-
tions of participants’ allocation. This showed no evidence
of bias due to non-blinded researchers
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors reported “missing scores were imputed, with
multiple imputations calculated using a linear regression
model, taking into account demographic variables, treat-
ment group and other scores provided at a given time point.
”
Withdrawals due to carer time constraints, poor health of
carer or relative with dementia. Specific dropouts from each
group not reported
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section and study pro-
tocol were reported. There was no evidence of selective out-
come reporting
Other bias Unclear risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Trial protocol reported “each group session is led by two
experienced facilitators, supported by a team, including vol-
unteers, health and social care staff and trainees to facilitate
small group discussion and activities and engage the people
with dementia. All members of the RYCT team attended a
training day led by one of the original RYCT programme
authors.”
Availability of manual or protocol for in-
tervention
All outcomes
Low risk The group reminiscence intervention followed the RYCT
programme for people with dementia and their family carers
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Goldwasser 1987
Methods RCT.
Participants 30 participants with clinical diagnosis of dementia based on subjective criteria and
MMSE scores. Recruited from a single nursing home in Virginia, USA
20 participants were in groups relevant to this review.
Mean age: 82.3 years.
Interventions Intervention: group RT.
Control: no treatment.
Supported group therapy (not included in this review).
Outcomes Cognitive: MMSE.
Behavioural: Katz Index Activities of Daily Living.
Mood-related outcomes: Beck Depression Inventory.
Length and frequency of intervention 30 minutes, twice per week, for 5 weeks.
Time points measured Preintervention, 1 week’ postintervention and 5 weeks’ postintervention
Number of participants who did not com-
plete study
2/20 (10%).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method unspecified, though paper stated, “thirty participants
were initially selected...and randomly assigned to three groups
of ten people.”
Allocation concealment (selection bias) Unclear risk No details given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessments carried out by a psychology graduate, a registered
nurse and a ’practical nurse,’ none of whom were aware of the
groups to which participants were assigned. As staff were in-
volved in carrying out the intervention, there may have been a
risk of contamination
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 person in the intervention group died so the authors randomly
excluded 1 person from each of the other 2 groups
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Unclear risk n/a.
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Goldwasser 1987 (Continued)
Availability of training and supervision
Objective outcome measures
Unclear risk Not formally specified in paper but facilitators seemed to have
been coached on some factors, such as rapport, “non-verbal ex-
pression” and ways to “help participants generate internal cues.
”
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Paper reported that a structured reminiscence protocol was de-
veloped with user involvement
Gonzalez 2015
Methods Cluster RCT.
Participants 42 participants with a diagnosis of AD living in 2 nursing homes in Valencia, Spain.
Diagnosis determined by DSM-IV-TR, MMSE < 23 and impairment on a neuropsy-
chological examination
Mean age: 80.24 years.
Interventions Intervention: group integrative reminiscence programme.
Control: treatment as usual.
Outcomes Quality of life: Ryff Psychological Well-Being scales.
Cognitive: MMSE (Spanish Version).
Mood-related outcomes: CES-D.
Length and frequency of intervention 10 weekly sessions, each lasting 60 minutes.
Time points measured Pretest (2 weeks before the intervention) and post-test (immediately after intervention)
Number of participants who did not com-
plete study
0/42.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Cluster randomisation. “Nursing homes were randomised to de-
termine where the intervention programwould be administered.
” No explanation was given of the randomisation procedure
Allocation concealment (selection bias) Unclear risk No details given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who administered assessments.
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Gonzalez 2015 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk n/a.
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Unclear risk Cluster RCT. The study had 2 clusters but was not large enough
to apply the methods detailed in the Cochrane Handbook for
Systematic Reviews of Interventions to reduce it to its effective
sample size.No evidence of baseline imbalanced,missing clusters
from the analysis or recruitment bias
Availability of training and supervision
Objective outcome measures
Unclear risk Programme led by a psychologist but no information regarding
current/previous training/supervision
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Paper stated that the authors “implemented a programme based
on earlier research.” No manual but paper described detailed
aims and activities for each individual session
Haight 2006
Methods RCT.
Participants 30 participants with dementia diagnosis (no diagnosis specification) recruited from 6
care homes in Northern Ireland
Age range: 60-99 years.
Interventions Intervention: individual life review with the production of a Life Story Book
Control: treatment as usual.
Outcomes Cognitive: MMSE.
Communication: COS.
Behavioural: MBS, FIM.
Mood-related outcomes: CSDD, AMS.
Length and frequency of intervention 1 hour per week for 6 weeks.
Time points measured Baseline and 8 weeks’ postbaseline.
Number of participants who did not com-
plete study
0.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Haight 2006 (Continued)
Random sequence generation (selection
bias)
Low risk Authors stated by e-mail that residents were randomised to each
condition by blinded researchers
Allocation concealment (selection bias) Unclear risk Unclear.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk n/a.
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Existing care home staff delivered the intervention. They en-
gaged in 2 hours of preliminary training + weekly supervision
with the researchers accounting for 10 hours of ongoing training
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Used The Life Review Experiences Form (Haight 1992).
Hsieh 2010
Methods RCT.
Participants 61 residents from 2 nursing homes in Northern Taiwan diagnosed with dementia using
the DSM-IV
Mean age: 77 years.
Interventions Intervention: group RT.
Control: no treatment.
Outcomes Mood-related outcomes: GDS, AES-C, NPI (Apathy subscale and Depression subscale)
Length and frequency of intervention 1 × 40- to 50-minute session per week for 12 weeks.
Time points measured Baseline and postintervention (12 weeks’ postbaseline).
Number of participants who did not com-
plete study
5/61 (8.2%).
Notes
Risk of bias
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Hsieh 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated that participants were randomised to either control or
treatment condition. Method not specified. Attempted to con-
tact author but no response received
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nursing home staff completed the NPI. Single investigator ad-
ministered the other scales but no details regarding blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4 withdrawals from intervention group and 1 from control
group. 1 participant died but no reasons given for the with-
drawal of the other 4 participants. Authors carried out analysis
with remaining 56 participants
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Unclear risk Not specified, though research teams who specialised in geriatric
psychiatric nursing served as leaders and coleaders in the inter-
vention group
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Paper stated, “the components of all the sessions had clear struc-
tures and guidelines for the leaders and co-leaders to facilitate
the group interventions’ and a ’research protocol was designed
to include 18 activities suitable for all elderly patients residing
in long-term care.”
Ito 2007
Methods RCT.
Participants 60 participants with clinical diagnosis of VD recruited from 2 nursing homes and 1
hospital in Japan
40 were in groups that were included in the current review.
Mean age: 82 years.
Interventions Intervention 1: group RT.
Control: supportive care.
Intervention 2: social contact (not included in this review).
Outcomes Cognitive: MMSE (Japanese Version), CASI.
Mood-related outcomes: MOSES.*
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Ito 2007 (Continued)
Length and frequency of intervention 1 hour per week for 12 weeks.
Time points measured Paper stated, “before and after the interventions.”
Number of participants who did not com-
plete study
6/40 (15%) (from groups relevant to the current review).
Notes *MOSESdata not included as no subscale data available, only the overall score.Contacted
author by email requesting further information but we have not received a response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 2-step randomised allocation of participants stratified by age
and education conducted by blinded researchers. Groups of 12
participants randomly divided into 3 subgroups by a computer,
based on education and age. Subgroups were then randomly
allocated to 3 arms by blinded researchers
Allocation concealment (selection bias) Low risk Group allocation. Paper reported allocators were blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessments were carried out by neuropsychologists blinded to
group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants dropped out of both the control and reminiscence
groups. Attrition due to ill health or transfer out of the care
home. 1 participant withdrew consent. Data from the ITT anal-
ysis was not extractable. Instead, authors extracted data from the
per protocol analysis
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Unclear risk Not specified though paper reports each group included a care
provider and 3 specialists, who were chosen among a psychol-
ogist, 2 speech therapists, 3 occupational therapists, 3 medical
social workers and a nurse
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Paper provided detailed schedule for each session and was based
on that proposed by Akanuma and colleagues (Akanuma 2006)
.
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Lai 2004
Methods RCT.
Participants 101 participants with a diagnosis of dementia according to the DSM-IV recruited from
2 nursing homes in Hong Kong
66 of these were in groups that were included in the present review. The remainder were
in a comparison group.
Mean age: 85.7 years.
Interventions Intervention 1: individual RT (specific reminiscence and life story)
Control: no treatment.
Intervention 2: social support (not included in this review).
Outcomes Quality of life: WIB.
Cognitive: MMSE (Cantonese Version).
Communication: SES.
Behavioural: Minimum Data Set - Activities of Daily Living.
Length and frequency of intervention 1 × 30-minute session per week for 6 weeks.
Time points measured Assessments carried out immediately before and after the 6-week treatment period, and
at 6 weeks’ follow-up
Number of participants who did not com-
plete study
10/66 (15.15%) (from groups relevant to the current review).
Notes Most participants were restrained either intermittently or continuously
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Paper stated that participants were randomly assigned to groups
using fixed random allocation methods
Allocation concealment (selection bias) Unclear risk No details.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Raters and assessors blinded to participant allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT and per protocol analysis reported in study paper. Authors
extracted data from the ITT analysis
Reasons for withdrawal included participants being wrongly in-
cluded, ill health, death or participant feeling depressed during
the sessions
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
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Lai 2004 (Continued)
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Interventions delivered by professional staff with additional
training
Mean number of hours of training provided to assessors was 25
(SD 3.6)
Availability of manual or protocol for in-
tervention
All outcomes
Low risk The development, testing and refining of the intervention pro-
gramme took place in 5 cycles. The contents of an LSB as pro-
posed by Hellen 1998 were adopted.
Melendez 2015
Methods Cluster RCT.
Participants 30 participants with AD according to DSM-IV with MMSE scores < 19 who were
attending day centres in Valencia, Spain
Mean age: 84.2 years.
Interventions Intervention: group RT.
Control: treatment as usual.
Outcomes Cognitive: AMI.
Length and frequency of intervention 2 × 30-minute sessions per week for 10 weeks.
Time points measured Paper stated, “pre-test, post-test and 2-month follow-up tests were performed.”
Number of participants who did not com-
plete study
2/30 (6.66%).
Notes Study also recruited participants with amnestic MCI but data from these participants
were excluded from the present review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Cluster randomisation. Paper reported, “The day centres were
randomised to determine where the intervention programme
would be administered. To randomise the groups, the names
of centres were introduced into a spreadsheet and programme
output file presented name of centre to receive treatment.”
Allocation concealment (selection bias) Low risk Randomised on level of day centre. Allocation decided using
spreadsheet and corresponding programme output file
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Melendez 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear who interviewed participants, but they were recorded
and 2 psychologists then independently analysed the scores
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant from each group dropped out. The participant
from the reminiscence intervention left the day centre to be “in-
stitutionalised.” Reason for control drop out unspecified. ITT
analysis completed
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Unclear risk Cluster RCT. The study had 2 clusters but was not large enough
to apply the methods detailed in the Cochrane Handbook for
Systematic Reviews of Interventions to reduce it to its effective
sample size.No evidence of baseline imbalanced,missing clusters
from the analysis or recruitment bias
Availability of training and supervision
Objective outcome measures
Low risk Led by a psychologist. Author stated by email that “an official
master gerontologist” oversaw the teaching and training of the
reminiscence processes
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Clear protocol outlined in the paper.
Morgan 2012
Methods RCT.
Participants 17 participants living in care homes in North Wales with mild to moderate dementia
(CDR used to determine severity)
Mean age: 80 years.
Interventions Intervention: structured individual life review.
Control: treatment as usual.
Outcomes Cognitive: AMI.
Mood-related outcomes: GDS-SF.
Length and frequency of intervention 30- to 60-minute session once per week for 12 weeks (or more, depending on progress
through the Life Review Experiencing Form, Haight 1992).
Time points measured Baseline, postintervention and 6 weeks’ postintervention.
Number of participants who did not com-
plete study
0/17.
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Morgan 2012 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Paper reported, “initial participants were randomly assigned al-
ternately to the groups. Subsequent participants were allocated
using the randomisation by minimization method (Altman
2005), which allocates the next participant in the trial according
to the characteristics of those already participating, so that each
allocation reduces any imbalance in the stratifying variables...
even when the sample size is small.”
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Half of the measures taken by primary researcher, unblinded to
allocation, the other half taken by blinded assistant psychologist.
There were no significant differences in scores of those assessed
by the researcher and the blind assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk n/a.
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Therapist was a clinical psychologist in her final year of doctoral
training under supervision of an experienced clinical psycholo-
gist. Total training time not specified
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Structured life review based on Haight’s Life Review Experience
form (Haight 1992).
O’Shea 2014
Methods Cluster RCT.
Participants 304 long-stay care home residents in Ireland living with dementia according to DSM-IV
or any other diagnosis by a clinician, nurses judgement, nurses records (or a combination)
or prescribed any medication for AD
Mean age: 85.4 years.
Interventions Intervention: group RT.
Control: treatment as usual.
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O’Shea 2014 (Continued)
Outcomes Quality of life: QoL-AD.
Behavioural: Cohen Mansfield Agitation Inventory.
Mood-related outcomes: CSDD.
Carer: Modified ZBI.
Length and frequency of intervention 3-4 sessions per week for a mean of 14 weeks (range 12-17 weeks). Session duration
unspecified
Time points measured Baseline and 18-22 weeks’ postrandomisation.
Number of participants who did not com-
plete study
76/304 (25%).
Notes Approximately 75% of care homes recorded close to the mean target of 3 or 4 sessions
per week
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation at the level of the long-stay residential unit
Randomisation was on a ratio of 1:1 and was stratified by pub-
lic and private residential units (one-third public to two-thirds
private, reflecting the overall distribution of beds in the region)
Allocation concealment (selection bias) Low risk Concealment of group allocation achieved by giving the respon-
sibility for sequence generation and group allocation to a re-
searcher who was independent of the study and its investigators
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Research nurses involved in data generation and collection were
blinded to group allocation of participating units. Data analy-
sis undertaken by researchers and statisticians blinded to group
allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 25 residents lost to follow-up in intervention group (18 died,
1 was transferred, 2 in hospital, 1 withdrew and 3 too ill to
participate) and 27 in control group (18 died, 3 too ill, 2 in
hospital and 1 was transferred)
Paper reported that all results were insensitive to the inclusion of
missingdata usingmultivariate imputationby chained equations
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section and study protocol
were reported and there was no evidence of selective outcome
reporting
Other bias Low risk Cluster RCT. 18 clusters (9 intervention and 9 control). Al-
though study authors analysed data appropriately, review au-
thors needed to extract data (from a table) that did not account
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O’Shea 2014 (Continued)
for clustering. The study authors reported the ICC for eachmea-
sure, which the review authors extracted and used to calculate the
effective sample size to enter into Review Manager 5 (RevMan
2014). No evidence of recruitment bias or missing clusters after
randomisation. Cluster-specific baseline adjustment was imple-
mented to prevent baseline imbalance creating bias
Availability of training and supervision
Objective outcome measures
Low risk Staff training involved a structured education programme, facil-
itated by experienced nurse educators, delivered over 3 days and
augmented by telephone support and onsite visits
Availability of manual or protocol for in-
tervention
All outcomes
Low risk A structured education programme for staff was delivered and
staff were trained in intervention design. Staff target was 1
planned formal session and 3 spontaneous sessions per week
Subramaniam 2013
Methods RCT.
Participants 24 participants with dementia as assessed by DSM-IV recruited from care homes in
North Wales, UK
Mean age: 86 years.
Interventions Intervention: individual life review/life story book (participants were involved in the
creation)
Control: life story book given to participants as a gift 12 weeks into the intervention
(just after post-treatment assessment)
Outcomes Quality of life: QoL-AD.
Cognitive: AMI-E.
Mood-related outcomes: GDS.
Carer: QCPR.
Length and frequency of intervention 1 hour per week for 12 weeks. Mean of 12 sessions (range 11-16)
Time points measured Baseline (T0), 12 weeks’ postbaseline (T2) and 6 weeks later (T3)
(T3 data not included in this review*).
Number of participants who did not com-
plete study
1/24 (4.17%).
Notes *Data fromT3 not included in the current review as participants in the control condition
were given life story books and used them between T2 and T3. Once they received their
books, the control condition was no longer treatment as usual or passive
Risk of bias
Bias Authors’ judgement Support for judgement
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Subramaniam 2013 (Continued)
Random sequence generation (selection
bias)
Low risk Participants were allocated using a sequential individual-based
randomisation, which randomised participants into parallel
groups using a dynamic stratification algorithm. The randomi-
sation process was carried out by an accredited clinical trials unit
Allocation concealment (selection bias) Low risk Randomisation process was undertaken by an accredited trials
unit
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome measures carried out by 2 assessors blinded to treat-
ment allocation with no other involvement in the process of the
research
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant died part way through the trial, their data were
excluded
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Therapist was a clinical psychologist trained in reminiscence
work. Weekly supervision was provided with consultant clinical
psychologist
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Life review intervention was based on Haight’s Life Review
model and Life Review Experiencing Form (Haight 1992).
Särkämö 2013
Methods RCT.
Participants 89 participants with mild-to-moderate dementia (assessed using CDR) recruited as per-
son with dementia - carer dyads from day units and inpatient facilities in Finland
Of these, 59 dyads belonged to groups relevant to the current study
Mean age: 78.91 years.
Interventions Intervention: music listening and reminiscing in a group setting
Control: care as usual.
Outcomes Quality of life: QoL-AD and Cornell-Brown Scale for Quality of Life in Dementia
Cognitive: MMSE, Frontal Assessment Battery and Modified Version of the Autobio-
graphical Fluency Task
Carer: ZBI, GHQ-12.
Length and frequency of intervention 1.5 hours per week for 10 weeks.
Time points measured Baseline, postintervention (3 months from baseline) and 9 months postbaseline
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Särkämö 2013 (Continued)
Number of participants who did not com-
plete study
9/57 (13.56%).
Notes Study also contained a singing coaching group (27 dyads). Data from these participants
were not included in the current review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation carried out by a blinded staffmember using
a random number generator
Allocation concealment (selection bias) Low risk An independent researcher was responsible for sequence gener-
ation and group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All assessments were carried out blinded to the group allocation
of the participants
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 participants dropped out from the intervention group and 7
from the control group. Reasons for withdrawals were not given.
Authors analysed the datawith the remainingparticipants. There
were no statistically significant differences between participants
who completed the study and who dropped out
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Paper reported that sessions were led by a trainedmusic therapist
Availability of manual or protocol for in-
tervention
All outcomes
Low risk The paper detailed each session clearly.
Tadaka 2007 (AD)
Methods RCT.
Participants 24 participants from a geriatric health services facility in Tokyo, Japan with a diagnosis
of AD according to the DSM-IV
Mean age: 81.85 years.
Interventions Intervention: group RT.
Control: treatment as usual.
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Tadaka 2007 (AD) (Continued)
Outcomes Cognitive: MMSE.
Communication: MOSES (Withdrawal subscale).
Behavioural: MOSES (Irritability subscale).
Mood-related outcomes: MOSES (Depression subscale).
Length and frequency of intervention 1 × 60- to 90-minute session per week for 8 weeks.
Time points measured Baseline, immediately postintervention and 6 months postintervention
Number of participants who did not com-
plete study
4/24 (16.67%).
Notes Study also investigated effects of RT on 36 people with VD (Tadaka 2007 (VD)).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list within each subset of
dementia type (AD or VD)
Allocation concealment (selection bias) Low risk 2 social workers from the facility with no connection to the study
allocated participants based on the computer-generated list
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk MMSE administered by a psychiatrist blinded to the allocation
of participants at all 3 time points
MOSES was completed by family members who were not
blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Per protocol analysis.
1 dropout from reminiscence group and 3 from control group.
All 4 dropped out because they were admitted to hospital
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk ’Specialists were trained public health nurses or clinical psychol-
ogists who hadMA or PhD degrees and several years’ experience
in the care of elderly people with dementia and trained in the
reminiscence group program techniques. Specialists performed
roles of group leader or co-leader to facilitate the reminscence
group program’
Availability of manual or protocol for in-
tervention
All outcomes
Low risk No evidence of a written protocol or manual although a clear
structure was described in the paper
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Tadaka 2007 (VD)
Methods RCT.
Participants 36 participants from a geriatric health services facility.
Diagnosis of VD according to the DSM-IV.
Mean age: 84.25 years.
Interventions Intervention: structured group RT.
Control: treatment as usual.
Outcomes Cognitive: MMSE.
Communication: MOSES (Withdrawal subscale).
Behavioural: MOSES (Irritability subscale).
Mood-related outcomes: MOSES (Depression subscale).
Length and frequency of intervention 1 × 60- to 90-minute session per week for 8 weeks.
Time points measured Prior to intervention, immediately postintervention and 6 months postintervention
Number of participants who did not com-
plete study
6/36 (16.67%).
Notes Study also investigated effects of RT on 24 people with AD (Tadaka 2007 (AD)).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list within each subset of
dementia type (AD or VD)
Allocation concealment (selection bias) Low risk 2 social workers from the facility with no connection to the study
allocated participants based on the computer-generated list
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk MMSE administered by a psychiatrist blinded to the allocation
of participants at all 3 time points
MOSES completed by family members who were not blinded
to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Per protocol analysis. 3 dropouts from intervention group and
3 from control group. 1 participant from each group died while
the other 4 were admitted to hospital
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
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Tadaka 2007 (VD) (Continued)
Availability of training and supervision
Objective outcome measures
Low risk ’Specialists were trained public health nurses or clinical psychol-
ogists who hadMA or PhD degrees and several years’ experience
in the care of elderly people with dementia and trained in the RT
group program techniques. Specialists performed roles of group
leader or co-leader to facilitate the reminsicence group program’
Availability of manual or protocol for in-
tervention
All outcomes
Low risk No evidence of a written protocol or manual, although a clear
structure was described in the paper
Thorgrimsen 2002
Methods RCT.
Participants 11 community-dwelling dyads (11 people with dementia and their carers) who had
been referred to a RYCT reminiscence group by community psychiatric nurses and
occupational therapists. No other diagnostic information specified.
Mean age of person with dementia: 76.3 years.
Interventions Intervention: joint reminiscence groups for the person with dementia and their carers
Control: no treatment.
Outcomes Quality of life: QoL-AD.
Cognitive: MMSE.
Communication: Holden Communication Scale.
Behavioural: CAPE-BRS.
Carer: GHQ-12, Relatives Stress Scale.
Length and frequency of intervention Programme comprised 18 weekly reminiscence sessions, 11 of which were attended only
by the informal carers and the volunteers involved in the project
Time points measured Baseline and 1 follow-up 18 weeks postbaseline assessment.
Number of participants who did not com-
plete study
2/22 (9.09%), i.e. 1 dyad.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to the intervention and control
groups using sealed envelopes
Allocation concealment (selection bias) Low risk Used sealed envelopes.
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Thorgrimsen 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor blind to group allocation. Participants were informed
about the importance of the assessor being blind with respect to
group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data excluded for missing dyad.
Dropout due to ill health of person with dementia.
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Age Exchange (internationally known for its work in all areas of
reminiscence) conducted the intervention. Carers were taught
the applications of reminiscence by Age Exchange in 11 weekly
sessions
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Intervention was the RYCT programme, based on the standard-
ised manual Reminiscing with People with Dementia - a Hand-
book for Carers (Bruce 1999).
Van Bogaert 2016
Methods RCT.
Participants 72 care home residents with a diagnosis of dementia according to the DSM-V criteria
and MMSE of 10-24
Mean age: 83.75 years.
Interventions Intervention: individual reminiscence based on the SolCos Model
Control: treatment as usual.
Outcomes Cognitive: MMSE, Frontal Assessment Battery.
Mood-related outcomes: CSDD.
Other: NPI.
Length and frequency of intervention 2 × 45-minute sessions per week for 8 weeks.
Time points measured Preintervention (week 0) and postintervention (week 9).
Number of participants who did not com-
plete study
12/72 (16.66%).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Van Bogaert 2016 (Continued)
Random sequence generation (selection
bias)
Low risk Participants were randomly selected into the intervention group
or control group using sequentially numbered, opaque sealed
envelope for each resident
Allocation concealment (selection bias) Low risk A person not involved with the study divided the envelopes into
2 blinded boxes manually and randomly
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A researcher who was not involved with any aspect of the inter-
vention programme, collected the study participants’ assessment
scales and other data before and after the trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12 withdrawals (7 from intervention group and 5 from control
group) because of sudden illness leading to admission to hospital
(1) or palliative care (1) and death (6), disruptive or aggressive
behaviour during the sessions (2) and withdrawal of consent
after baseline (2)
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section and study protocol
were reported. No evidence of selective outcome reporting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk 1 researcher ran a training programme with 18 nursing home
volunteers as facilitators. This researcher also provided support
and advice to the facilitators throughout the intervention
Availability of manual or protocol for in-
tervention
All outcomes
Low risk The standardised individual reminiscence intervention was
based on the SolCos model (Soltys 1994). A clear and standard-
ised structure was reported in the paper
Woods 2012a
Methods Multicentre RCT.
Participants 488 participants living in the community meeting DSM-IV criteria for dementia. Par-
ticipants participated in dyads with informal carers, most of whom were spouses
Mean age: 77.5 years.
Interventions Intervention: joint reminiscence groups for the person with dementia and their carer
Control: treatment as usual.
Outcomes Quality of life: QoL-AD, QCPR, EQ-5D.
Cognitive: AMI-E.
Behavioural: BADLS.
Mood-related outcomes: CSDD, RAID.
Carer: GHQ-28, HADS, RSS, QCPR, EQ-5D.
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Woods 2012a (Continued)
Length and frequency of intervention 1 × 2-hour session per week for 12 weeks followed by 1 maintenance session per month
for 7 months
Time points measured Baseline before randomisation, 3 months postbaseline (following completion of the
weekly reminiscence sessions) and 10 months postbaseline (following completion of the
monthly maintenance reminiscence sessions)
Number of participants who did not com-
plete study
138/488 dyads (28.28%).
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was completed using a dynamic allocation
method stratifying for spousal or non-spousal relationship of the
dyad. Complete list randomisation for each wave of recruitment
within each centre was completed by an accredited trials unit
Allocation concealment (selection bias) Low risk By undertaking a complete list randomisation for each wave at
each centre, allocation knowledge of the next assignment would
be irrelevant as all participants for a centre would be randomised
together
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unblinded researchers (responsible for allocation and running
sessions) were the only staff informed at each of the centres of the
participant’s allocation. Researchers blinded to group allocation
carried out all follow-up assessments
Incomplete outcome data (attrition bias)
All outcomes
Low risk 137 total withdrawals from trial including 29 deaths. Reasons
included death, ill health, no wish to continue, family circum-
stances, no time and no reason given. 1 dyad was excluded due
to re-recruitment. A linear regression model was applied to take
missing data into account
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section and study protocol
were reported. There was no evidence of selective outcome re-
porting
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk 2 × half day training sessions for volunteers and facilitators took
place before each group commenced
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Woods 2012a (Continued)
Availability of manual or protocol for in-
tervention
All outcomes
Low risk Intervention followed the RYCT manual.
Yamagami 2012
Methods RCT.
Participants 54 participants from 4 residential care homes in Japan with a diagnosis of dementia
Mean age: 85.2 years.
Interventions Intervention: group RT.
Group: no treatment.
Outcomes Cognitive: CDR-SB, Hasegawa Dementia Scale Revised.
Communication: MOSES (Withdrawal subscale).
Behavioural: MOSES (Irritability subscale).
Mood-related outcomes: MOSES (Depression subscale).
Length and frequency of intervention 1 hour, twice per week, for 12 weeks.
Time points measured Paper described, “before test and after test.”
Number of participants who did not com-
plete study
1/54 (1.85%).
Notes Paper reported intervention “Brain Activating Rehabilitation” but inspection of paper
indicates that this was mainly reminiscence activities)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly allocated to conditions, stratifying
for severity of dementia. No further details
Allocation concealment (selection bias) Unclear risk No details.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Paper reported, “care staff who did not participate in the inter-
vention primarily evaluated participants.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant dropped out of the control group due to sickness.
Analysis carried out with 53 remaining participants
Selective reporting (reporting bias) Low risk All outcomes listed in the methods section were reported and
there was no evidence of selective outcome reporting
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Yamagami 2012 (Continued)
Other bias Low risk n/a.
Availability of training and supervision
Objective outcome measures
Low risk Paper reported that staff of each residential care home had stud-
ied the principles of the intervention and received 4 hours train-
ing. After each session of the intervention, an evaluation meet-
ing was held to improve the skills of the staff
Availability of manual or protocol for in-
tervention
All outcomes
Low risk No evidence of amanual although a clear structure was described
in paper
AD: Alzheimer’s disease; ADAS-Cog: Alzheimer’s Disease Assessment Scale for Cognition; ADCS-ADL: Alzheimer’s Disease Cooper-
ative Study - Activities of Daily Living; ADDTC: Alzheimer’s Disease Diagnostic and Treatment Centers; ADL: activities of daily
living; AES-C: Apathy Evaluation Scale - Clinician; AGGIR: Grille d’Autonomie Gérontologique Groups Iso-Ressources; AMI:
Autobiographical Memory Interview; AMI-E: Autobiographical Memory Interview Extended Version; AMS: Alzheimer’s Mood
Scale; BADLS: Bristol Activities of Daily Living Scale; BRSE: Brief Retirement Self-Efficacy; CAPE: Clifton Assessment Procedures
for the Elderly; CASI: Cognitive Abilities Screening Instrument; CDR: Clinical Dementia Rating; CDR-SB: Clinical Dementia
Rating - Sum of Boxes; CES-D:Center for Epidemiological Studies - Depression; COPE-PAC: amultidimensional coping inventory;
COS: Communication Observation Scale; CSDD: Cornell Scale for Depression in Dementia; CT: computer tomography; DAD:
Disablement Assessment for Dementia; DEMQOL: a self-reported outcome measure designed to enable the assessment health-
related quality of life of people with dementia; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders - fourth edition;
DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders - fourth edition, Text Revision; EQ-5D: European Quality of
Life 5 Dimensions; FIM: Functional Independence Measure; GDS: Geriatric Depression Scale; GDS-SF: Geriatric Depression Scale
- Short Form; GHQ-12: 12-item General Health Questionnaire; HADS: Hospital Anxiety and Depression Scale; ICC: intraclass
correlation coefficient; ITT: intention to treat; LSB: life story book; MADRS: Montgomery-Åsberg Depression Rating Scale; MBS:
Memory and Behaviour Problems; MCI: mild cognitive impairment; MMSE: Mini-Mental State Examination; MOSES: Multi-
dimensional Observation Scale for Elderly Subjects; MRI: magnetic resonance imaging; n/a: not available; NPI: Neuropsychiatric
Inventory; NPI-D: Neuropsychiatric Inventory - Caregiver Distress; PANAS: Positive and Negative Affect Schedule; PET: positron
emission tomography; PGI: Patient Global Impression; QCPR: Quality of Carer and Patient Relationship; QoL-AD: Quality of
Life in Alzheimer’s Disease; RAID: Rating Anxiety In Dementia; RCT: randomised controlled trial; ROI: return on investment;
RSS: Relative Stress Scale; RT: reminiscence therapy; RYCT: Remembering Yesterday, Caring Today; SD: standard deviation; SES:
Social Engagement Scale; SolCos: a transformational reminiscence model on depressive symptoms; SR-QoL: Self-Report Quality
of Life; VD: vascular dementia; WIB: Well-being/Ill-being Scale; ZBI: Zarit Burden Interview.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Afonso 2009 Older population with no diagnosis of dementia.
Akhoondzadeh 2014 Healthy older adults and no control group.
Allen 2014 Not specific to dementia.
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Asiret 2016 Not an RCT. Authors stated “Patients were listed through their mini mental test scores, and randomized
as odd numbers to control group and even numbers to intervention group.” This is allocation rather than
randomisation
Baillon 2004 Only 3 sessions of reminiscence therapy. No control group.
Baillon 2005 Only 3 sessions of reminiscence therapy. No control group.
Barban 2016 Reminiscence therapy combined with process-based cognitive training
Bogaert 2013 Inadequate generation of a randomised sequence meaning study was not an RCT
Bohlmeijer 2008 Not specific to dementia.
Brooker 2000 Not an RCT.
Burckhardt 1987 Not an intervention study and not specific to reminiscence and dementia
Chao 2006 An MMSE score < 24 was an exclusion criteria, i.e. population did not have a clear diagnosis of dementia
Chenoweth 2009 Not reminiscence therapy.
Chiang 2010 MMSE score > 20 was necessary to be included in the study, i.e. population did not have a clear diagnosis
of dementia
Choy 2016 Participants did not have dementia.
Chueh 2014 No mention of diagnosis of dementia.
Chung 2009 Single group experimental design, i.e. not an RCT.
Crook 2016 Not an RCT.
Curto Prieto 2015 No passive control group.
Eritz 2016 Study used a life history intervention which was not carried out directly with the person with dementia
Gudex 2010 Residential home population that specifically excluded residents with severe dementia. No diagnostic infor-
mation provided; no data given for people with dementia
Haight 2003 Randomisation not mentioned
Haslam 2010 Comparison was against an activity (playing skittles) rather than no treatment/social contact
Haslam 2014 No passive control condition.
Head 1990 No randomisation.
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(Continued)
Hilgeman 2014 Mixed intervention, mostly focusing on advance care planning
Hsu 2009 Population did not have a clear diagnosis of dementia.
Hutson 2014 Not sufficient reminiscence therapy content.
Jo 2015 Not an RCT.
Lalanne 2015 Control condition was a cognitive training programme.
Lancioni 2014 Feasibility study, not an RCT.
Lin 2011 Not an RCT.
Liu 2007 Excluded people with a diagnosis of dementia.
Lopes 2016 Inclusion criteria appeared to include people with MCI, according to cut-off scores on Montreal Cognitive
Assessment which is used to determine eligibility for the study. Data not available separately for participants
meeting criteria for mild dementia. Less than 10% of participants had formal diagnosis of dementia
MacKinlay 2009 Qualitative study.
Mackinlay 2010 Intervention was not reminiscence therapy.
McKee 2003 Reminiscence used with a general care home population. Data for people with dementia not presented
separately
McMurdo 2000 Residential home population with MMSE score >12; no diagnostic information provided; no data given
for people with dementia
Melendez-Moral 2013 Not specific to dementia.
Morris 2015 No mention of dementia.
Nakamae 2014 Not sufficient reminiscence therapy content, correspondence with authors stated that participants engaged
in 5 minutes of reminiscence per session
Nakatsuka 2015 Only included participants with MCI.
Orten 1989 Population without clear diagnosis of dementia.
Politis 2004 Not enough reminiscence therapy content
Rattenbury 1989 Cognitive impairment was an exclusion factor for this study, i.e. population did not have a clear diagnosis
of dementia
Rawtaer 2015 Inclusion criteria include MMSE of ≥ 24, i.e. not a population with dementia
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(Continued)
Sabir 2016 People with dementia excluded.
Serrano 2004 Diagnosis of dementia was an exclusion factor.
Stinson 2006 Significant cognitive impairment was an exclusion factor for this study, i.e. population did not have a clear
diagnosis of dementia
Tadaka 2004 Study used the same participants and measures as the Tadaka 2007 (AD); Tadaka 2007 (VD) studies which
were included in this review. The 2004 version was excluded to avoid double counting the same data in the
analysis
Tanaka 2017 Intervention includes reality orientation and physical exercise as well as reminiscence. Described as cognitive
rehabilitation
Thornton 1987 Not an intervention study.
Tolson 2012 Intervention was not reminiscence therapy.
Van Dijk 2012 Not enough reminiscence therapy (1 session only).
Wang 2004 Cognitive impairment was an exclusion factor for this study, i.e. population did not have a clear diagnosis
of dementia
Wang 2007 Inadequate generation of a randomised sequence meaning not an RCT
Wang 2009 Inadequate generation of a randomised sequence meaning not an RCT
Wingbermuehle 2014 Not an intervention study.
Wu 2016 Intervention described as spiritual reminiscence but the content does not reflect reminiscence work
Yamagami 2007 Not an RCT.
Yasuda 2009 1 group, not an RCT.
Yousefi 2015 No mention of dementia in paper.
Zauszniewski 2004 A diagnosis of dementia was an exclusion factor for this study
MCI: mild cognitive impairment; MMSE: Mini-Mental State Examination; RCT: randomised controlled trial.
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Characteristics of ongoing studies [ordered by study ID]
Dwolatzky 2014
Trial name or title Computer-Supported Personal Interventions for Older People with Cognitive Impairment and Dementia
Methods RCT.
Participants Participants in adult daycare centres aged≥ 65 years with cognitive impairment or dementia (only data from
participants with dementia will be extracted)
Interventions Intervention: computerised personal reminiscence.
Control: treatment as usual.
Intervention 2: computerised cognitive training*.
Outcomes Quality of life: QoL-AD, Will To Live and NPI.
Cognitive: Mindstreams computerised cognitive assessment battery
Carer outcomes: short version of Zarit Caregiver Burden Interview
Starting date Unknown.
Contact information Name: Tzvi Dwolatzky.
Contact e-mail: Tzvidov@bgu.ac.il.
Notes Data from computerised cognitive arm will not be included in this review
NPI: Neuropsychiatric Inventory; QoL-AD: Quality of Life in Alzheimer’s Disease; RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Reminiscence therapy versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self-reported quality of life
post-treatment
8 1060 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.12, 0.33]
1.1 SR-QoL (care home) 1 88 Std. Mean Difference (IV, Random, 95% CI) 0.45 [0.03, 0.88]
1.2 QoL-AD rated by person
with dementia (care home)
2 105 Std. Mean Difference (IV, Random, 95% CI) 0.47 [0.08, 0.86]
1.3 QoL-AD rated by person
with dementia (community)
5 867 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.24, 0.06]
2 Proxy rated quality of life
post-treatment
5 763 Mean Difference (IV, Random, 95% CI) 0.35 [-1.23, 1.94]
2.1 QoL-AD rated by carer
(community)
4 577 Mean Difference (IV, Random, 95% CI) 0.29 [-1.75, 2.33]
2.2 QoL-AD rated by carer
(care home)
1 186 Mean Difference (IV, Random, 95% CI) 1.08 [-1.33, 3.49]
3 Observed quality of life
(post-treatment)
2 154 Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.17, 0.18]
3.1 WIB (care home) 2 154 Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.17, 0.18]
4 Cognition post-treatment 14 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 MMSE (care home) 4 190 Std. Mean Difference (IV, Fixed, 95% CI) 0.24 [-0.05, 0.53]
4.2 MMSE (community) 5 247 Std. Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.06, 0.47]
4.3 AMI-PSS (care home) 2 40 Std. Mean Difference (IV, Fixed, 95% CI) 0.55 [-0.08, 1.19]
4.4 AMI-PSS (community) 1 30 Std. Mean Difference (IV, Fixed, 95% CI) 0.52 [-0.21, 1.25]
4.5 AMI-E-PSS (community) 1 386 Std. Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.09, 0.31]
4.6 AMI-AIS (care home) 2 40 Std. Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.52, 0.77]
4.7 AMI-AIS (community) 1 30 Std. Mean Difference (IV, Fixed, 95% CI) 0.76 [0.02, 1.51]
4.8 AMI-E-AIS (community) 1 386 Std. Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.16, 0.25]
4.9 ADAS-Cog (community) 1 326 Std. Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.31, 0.12]
5 Cognition (overall)
post-treatment
14 1219 Std. Mean Difference (IV, Fixed, 95% CI) 0.11 [0.00, 0.23]
5.1 MMSE (care home) 4 190 Std. Mean Difference (IV, Fixed, 95% CI) 0.24 [-0.05, 0.53]
5.2 MMSE (community) 5 247 Std. Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.06, 0.47]
5.3 AMI-PSS (care home) 2 40 Std. Mean Difference (IV, Fixed, 95% CI) 0.55 [-0.08, 1.19]
5.4 AMI-PSS (community) 1 30 Std. Mean Difference (IV, Fixed, 95% CI) 0.52 [-0.21, 1.25]
5.5 AMI-E-PSS (community) 1 386 Std. Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.09, 0.31]
5.6 ADAS-Cog (community) 1 326 Std. Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.31, 0.12]
6 Quality of caring relationship
post-treatment
3 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 QCPR Warmth rated by
person with dementia (care
home)
1 23 Std. Mean Difference (IV, Fixed, 95% CI) 0.39 [-0.44, 1.21]
6.2 QCPR Warmth rated
by person with dementia
(community)
2 505 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.17, 0.20]
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6.3 QCPR conflict rated by
person with dementia (care
home)
1 23 Std. Mean Difference (IV, Fixed, 95% CI) -0.67 [-1.51, 0.18]
6.4 QCPR conflict rated
by person with dementia
(community)
2 500 Std. Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.22, 0.14]
7 Communication and interaction
post-treatment
6 249 Std. Mean Difference (IV, Random, 95% CI) -0.51 [-0.97, -0.05]
7.1 Social Engagement Scale
(care home)
2 154 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.44, 0.19]
7.2 Communication
Observation Scale for
Cognitively Impaired (care
home)
1 30 Std. Mean Difference (IV, Random, 95% CI) -1.62 [-2.46, -0.78]
7.3 Holden Communication
Scale (community)
1 10 Std. Mean Difference (IV, Random, 95% CI) -0.16 [-1.51, 1.20]
7.4 MOSES Withdrawal
subscale (community)
2 55 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-1.18, -0.09]
8 Behaviour (function)
post-treatment
6 1030 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.69, 0.21]
8.1 MDS-ADL (care home) 1 66 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.52, 0.45]
8.2 Functional Independence
Measure (care home)
1 30 Std. Mean Difference (IV, Random, 95% CI) 0.31 [-0.41, 1.03]
8.3 ADL (care home) 1 88 Std. Mean Difference (IV, Random, 95% CI) -1.83 [-2.33, -1.33]
8.4 Bristol Activities of Daily
Living Scale (community)
1 391 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.09, 0.31]
8.5 ADCS-ADL (community) 1 129 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.41, 0.35]
8.6 DAD (community) 1 326 Std. Mean Difference (IV, Random, 95% CI) -0.00 [-0.22, 0.21]
9 Behaviour (agitation/irritability)
post-treatment
3 359 Std. Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.17, 0.24]
9.1 Cohen-Mansfield
Agitation Inventory (care
home)
1 304 Std. Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.14, 0.31]
9.2 MOSES Irritability
subscale (community)
2 55 Std. Mean Difference (IV, Fixed, 95% CI) -0.26 [-0.79, 0.27]
10 Mood-related outcomes
(depression) post-treatment
10 973 Std. Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.15, 0.10]
10.1 CSDD (care home) 3 147 Std. Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.50, 0.15]
10.2 CSDD (community) 1 276 Std. Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.38, 0.10]
10.3 Geriatric Depression
Scale (care home)
1 23 Std. Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.90, 0.74]
10.4 Geriatric Depression
Scale Short Form (care home)
1 17 Std. Mean Difference (IV, Fixed, 95% CI) -0.53 [-1.51, 0.44]
10.5 MOSES Depression
subscale (community)
2 55 Std. Mean Difference (IV, Fixed, 95% CI) -0.32 [-0.85, 0.22]
10.6 HADS Depression
(community)
1 129 Std. Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.26, 0.49]
10.7 MADRS (community) 1 326 Std. Mean Difference (IV, Fixed, 95% CI) 0.17 [-0.05, 0.38]
11 Mood-related outcomes
(anxiety) post-treatment
2 436 Std. Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.22, 0.16]
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11.1 HADS Anxiety
(community)
1 129 Std. Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.40, 0.35]
11.2 RAID (community) 1 307 Std. Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.25, 0.20]
12 Carer outcomes (stress related
to caring) post-treatment
7 1155 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.21, 0.14]
12.1 Zarit Burden Interview
Short Form (care home)
1 88 Std. Mean Difference (IV, Random, 95% CI) -0.61 [-1.04, -0.19]
12.2 Zarit Burden Interview
Short Form (community)
1 37 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.73, 0.56]
12.3 Relatives Stress Scale
(community)
2 385 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-1.82, 0.90]
12.4 NPI (community) 1 129 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.26, 0.49]
12.5 Modified Zarit Burden
Interview - care assistant (care
home)
1 90 Std. Mean Difference (IV, Random, 95% CI) 0.03 [-0.38, 0.44]
12.6 Modified Zarit Burden
Interview - nurse report (care
home)
1 100 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.31, 0.47]
12.7 Zarit Burden Interview 1 326 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.14, 0.30]
13 Carer outcomes (depression)
post-treatment
2 517 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.59, 0.44]
13.1 HADS - Depression
(community)
2 517 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.59, 0.44]
14 Carer outcomes (anxiety)
post-treatment
2 517 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.54, 0.66]
14.1 HADS - Anxiety
(community)
2 517 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.54, 0.66]
15 Carer outcomes (quality of life)
post-treatment
4 530 Std. Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.22, 0.13]
15.1 GHQ-12 carer
(community)
2 47 Std. Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.82, 0.36]
15.2 GHQ-28 (community) 1 354 Std. Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.18, 0.24]
15.3 SF Mental (community) 1 129 Std. Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.59, 0.16]
16 Carer outcomes (quality
of caring relationship)
post-treatment
3 1051 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.67, 0.39]
16.1 QCPR Absence of
conflict carer (care home)
1 23 Mean Difference (IV, Fixed, 95% CI) -0.20 [-5.27, 4.87]
16.2 QCPR Absence of
conflict carer (community)
2 500 Mean Difference (IV, Fixed, 95% CI) -0.27 [-1.02, 0.48]
16.3 QCPR Warmth carer
(care home)
1 23 Mean Difference (IV, Fixed, 95% CI) -1.2 [-6.07, 3.67]
16.4 QCPR Warmth carer
(community)
2 505 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.75, 0.80]
17 Self-reported quality of life at
follow-up
5 874 Std. Mean Difference (IV, Random, 95% CI) 0.35 [-0.11, 0.80]
17.1 SR-QoL (care home) 1 88 Std. Mean Difference (IV, Random, 95% CI) 1.48 [1.00, 1.95]
17.2 QoL-AD rated by person
with dementia (community)
4 786 Std. Mean Difference (IV, Random, 95% CI) 0.01 [-0.13, 0.15]
18 Proxy rated quality of life at
follow-up
3 505 Mean Difference (IV, Fixed, 95% CI) -0.15 [-1.14, 0.83]
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18.1 QoL-AD rated by carer
(community)
3 505 Mean Difference (IV, Fixed, 95% CI) -0.15 [-1.14, 0.83]
19 Observed quality of life at
follow-up
2 154 Mean Difference (IV, Random, 95% CI) -0.40 [-1.34, 0.54]
19.1 WIB (care home) 2 154 Mean Difference (IV, Random, 95% CI) -0.40 [-1.34, 0.54]
20 Cognition follow-up 9 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 MMSE (care home) 1 66 Std. Mean Difference (IV, Fixed, 95% CI) 0.31 [-0.17, 0.80]
20.2 MMSE (community) 4 216 Std. Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.08, 0.48]
20.3 AMI-PSS (care home) 1 17 Std. Mean Difference (IV, Fixed, 95% CI) 0.51 [-0.46, 1.48]
20.4 AMI-PSS (community) 1 30 Std. Mean Difference (IV, Fixed, 95% CI) 0.55 [-0.18, 1.28]
20.5 AMI-E-PSS
(community)
1 328 Std. Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.26, 0.18]
20.6 AMI-AIS (care home) 1 17 Std. Mean Difference (IV, Fixed, 95% CI) -0.25 [-1.20, 0.71]
20.7 AMI-AIS (community) 1 30 Std. Mean Difference (IV, Fixed, 95% CI) 0.63 [-0.11, 1.36]
20.8 AMI-E-AIS
(community)
1 325 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.21, 0.23]
20.9 ADAS-Cog (community) 1 326 Std. Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.32, 0.11]
21 Cognition (overall) at follow-up 9 983 Std. Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.09, 0.17]
21.1 MMSE (care home) 1 66 Std. Mean Difference (IV, Fixed, 95% CI) 0.31 [-0.17, 0.80]
21.2 MMSE (community) 4 216 Std. Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.08, 0.48]
21.3 AMI-PSS (care home) 1 17 Std. Mean Difference (IV, Fixed, 95% CI) 0.51 [-0.46, 1.48]
21.4 AMI-PSS (community) 1 30 Std. Mean Difference (IV, Fixed, 95% CI) 0.55 [-0.18, 1.28]
21.5 AMI-E-PSS
(community)
1 328 Std. Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.26, 0.18]
21.6 ADAS-Cog (community) 1 326 Std. Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.32, 0.11]
22 Communication and
interaction at follow-up
4 204 Std. Mean Difference (IV, Fixed, 95% CI) -0.49 [-0.77, -0.21]
22.1 Social Engagement Scale
(care home)
2 154 Std. Mean Difference (IV, Fixed, 95% CI) -0.46 [-0.79, -0.14]
22.2 MOSES withdrawal
subscale (community)
2 50 Std. Mean Difference (IV, Fixed, 95% CI) -0.56 [-1.12, 0.01]
23 Quality of caring relationship
at follow-up
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
23.1 QCPR warmth rated
by person with dementia
(community)
2 415 Mean Difference (IV, Fixed, 95% CI) 0.25 [-0.61, 1.11]
23.2 QCPR conflict rated
by person with dementia
(community)
2 409 Mean Difference (IV, Fixed, 95% CI) -0.38 [-1.28, 0.51]
24 Behaviour (functional) at
follow-up
5 941 Std. Mean Difference (IV, Random, 95% CI) -0.31 [-0.66, 0.03]
24.1 MDS-ADL (care home) 1 66 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.53, 0.44]
24.2 ADL (care home) 1 88 Std. Mean Difference (IV, Random, 95% CI) -1.29 [-1.75, -0.82]
24.3 ADCS-ADL
(community)
1 119 Std. Mean Difference (IV, Random, 95% CI) -0.14 [-0.53, 0.25]
24.4 Bristol Activities of Daily
Living Scale (community)
1 342 Std. Mean Difference (IV, Random, 95% CI) -0.14 [-0.35, 0.08]
24.5 DAD (community) 1 326 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-0.32, 0.11]
25 Behaviour
(agitation/irritability) at
follow-up
2 50 Mean Difference (IV, Fixed, 95% CI) -1.52 [-4.07, 1.03]
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25.1 MOSES Irritability
subscale (community)
2 50 Mean Difference (IV, Fixed, 95% CI) -1.52 [-4.07, 1.03]
26 Mood-related outcomes
(depression) at follow-up
6 747 Std. Mean Difference (IV, Random, 95% CI) -0.16 [-0.43, 0.11]
26.1 Geriatric Depression
Scale Short Form (care home)
1 17 Std. Mean Difference (IV, Random, 95% CI) -1.63 [-2.77, -0.49]
26.2 CSDD (community) 1 235 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.43, 0.09]
26.3 MOSES Depression
subscale (community)
2 50 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.82, 0.30]
26.4 HADS Depression
(community)
1 119 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.48, 0.30]
26.5 MADRS (community) 1 326 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.11, 0.32]
27 Mood-related outcomes
(anxiety) at follow-up
2 391 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.20, 0.21]
27.1 RAID (community) 1 272 Std. Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.25, 0.23]
27.2 HADS Anxiety
(community)
1 119 Std. Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.34, 0.44]
28 Carer outcomes (stress related
to caring) at follow-up
5 895 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.54, 0.16]
28.1 Zarit Burden Interview
Short Form (care home)
1 88 Std. Mean Difference (IV, Random, 95% CI) -1.07 [-1.51, -0.62]
28.2 Zarit Burden Interview
Short Form (community)
1 35 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.74, 0.59]
28.3 Relatives Stress Scale
(community)
1 327 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.28, 0.16]
28.4 NPI (community) 1 119 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.33, 0.45]
28.5 Zarit Burden Interview
(community)
1 326 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.11, 0.32]
29 Carer outcomes (depression) at
follow-up
2 464 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.71, 0.60]
29.1 HADS Depression
(community)
2 464 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.71, 0.60]
30 Carer outcomes (anxiety) at
follow-up
2 464 Mean Difference (IV, Fixed, 95% CI) 0.56 [-0.17, 1.30]
30.1 HADS Anxiety
(community)
2 464 Mean Difference (IV, Fixed, 95% CI) 0.56 [-0.17, 1.30]
31 Carer outcomes (quality of life)
at follow-up
3 467 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.18, 0.19]
31.1 GHQ-12 (community) 1 35 Std. Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.78, 0.55]
31.2 GHQ-28 (community) 1 313 Std. Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.15, 0.29]
31.3 SF Mental (community) 1 119 Std. Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.54, 0.24]
32 Carer outcomes (quality
of caring relationship) at
follow-up
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
32.1 QCPR Conflict
(community)
2 495 Mean Difference (IV, Fixed, 95% CI) -0.37 [-1.23, 0.50]
32.2 QCPR Warmth
(community)
2 456 Mean Difference (IV, Fixed, 95% CI) -0.66 [-1.59, 0.27]
33 Mood-related outcomes
(apathy) post-treatment
1 326 Mean Difference (IV, Fixed, 95% CI) 1.40 [-1.30, 4.10]
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33.1 Apathy Index (carer
rated) (community)
1 326 Mean Difference (IV, Fixed, 95% CI) 1.40 [-1.30, 4.10]
34 Mood-related outcomes
(apathy) at follow-up
(community)
1 326 Mean Difference (IV, Fixed, 95% CI) 1.25 [-1.89, 4.39]
34.1 Apathy Index (carer
rated) (community)
1 326 Mean Difference (IV, Fixed, 95% CI) 1.25 [-1.89, 4.39]
Analysis 1.1. Comparison 1 Reminiscence therapy versus no treatment, Outcome 1 Self-reported quality of
life post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 1 Self-reported quality of life post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SR-QoL (care home)
Azcurra 2012 44 3.8 (9.66) 44 0.2 (5.52) 13.3 % 0.45 [ 0.03, 0.88 ]
Subtotal (95% CI) 44 44 13.3 % 0.45 [ 0.03, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
2 QoL-AD rated by person with dementia (care home)
O’Shea 2014 41 0.9 (6.25) 41 -1.99 (8.41) 12.9 % 0.39 [ -0.05, 0.82 ]
Subramaniam 2013 11 6.8 (10.95) 12 -0.2 (5.32) 5.4 % 0.80 [ -0.06, 1.65 ]
Subtotal (95% CI) 52 53 18.4 % 0.47 [ 0.08, 0.86 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
3 QoL-AD rated by person with dementia (community)
Amieva 2016 172 32.34 (8.8) 154 33.28 (7.7) 20.5 % -0.11 [ -0.33, 0.10 ]
Charlesworth 2016 90 -0.37 (8.04) 39 0.2 (8.28) 14.8 % -0.07 [ -0.45, 0.31 ]
Sa¨rka¨mo¨ 2013 28 2.94 (6.94) 24 0.07 (7.94) 10.1 % 0.38 [ -0.17, 0.93 ]
Thorgrimsen 2002 7 -0.2 (3.2) 3 5.3 (8.6) 2.2 % -0.97 [ -2.43, 0.49 ]
Woods 2012a 202 -0.7 (4.42) 148 -0.09 (4.55) 20.7 % -0.14 [ -0.35, 0.08 ]
Subtotal (95% CI) 499 368 68.3 % -0.09 [ -0.24, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.45, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.16 (P = 0.24)
Total (95% CI) 595 465 100.0 % 0.11 [ -0.12, 0.33 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 17.00, df = 7 (P = 0.02); I2 =59%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Chi2 = 11.19, df = 2 (P = 0.00), I2 =82%
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Analysis 1.2. Comparison 1 Reminiscence therapy versus no treatment, Outcome 2 Proxy rated quality of
life post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 2 Proxy rated quality of life post-treatment
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 QoL-AD rated by carer (community)
Charlesworth 2016 90 -0.82 (7.25) 39 0.26 (9.08) 16.1 % -1.08 [ -4.30, 2.14 ]
Sa¨rka¨mo¨ 2013 27 0.26 (7.83) 26 -1.34 (6.59) 12.3 % 1.60 [ -2.29, 5.49 ]
Thorgrimsen 2002 7 0.3 (6.1) 3 -5 (2.7) 7.2 % 5.30 [ -0.15, 10.75 ]
Woods 2012a 223 -1.33 (4.47) 162 -0.62 (4.48) 41.7 % -0.71 [ -1.62, 0.20 ]
Subtotal (95% CI) 347 230 77.2 % 0.29 [ -1.75, 2.33 ]
Heterogeneity: Tau2 = 2.05; Chi2 = 5.79, df = 3 (P = 0.12); I2 =48%
Test for overall effect: Z = 0.28 (P = 0.78)
2 QoL-AD rated by carer (care home)
O’Shea 2014 93 0.04 (8.4) 93 -1.04 (8.37) 22.8 % 1.08 [ -1.33, 3.49 ]
Subtotal (95% CI) 93 93 22.8 % 1.08 [ -1.33, 3.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 440 323 100.0 % 0.35 [ -1.23, 1.94 ]
Heterogeneity: Tau2 = 1.35; Chi2 = 7.24, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
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Analysis 1.3. Comparison 1 Reminiscence therapy versus no treatment, Outcome 3 Observed quality of life
(post-treatment).
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 3 Observed quality of life (post-treatment)
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 WIB (care home)
Azcurra 2012 44 -0.3 (0.94) 44 -0.1 (1.18) 14.6 % -0.20 [ -0.65, 0.25 ]
Lai 2004 36 0.11 (0.31) 30 0.07 (0.43) 85.4 % 0.04 [ -0.14, 0.22 ]
Total (95% CI) 80 74 100.0 % 0.00 [ -0.17, 0.18 ]
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Reminiscence therapy versus no treatment, Outcome 4 Cognition post-
treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 4 Cognition post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 MMSE (care home)
Haight 2006 14 3.36 (7.5) 16 -3.91 (7.81) 14.3 % 0.92 [ 0.16, 1.68 ]
Ito 2007 17 0 (6.66) 17 -0.8 (5.53) 18.3 % 0.13 [ -0.55, 0.80 ]
Lai 2004 36 0.6 (6.91) 30 -0.14 (8.96) 35.2 % 0.09 [ -0.39, 0.58 ]
Van Bogaert 2016 29 0.86 (5.52) 31 -0.16 (6.93) 32.2 % 0.16 [ -0.35, 0.67 ]
Subtotal (95% CI) 96 94 100.0 % 0.24 [ -0.05, 0.53 ]
Heterogeneity: Chi2 = 3.66, df = 3 (P = 0.30); I2 =18%
Test for overall effect: Z = 1.63 (P = 0.10)
2 MMSE (community)
Charlesworth 2016 90 -0.81 (10.22) 39 -1.34 (9.07) 49.0 % 0.05 [ -0.32, 0.43 ]
Sa¨rka¨mo¨ 2013 28 0.62 (7.52) 25 -1.25 (8.05) 23.6 % 0.24 [ -0.30, 0.78 ]
Tadaka 2007 (AD) 11 0.7 (5.63) 10 0.6 (5.02) 9.4 % 0.02 [ -0.84, 0.87 ]
Tadaka 2007 (VD) 17 2.9 (5.17) 17 -0.7 (5.55) 14.4 % 0.66 [ -0.04, 1.35 ]
Thorgrimsen 2002 7 0.2 (6) 3 -3.7 (0.6) 3.5 % 0.68 [ -0.73, 2.08 ]
Subtotal (95% CI) 153 94 100.0 % 0.20 [ -0.06, 0.47 ]
Heterogeneity: Chi2 = 2.88, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
3 AMI-PSS (care home)
Morgan 2012 8 11.69 (18.07) 9 -1.39 (19.03) 41.6 % 0.67 [ -0.32, 1.65 ]
Subramaniam 2013 11 5.3 (29.23) 12 -7.8 (23.98) 58.4 % 0.47 [ -0.36, 1.31 ]
Subtotal (95% CI) 19 21 100.0 % 0.55 [ -0.08, 1.19 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
4 AMI-PSS (community)
Melendez 2015 15 3.64 (15.79) 15 -4.04 (12.99) 100.0 % 0.52 [ -0.21, 1.25 ]
Subtotal (95% CI) 15 15 100.0 % 0.52 [ -0.21, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
5 AMI-E-PSS (community)
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(. . . Continued)
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Woods 2012a 224 -3.69 (11.92) 162 -5.08 (14.17) 100.0 % 0.11 [ -0.09, 0.31 ]
Subtotal (95% CI) 224 162 100.0 % 0.11 [ -0.09, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
6 AMI-AIS (care home)
Morgan 2012 8 -2.63 (7.83) 9 2.55 (6.94) 42.6 % -0.67 [ -1.65, 0.32 ]
Subramaniam 2013 11 4.8 (8.66) 12 -0.7 (6.01) 57.4 % 0.72 [ -0.13, 1.57 ]
Subtotal (95% CI) 19 21 100.0 % 0.13 [ -0.52, 0.77 ]
Heterogeneity: Chi2 = 4.35, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.39 (P = 0.70)
7 AMI-AIS (community)
Melendez 2015 15 4.06 (7.79) 15 -1.2 (5.47) 100.0 % 0.76 [ 0.02, 1.51 ]
Subtotal (95% CI) 15 15 100.0 % 0.76 [ 0.02, 1.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
8 AMI-E-AIS (community)
Woods 2012a 224 -1.21 (6.02) 162 -1.49 (6.26) 100.0 % 0.05 [ -0.16, 0.25 ]
Subtotal (95% CI) 224 162 100.0 % 0.05 [ -0.16, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
9 ADAS-Cog (community)
Amieva 2016 172 -21.02 (13.2) 154 -19.84 (11.5) 100.0 % -0.09 [ -0.31, 0.12 ]
Subtotal (95% CI) 172 154 100.0 % -0.09 [ -0.31, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
-2 -1 0 1 2
Favours no treatment Favours reminiscence
92Reminiscence therapy for dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Reminiscence therapy versus no treatment, Outcome 5 Cognition (overall)
post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 5 Cognition (overall) post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 MMSE (care home)
Ito 2007 17 0 (6.66) 17 -0.8 (5.53) 2.9 % 0.13 [ -0.55, 0.80 ]
Haight 2006 14 3.36 (7.5) 16 -3.91 (7.81) 2.3 % 0.92 [ 0.16, 1.68 ]
Van Bogaert 2016 29 0.86 (5.52) 31 -0.16 (6.93) 5.1 % 0.16 [ -0.35, 0.67 ]
Lai 2004 36 0.6 (6.91) 30 -0.14 (8.96) 5.6 % 0.09 [ -0.39, 0.58 ]
Subtotal (95% CI) 96 94 15.8 % 0.24 [ -0.05, 0.53 ]
Heterogeneity: Chi2 = 3.66, df = 3 (P = 0.30); I2 =18%
Test for overall effect: Z = 1.63 (P = 0.10)
2 MMSE (community)
Sa¨rka¨mo¨ 2013 28 0.62 (7.52) 25 -1.25 (8.05) 4.5 % 0.24 [ -0.30, 0.78 ]
Tadaka 2007 (AD) 11 0.7 (5.63) 10 0.6 (5.02) 1.8 % 0.02 [ -0.84, 0.87 ]
Tadaka 2007 (VD) 17 2.9 (5.17) 17 -0.7 (5.55) 2.7 % 0.66 [ -0.04, 1.35 ]
Charlesworth 2016 90 -0.81 (10.22) 39 -1.34 (9.07) 9.3 % 0.05 [ -0.32, 0.43 ]
Thorgrimsen 2002 7 0.2 (6) 3 -3.7 (0.6) 0.7 % 0.68 [ -0.73, 2.08 ]
Subtotal (95% CI) 153 94 18.9 % 0.20 [ -0.06, 0.47 ]
Heterogeneity: Chi2 = 2.88, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
3 AMI-PSS (care home)
Morgan 2012 8 11.69 (18.07) 9 -1.39 (19.03) 1.3 % 0.67 [ -0.32, 1.65 ]
Subramaniam 2013 11 5.3 (29.23) 12 -7.8 (23.98) 1.9 % 0.47 [ -0.36, 1.31 ]
Subtotal (95% CI) 19 21 3.2 % 0.55 [ -0.08, 1.19 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
4 AMI-PSS (community)
Melendez 2015 15 3.64 (15.79) 15 -4.04 (12.99) 2.5 % 0.52 [ -0.21, 1.25 ]
Subtotal (95% CI) 15 15 2.5 % 0.52 [ -0.21, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
5 AMI-E-PSS (community)
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Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Woods 2012a 224 -3.69 (11.92) 162 -5.08 (14.17) 32.0 % 0.11 [ -0.09, 0.31 ]
Subtotal (95% CI) 224 162 32.0 % 0.11 [ -0.09, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
6 ADAS-Cog (community)
Amieva 2016 172 -21.02 (13.2) 154 -19.84 (11.5) 27.6 % -0.09 [ -0.31, 0.12 ]
Subtotal (95% CI) 172 154 27.6 % -0.09 [ -0.31, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Total (95% CI) 679 540 100.0 % 0.11 [ 0.00, 0.23 ]
Heterogeneity: Chi2 = 14.35, df = 13 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Chi2 = 7.72, df = 5 (P = 0.17), I2 =35%
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Analysis 1.6. Comparison 1 Reminiscence therapy versus no treatment, Outcome 6 Quality of caring
relationship post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 6 Quality of caring relationship post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 QCPR Warmth rated by person with dementia (care home)
Subramaniam 2013 11 -0.1 (2.51) 12 -1 (1.97) 100.0 % 0.39 [ -0.44, 1.21 ]
Subtotal (95% CI) 11 12 100.0 % 0.39 [ -0.44, 1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
2 QCPR Warmth rated by person with dementia (community)
Charlesworth 2016 90 -0.25 (5.04) 39 -0.91 (4.74) 23.0 % 0.13 [ -0.24, 0.51 ]
Woods 2012a 221 -0.82 (4.08) 155 -0.74 (3.82) 77.0 % -0.02 [ -0.23, 0.19 ]
Subtotal (95% CI) 311 194 100.0 % 0.01 [ -0.17, 0.20 ]
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
3 QCPR conflict rated by person with dementia (care home)
Subramaniam 2013 11 -2 (2.25) 12 -0.5 (2.08) 100.0 % -0.67 [ -1.51, 0.18 ]
Subtotal (95% CI) 11 12 100.0 % -0.67 [ -1.51, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
4 QCPR conflict rated by person with dementia (community)
Charlesworth 2016 90 0.78 (7.04) 39 0.07 (6.11) 23.1 % 0.10 [ -0.27, 0.48 ]
Woods 2012a 215 -0.2 (3.64) 156 0.1 (3.96) 76.9 % -0.08 [ -0.29, 0.13 ]
Subtotal (95% CI) 305 195 100.0 % -0.04 [ -0.22, 0.14 ]
Heterogeneity: Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
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Analysis 1.7. Comparison 1 Reminiscence therapy versus no treatment, Outcome 7 Communication and
interaction post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 7 Communication and interaction post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Social Engagement Scale (care home)
Azcurra 2012 44 -0.6 (2.09) 44 -0.1 (1.7) 23.5 % -0.26 [ -0.68, 0.16 ]
Lai 2004 36 -0.42 (2.43) 30 -0.55 (2.26) 22.1 % 0.05 [ -0.43, 0.54 ]
Subtotal (95% CI) 80 74 45.6 % -0.13 [ -0.44, 0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Communication Observation Scale for Cognitively Impaired (care home)
Haight 2006 15 -4.33 (5.73) 15 5.26 (5.81) 14.8 % -1.62 [ -2.46, -0.78 ]
Subtotal (95% CI) 15 15 14.8 % -1.62 [ -2.46, -0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.77 (P = 0.00016)
3 Holden Communication Scale (community)
Thorgrimsen 2002 7 -4.2 (7.9) 3 -3 (2.7) 8.2 % -0.16 [ -1.51, 1.20 ]
Subtotal (95% CI) 7 3 8.2 % -0.16 [ -1.51, 1.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
4 MOSES Withdrawal subscale (community)
Tadaka 2007 (AD) 11 -5 (5.35) 10 0.2 (5.81) 13.6 % -0.90 [ -1.80, 0.01 ]
Tadaka 2007 (VD) 17 -3.8 (6.75) 17 -0.2 (7.53) 17.7 % -0.49 [ -1.18, 0.19 ]
Subtotal (95% CI) 28 27 31.4 % -0.64 [ -1.18, -0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.29 (P = 0.022)
Total (95% CI) 130 119 100.0 % -0.51 [ -0.97, -0.05 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 13.19, df = 5 (P = 0.02); I2 =62%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Chi2 = 11.78, df = 3 (P = 0.01), I2 =75%
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Analysis 1.8. Comparison 1 Reminiscence therapy versus no treatment, Outcome 8 Behaviour (function)
post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 8 Behaviour (function) post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 MDS-ADL (care home)
Lai 2004 36 0.43 (11.38) 30 0.85 (10.69) 16.0 % -0.04 [ -0.52, 0.45 ]
Subtotal (95% CI) 36 30 16.0 % -0.04 [ -0.52, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Functional Independence Measure (care home)
Haight 2006 15 12.95 (31.62) 15 1.78 (37.36) 13.1 % 0.31 [ -0.41, 1.03 ]
Subtotal (95% CI) 15 15 13.1 % 0.31 [ -0.41, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
3 ADL (care home)
Azcurra 2012 44 -0.31 (0.3) 44 0.71 (0.72) 15.8 % -1.83 [ -2.33, -1.33 ]
Subtotal (95% CI) 44 44 15.8 % -1.83 [ -2.33, -1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.17 (P < 0.00001)
4 Bristol Activities of Daily Living Scale (community)
Woods 2012a 226 1.92 (5.33) 165 1.31 (5.67) 18.9 % 0.11 [ -0.09, 0.31 ]
Subtotal (95% CI) 226 165 18.9 % 0.11 [ -0.09, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
5 ADCS-ADL (community)
Charlesworth 2016 90 -2.68 (25.5) 39 -1.91 (27.3) 17.3 % -0.03 [ -0.41, 0.35 ]
Subtotal (95% CI) 90 39 17.3 % -0.03 [ -0.41, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
6 DAD (community)
Amieva 2016 172 -0.41 (15.42) 154 -0.34 (13.02) 18.8 % 0.00 [ -0.22, 0.21 ]
Subtotal (95% CI) 172 154 18.8 % 0.00 [ -0.22, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.96)
Total (95% CI) 583 447 100.0 % -0.24 [ -0.69, 0.21 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 52.13, df = 5 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 52.13, df = 5 (P = 0.00), I2 =90%
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Analysis 1.9. Comparison 1 Reminiscence therapy versus no treatment, Outcome 9 Behaviour
(agitation/irritability) post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 9 Behaviour (agitation/irritability) post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cohen-Mansfield Agitation Inventory (care home)
O’Shea 2014 153 1.74 (20.79) 151 -0.12 (21.42) 84.8 % 0.09 [ -0.14, 0.31 ]
Subtotal (95% CI) 153 151 84.8 % 0.09 [ -0.14, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
2 MOSES Irritability subscale (community)
Tadaka 2007 (AD) 11 -0.8 (4.49) 10 0.5 (4.81) 5.8 % -0.27 [ -1.13, 0.59 ]
Tadaka 2007 (VD) 17 -0.8 (4.41) 17 0.4 (4.63) 9.4 % -0.26 [ -0.93, 0.42 ]
Subtotal (95% CI) 28 27 15.2 % -0.26 [ -0.79, 0.27 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 181 178 100.0 % 0.03 [ -0.17, 0.24 ]
Heterogeneity: Chi2 = 1.42, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 1.42, df = 1 (P = 0.23), I2 =30%
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Analysis 1.10. Comparison 1 Reminiscence therapy versus no treatment, Outcome 10 Mood-related
outcomes (depression) post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 10 Mood-related outcomes (depression) post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 CSDD (care home)
Haight 2006 15 -4.32 (6.34) 16 0.65 (11.18) 3.2 % -0.53 [ -1.25, 0.19 ]
O’Shea 2014 28 1.07 (7.02) 28 -1.02 (6.59) 5.9 % 0.30 [ -0.22, 0.83 ]
Van Bogaert 2016 29 -2.49 (5.61) 31 0.19 (6.16) 6.2 % -0.45 [ -0.96, 0.06 ]
Subtotal (95% CI) 72 75 15.3 % -0.18 [ -0.50, 0.15 ]
Heterogeneity: Chi2 = 5.17, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 1.05 (P = 0.29)
2 CSDD (community)
Woods 2012a 154 -0.01 (4.7) 122 0.63 (4.39) 28.9 % -0.14 [ -0.38, 0.10 ]
Subtotal (95% CI) 154 122 28.9 % -0.14 [ -0.38, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
3 Geriatric Depression Scale (care home)
Subramaniam 2013 11 -0.4 (4.83) 12 -0.1 (2.28) 2.4 % -0.08 [ -0.90, 0.74 ]
Subtotal (95% CI) 11 12 2.4 % -0.08 [ -0.90, 0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
4 Geriatric Depression Scale Short Form (care home)
Morgan 2012 8 -1.5 (3.02) 9 -0.22 (1.3) 1.7 % -0.53 [ -1.51, 0.44 ]
Subtotal (95% CI) 8 9 1.7 % -0.53 [ -1.51, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
5 MOSES Depression subscale (community)
Tadaka 2007 (AD) 11 0.1 (7.35) 10 0.6 (7.47) 2.2 % -0.06 [ -0.92, 0.79 ]
Tadaka 2007 (VD) 17 -1.8 (7.65) 17 1.4 (5.12) 3.5 % -0.48 [ -1.16, 0.20 ]
Subtotal (95% CI) 28 27 5.7 % -0.32 [ -0.85, 0.22 ]
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
6 HADS Depression (community)
Charlesworth 2016 90 0.55 (5.4) 39 -0.07 (5.33) 11.6 % 0.11 [ -0.26, 0.49 ]
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(. . . Continued)
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 90 39 11.6 % 0.11 [ -0.26, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
7 MADRS (community)
Amieva 2016 172 10.47 (10.6) 154 8.82 (9.1) 34.4 % 0.17 [ -0.05, 0.38 ]
Subtotal (95% CI) 172 154 34.4 % 0.17 [ -0.05, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Total (95% CI) 535 438 100.0 % -0.03 [ -0.15, 0.10 ]
Heterogeneity: Chi2 = 13.14, df = 9 (P = 0.16); I2 =32%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 7.42, df = 6 (P = 0.28), I2 =19%
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Analysis 1.11. Comparison 1 Reminiscence therapy versus no treatment, Outcome 11 Mood-related
outcomes (anxiety) post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 11 Mood-related outcomes (anxiety) post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HADS Anxiety (community)
Charlesworth 2016 90 0.49 (4.71) 39 0.62 (4.53) 26.5 % -0.03 [ -0.40, 0.35 ]
Subtotal (95% CI) 90 39 26.5 % -0.03 [ -0.40, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.88)
2 RAID (community)
Woods 2012a 172 -0.27 (6.17) 135 -0.1 (5.57) 73.5 % -0.03 [ -0.25, 0.20 ]
Subtotal (95% CI) 172 135 73.5 % -0.03 [ -0.25, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 262 174 100.0 % -0.03 [ -0.22, 0.16 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 1.12. Comparison 1 Reminiscence therapy versus no treatment, Outcome 12 Carer outcomes
(stress related to caring) post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 12 Carer outcomes (stress related to caring) post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Zarit Burden Interview Short Form (care home)
Azcurra 2012 44 -2.1 (5.02) 44 2.8 (9.98) 11.1 % -0.61 [ -1.04, -0.19 ]
Subtotal (95% CI) 44 44 11.1 % -0.61 [ -1.04, -0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0049)
2 Zarit Burden Interview Short Form (community)
Sa¨rka¨mo¨ 2013 18 0.36 (10.76) 19 1.33 (12.49) 6.1 % -0.08 [ -0.73, 0.56 ]
Subtotal (95% CI) 18 19 6.1 % -0.08 [ -0.73, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
3 Relatives Stress Scale (community)
Thorgrimsen 2002 7 -11.5 (13.5) 3 7.3 (6.4) 1.2 % -1.40 [ -2.97, 0.16 ]
Woods 2012a 218 1.06 (7.19) 157 0.69 (7.08) 22.6 % 0.05 [ -0.15, 0.26 ]
Subtotal (95% CI) 225 160 23.8 % -0.46 [ -1.82, 0.90 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 3.25, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.66 (P = 0.51)
4 NPI (community)
Charlesworth 2016 90 -0.01 (30.3) 39 -3.35 (25.33) 13.1 % 0.11 [ -0.26, 0.49 ]
Subtotal (95% CI) 90 39 13.1 % 0.11 [ -0.26, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
5 Modified Zarit Burden Interview - care assistant (care home)
O’Shea 2014 45 -1.14 (9.85) 45 -1.46 (12.11) 11.7 % 0.03 [ -0.38, 0.44 ]
Subtotal (95% CI) 45 45 11.7 % 0.03 [ -0.38, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
6 Modified Zarit Burden Interview - nurse report (care home)
O’Shea 2014 50 -0.44 (11.19) 50 -1.37 (11.65) 12.5 % 0.08 [ -0.31, 0.47 ]
Subtotal (95% CI) 50 50 12.5 % 0.08 [ -0.31, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
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(. . . Continued)
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
7 Zarit Burden Interview
Amieva 2016 172 9.45 (31.28) 154 6.95 (29.62) 21.8 % 0.08 [ -0.14, 0.30 ]
Subtotal (95% CI) 172 154 21.8 % 0.08 [ -0.14, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 644 511 100.0 % -0.03 [ -0.21, 0.14 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 12.38, df = 7 (P = 0.09); I2 =43%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 9.48, df = 6 (P = 0.15), I2 =37%
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Analysis 1.13. Comparison 1 Reminiscence therapy versus no treatment, Outcome 13 Carer outcomes
(depression) post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 13 Carer outcomes (depression) post-treatment
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HADS - Depression (community)
Charlesworth 2016 90 0.33 (6.69) 39 0.16 (6.28) 4.6 % 0.17 [ -2.24, 2.58 ]
Woods 2012a 222 0.25 (2.54) 166 0.34 (2.68) 95.4 % -0.09 [ -0.62, 0.44 ]
Total (95% CI) 312 205 100.0 % -0.08 [ -0.59, 0.44 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Reminiscence therapy versus no treatment, Outcome 14 Carer outcomes
(anxiety) post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 14 Carer outcomes (anxiety) post-treatment
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HADS - Anxiety (community)
Charlesworth 2016 90 0.83 (6.35) 39 0.41 (6.91) 5.6 % 0.42 [ -2.11, 2.95 ]
Woods 2012a 222 0.31 (3.05) 166 0.27 (3.09) 94.4 % 0.04 [ -0.58, 0.66 ]
Total (95% CI) 312 205 100.0 % 0.06 [ -0.54, 0.66 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Reminiscence therapy versus no treatment, Outcome 15 Carer outcomes
(quality of life) post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 15 Carer outcomes (quality of life) post-treatment
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 GHQ-12 carer (community)
Sa¨rka¨mo¨ 2013 18 0.1 (7.16) 19 0.73 (8.08) 7.4 % -0.08 [ -0.73, 0.56 ]
Thorgrimsen 2002 7 -1.2 (2.8) 3 1.7 (1.5) 1.4 % -1.03 [ -2.50, 0.44 ]
Subtotal (95% CI) 25 22 8.8 % -0.23 [ -0.82, 0.36 ]
Heterogeneity: Chi2 = 1.35, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 0.78 (P = 0.44)
2 GHQ-28 (community)
Woods 2012a 201 0.41 (9.71) 153 0.09 (9.4) 69.5 % 0.03 [ -0.18, 0.24 ]
Subtotal (95% CI) 201 153 69.5 % 0.03 [ -0.18, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
3 SF Mental (community)
Charlesworth 2016 90 0.11 (10.99) 39 2.38 (9.82) 21.7 % -0.21 [ -0.59, 0.16 ]
Subtotal (95% CI) 90 39 21.7 % -0.21 [ -0.59, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 316 214 100.0 % -0.04 [ -0.22, 0.13 ]
Heterogeneity: Chi2 = 3.02, df = 3 (P = 0.39); I2 =1%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 1.68, df = 2 (P = 0.43), I2 =0.0%
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Analysis 1.16. Comparison 1 Reminiscence therapy versus no treatment, Outcome 16 Carer outcomes
(quality of caring relationship) post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 16 Carer outcomes (quality of caring relationship) post-treatment
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 QCPR Absence of conflict carer (care home)
Subramaniam 2013 11 -1.2 (6.24) 12 -1 (6.16) 1.1 % -0.20 [ -5.27, 4.87 ]
Subtotal (95% CI) 11 12 1.1 % -0.20 [ -5.27, 4.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 QCPR Absence of conflict carer (community)
Charlesworth 2016 90 -0.39 (6.53) 39 -0.45 (6.4) 4.9 % 0.06 [ -2.36, 2.48 ]
Woods 2012a 215 -0.2 (3.64) 156 0.1 (3.96) 45.6 % -0.30 [ -1.09, 0.49 ]
Subtotal (95% CI) 305 195 50.5 % -0.27 [ -1.02, 0.48 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
3 QCPR Warmth carer (care home)
Subramaniam 2013 11 -0.9 (5.38) 12 0.3 (6.51) 1.2 % -1.20 [ -6.07, 3.67 ]
Subtotal (95% CI) 11 12 1.2 % -1.20 [ -6.07, 3.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
4 QCPR Warmth carer (community)
Charlesworth 2016 90 -0.55 (7.56) 39 0.14 (7.48) 3.6 % -0.69 [ -3.51, 2.13 ]
Woods 2012a 221 0.82 (4.08) 155 0.74 (3.82) 43.6 % 0.08 [ -0.73, 0.89 ]
Subtotal (95% CI) 311 194 47.2 % 0.02 [ -0.75, 0.80 ]
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 638 413 100.0 % -0.14 [ -0.67, 0.39 ]
Heterogeneity: Chi2 = 0.80, df = 5 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
Test for subgroup differences: Chi2 = 0.46, df = 3 (P = 0.93), I2 =0.0%
-10 -5 0 5 10
Favours reminiscence Favours no treatment
106Reminiscence therapy for dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.17. Comparison 1 Reminiscence therapy versus no treatment, Outcome 17 Self-reported quality
of life at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 17 Self-reported quality of life at follow-up
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SR-QoL (care home)
Azcurra 2012 44 11.3 (7.23) 44 1.5 (5.87) 18.7 % 1.48 [ 1.00, 1.95 ]
Subtotal (95% CI) 44 44 18.7 % 1.48 [ 1.00, 1.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.10 (P < 0.00001)
2 QoL-AD rated by person with dementia (community)
Amieva 2016 172 27.81 (9.8) 154 28.83 (9.5) 22.3 % -0.11 [ -0.32, 0.11 ]
Charlesworth 2016 83 0.47 (8.21) 36 -0.27 (9.26) 20.0 % 0.09 [ -0.31, 0.48 ]
Sa¨rka¨mo¨ 2013 26 2.04 (7.51) 20 -0.94 (7.51) 16.8 % 0.39 [ -0.20, 0.98 ]
Woods 2012a 174 -1.02 (5.33) 121 -1.3 (4.87) 22.2 % 0.05 [ -0.18, 0.29 ]
Subtotal (95% CI) 455 331 81.3 % 0.01 [ -0.13, 0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.96, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI) 499 375 100.0 % 0.35 [ -0.11, 0.80 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 36.69, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 33.72, df = 1 (P = 0.00), I2 =97%
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Analysis 1.18. Comparison 1 Reminiscence therapy versus no treatment, Outcome 18 Proxy rated quality
of life at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 18 Proxy rated quality of life at follow-up
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 QoL-AD rated by carer (community)
Charlesworth 2016 83 -2.78 (7.46) 36 -1.69 (8.7) 9.1 % -1.09 [ -4.35, 2.17 ]
Sa¨rka¨mo¨ 2013 26 0.74 (7.65) 23 -2.37 (7.39) 5.5 % 3.11 [ -1.11, 7.33 ]
Woods 2012a 196 -1.91 (4.84) 141 -1.65 (4.98) 85.4 % -0.26 [ -1.33, 0.81 ]
Total (95% CI) 305 200 100.0 % -0.15 [ -1.14, 0.83 ]
Heterogeneity: Chi2 = 2.66, df = 2 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Reminiscence therapy versus no treatment, Outcome 19 Observed quality of
life at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 19 Observed quality of life at follow-up
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 WIB (care home)
Azcurra 2012 44 -0.4 (1.06) 44 0.5 (1.1) 47.7 % -0.90 [ -1.35, -0.45 ]
Lai 2004 36 0.11 (0.3) 30 0.05 (0.47) 52.3 % 0.06 [ -0.13, 0.25 ]
Total (95% CI) 80 74 100.0 % -0.40 [ -1.34, 0.54 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 14.65, df = 1 (P = 0.00013); I2 =93%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Reminiscence therapy versus no treatment, Outcome 20 Cognition follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 20 Cognition follow-up
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 MMSE (care home)
Lai 2004 36 3.38 (8.63) 30 0.6 (8.95) 100.0 % 0.31 [ -0.17, 0.80 ]
Subtotal (95% CI) 36 30 100.0 % 0.31 [ -0.17, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 MMSE (community)
Charlesworth 2016 83 -1.87 (10.03) 36 -3.36 (9.04) 51.5 % 0.15 [ -0.24, 0.54 ]
Sa¨rka¨mo¨ 2013 27 -1.38 (7.47) 20 -3.1 (8.22) 23.5 % 0.22 [ -0.36, 0.80 ]
Tadaka 2007 (AD) 11 -1.1 (5.6) 9 -1 (5.02) 10.2 % -0.02 [ -0.90, 0.86 ]
Tadaka 2007 (VD) 15 2.3 (5.22) 15 -0.4 (5.6) 14.9 % 0.49 [ -0.24, 1.21 ]
Subtotal (95% CI) 136 80 100.0 % 0.20 [ -0.08, 0.48 ]
Heterogeneity: Chi2 = 0.89, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
3 AMI-PSS (care home)
Morgan 2012 8 3.04 (17.81) 9 -5.95 (15.76) 100.0 % 0.51 [ -0.46, 1.48 ]
Subtotal (95% CI) 8 9 100.0 % 0.51 [ -0.46, 1.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
4 AMI-PSS (community)
Melendez 2015 15 3.04 (15.48) 15 -4.94 (12.62) 100.0 % 0.55 [ -0.18, 1.28 ]
Subtotal (95% CI) 15 15 100.0 % 0.55 [ -0.18, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
5 AMI-E-PSS (community)
Woods 2012a 194 -9.91 (16.64) 134 -9.3 (14.64) 100.0 % -0.04 [ -0.26, 0.18 ]
Subtotal (95% CI) 194 134 100.0 % -0.04 [ -0.26, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
6 AMI-AIS (care home)
Morgan 2012 8 -1.69 (7.13) 9 0.11 (6.68) 100.0 % -0.25 [ -1.20, 0.71 ]
Subtotal (95% CI) 8 9 100.0 % -0.25 [ -1.20, 0.71 ]
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(. . . Continued)
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
7 AMI-AIS (community)
Melendez 2015 15 2.73 (8.03) 15 -1.87 (6.16) 100.0 % 0.63 [ -0.11, 1.36 ]
Subtotal (95% CI) 15 15 100.0 % 0.63 [ -0.11, 1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
8 AMI-E-AIS (community)
Woods 2012a 192 -2.45 (7.02) 133 -2.52 (7.62) 100.0 % 0.01 [ -0.21, 0.23 ]
Subtotal (95% CI) 192 133 100.0 % 0.01 [ -0.21, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
9 ADAS-Cog (community)
Amieva 2016 172 -40.83 (25.2) 154 -38.25 (24.5) 100.0 % -0.10 [ -0.32, 0.11 ]
Subtotal (95% CI) 172 154 100.0 % -0.10 [ -0.32, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
-1 -0.5 0 0.5 1
Favours no treatment Favours reminiscence
111Reminiscence therapy for dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.21. Comparison 1 Reminiscence therapy versus no treatment, Outcome 21 Cognition (overall)
at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 21 Cognition (overall) at follow-up
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 MMSE (care home)
Lai 2004 36 3.38 (8.63) 30 0.6 (8.95) 6.8 % 0.31 [ -0.17, 0.80 ]
Subtotal (95% CI) 36 30 6.8 % 0.31 [ -0.17, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
2 MMSE (community)
Charlesworth 2016 83 -1.87 (10.03) 36 -3.36 (9.04) 10.6 % 0.15 [ -0.24, 0.54 ]
Sa¨rka¨mo¨ 2013 27 -1.38 (7.47) 20 -3.1 (8.22) 4.8 % 0.22 [ -0.36, 0.80 ]
Tadaka 2007 (AD) 11 -1.1 (5.6) 9 -1 (5.02) 2.1 % -0.02 [ -0.90, 0.86 ]
Tadaka 2007 (VD) 15 2.3 (5.22) 15 -0.4 (5.6) 3.1 % 0.49 [ -0.24, 1.21 ]
Subtotal (95% CI) 136 80 20.6 % 0.20 [ -0.08, 0.48 ]
Heterogeneity: Chi2 = 0.89, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
3 AMI-PSS (care home)
Morgan 2012 8 3.04 (17.81) 9 -5.95 (15.76) 1.7 % 0.51 [ -0.46, 1.48 ]
Subtotal (95% CI) 8 9 1.7 % 0.51 [ -0.46, 1.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
4 AMI-PSS (community)
Melendez 2015 15 3.04 (15.48) 15 -4.94 (12.62) 3.0 % 0.55 [ -0.18, 1.28 ]
Subtotal (95% CI) 15 15 3.0 % 0.55 [ -0.18, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
5 AMI-E-PSS (community)
Woods 2012a 194 -9.91 (16.64) 134 -9.3 (14.64) 33.5 % -0.04 [ -0.26, 0.18 ]
Subtotal (95% CI) 194 134 33.5 % -0.04 [ -0.26, 0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
6 ADAS-Cog (community)
Amieva 2016 172 -40.83 (25.2) 154 -38.25 (24.5) 34.3 % -0.10 [ -0.32, 0.11 ]
-2 -1 0 1 2
Favours no treatment Favours reminiscence
(Continued . . . )
112Reminiscence therapy for dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 172 154 34.3 % -0.10 [ -0.32, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 561 422 100.0 % 0.04 [ -0.09, 0.17 ]
Heterogeneity: Chi2 = 8.25, df = 8 (P = 0.41); I2 =3%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 7.37, df = 5 (P = 0.19), I2 =32%
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Analysis 1.22. Comparison 1 Reminiscence therapy versus no treatment, Outcome 22 Communication and
interaction at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 22 Communication and interaction at follow-up
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Social Engagement Scale (care home)
Azcurra 2012 44 -1.5 (2.05) 44 -0.2 (1.78) 42.4 % -0.67 [ -1.10, -0.24 ]
Lai 2004 36 -0.64 (2.04) 30 -0.21 (2.22) 33.2 % -0.20 [ -0.69, 0.29 ]
Subtotal (95% CI) 80 74 75.7 % -0.46 [ -0.79, -0.14 ]
Heterogeneity: Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 2.83 (P = 0.0047)
2 MOSES withdrawal subscale (community)
Tadaka 2007 (AD) 11 -2.9 (5.32) 9 0.2 (5.92) 9.7 % -0.53 [ -1.43, 0.37 ]
Tadaka 2007 (VD) 15 -4.3 (6.75) 15 -0.1 (7.53) 14.6 % -0.57 [ -1.30, 0.16 ]
Subtotal (95% CI) 26 24 24.3 % -0.56 [ -1.12, 0.01 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
-2 -1 0 1 2
Favours reminiscence Favours no treatment
(Continued . . . )
113Reminiscence therapy for dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for overall effect: Z = 1.92 (P = 0.055)
Total (95% CI) 106 98 100.0 % -0.49 [ -0.77, -0.21 ]
Heterogeneity: Chi2 = 2.11, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00067)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.78), I2 =0.0%
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Analysis 1.23. Comparison 1 Reminiscence therapy versus no treatment, Outcome 23 Quality of caring
relationship at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 23 Quality of caring relationship at follow-up
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 QCPR warmth rated by person with dementia (community)
Charlesworth 2016 83 -1.58 (5.72) 36 -0.37 (4.68) 19.2 % -1.21 [ -3.17, 0.75 ]
Woods 2012a 176 -0.51 (4.09) 120 -1.11 (4.15) 80.8 % 0.60 [ -0.36, 1.56 ]
Subtotal (95% CI) 259 156 100.0 % 0.25 [ -0.61, 1.11 ]
Heterogeneity: Chi2 = 2.64, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.57 (P = 0.57)
2 QCPR conflict rated by person with dementia (community)
Charlesworth 2016 83 0.77 (7.12) 36 -0.26 (7.03) 10.5 % 1.03 [ -1.73, 3.79 ]
Woods 2012a 169 -0.27 (3.77) 121 0.28 (4.24) 89.5 % -0.55 [ -1.50, 0.40 ]
Subtotal (95% CI) 252 157 100.0 % -0.38 [ -1.28, 0.51 ]
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =11%
Test for overall effect: Z = 0.84 (P = 0.40)
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Analysis 1.24. Comparison 1 Reminiscence therapy versus no treatment, Outcome 24 Behaviour
(functional) at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 24 Behaviour (functional) at follow-up
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 MDS-ADL (care home)
Lai 2004 36 -0.6 (10.8) 30 -0.15 (11.11) 16.9 % -0.04 [ -0.53, 0.44 ]
Subtotal (95% CI) 36 30 16.9 % -0.04 [ -0.53, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
2 ADL (care home)
Azcurra 2012 44 -0.41 (0.3) 44 0.53 (0.98) 17.5 % -1.29 [ -1.75, -0.82 ]
Subtotal (95% CI) 44 44 17.5 % -1.29 [ -1.75, -0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.47 (P < 0.00001)
3 ADCS-ADL (community)
Charlesworth 2016 83 -6.42 (25.83) 36 -2.64 (29.24) 19.2 % -0.14 [ -0.53, 0.25 ]
Subtotal (95% CI) 83 36 19.2 % -0.14 [ -0.53, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
4 Bristol Activities of Daily Living Scale (community)
Woods 2012a 200 3.91 (6.59) 142 4.87 (7.52) 23.2 % -0.14 [ -0.35, 0.08 ]
Subtotal (95% CI) 200 142 23.2 % -0.14 [ -0.35, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
5 DAD (community)
Amieva 2016 172 -0.41 (15.42) 154 1.22 (16.03) 23.2 % -0.10 [ -0.32, 0.11 ]
Subtotal (95% CI) 172 154 23.2 % -0.10 [ -0.32, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 535 406 100.0 % -0.31 [ -0.66, 0.03 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 22.89, df = 4 (P = 0.00013); I2 =83%
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Chi2 = 22.89, df = 4 (P = 0.00), I2 =83%
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Analysis 1.25. Comparison 1 Reminiscence therapy versus no treatment, Outcome 25 Behaviour
(agitation/irritability) at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 25 Behaviour (agitation/irritability) at follow-up
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 MOSES Irritability subscale (community)
Tadaka 2007 (AD) 11 -0.6 (4.49) 9 1.6 (4.85) 38.2 % -2.20 [ -6.33, 1.93 ]
Tadaka 2007 (VD) 15 -0.4 (4.44) 15 0.7 (4.63) 61.8 % -1.10 [ -4.35, 2.15 ]
Total (95% CI) 26 24 100.0 % -1.52 [ -4.07, 1.03 ]
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Reminiscence therapy versus no treatment, Outcome 26 Mood-related
outcomes (depression) at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 26 Mood-related outcomes (depression) at follow-up
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Geriatric Depression Scale Short Form (care home)
Morgan 2012 8 -3.25 (2.05) 9 0.45 (2.24) 4.9 % -1.63 [ -2.77, -0.49 ]
Subtotal (95% CI) 8 9 4.9 % -1.63 [ -2.77, -0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
2 CSDD (community)
Woods 2012a 135 0.15 (4.96) 100 0.99 (4.64) 27.4 % -0.17 [ -0.43, 0.09 ]
Subtotal (95% CI) 135 100 27.4 % -0.17 [ -0.43, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
3 MOSES Depression subscale (community)
Tadaka 2007 (AD) 11 0.1 (7.35) 9 0.3 (7.5) 7.5 % -0.03 [ -0.91, 0.86 ]
Tadaka 2007 (VD) 15 -2 (7.65) 15 0.8 (5.12) 10.1 % -0.42 [ -1.14, 0.31 ]
Subtotal (95% CI) 26 24 17.5 % -0.26 [ -0.82, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
4 HADS Depression (community)
Charlesworth 2016 83 -0.11 (5.63) 36 0.39 (5.2) 20.7 % -0.09 [ -0.48, 0.30 ]
Subtotal (95% CI) 83 36 20.7 % -0.09 [ -0.48, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
5 MADRS (community)
Amieva 2016 172 20.34 (17.7) 154 18.51 (17.1) 29.5 % 0.10 [ -0.11, 0.32 ]
Subtotal (95% CI) 172 154 29.5 % 0.10 [ -0.11, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI) 424 323 100.0 % -0.16 [ -0.43, 0.11 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 11.21, df = 5 (P = 0.05); I2 =55%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 10.75, df = 4 (P = 0.03), I2 =63%
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Analysis 1.27. Comparison 1 Reminiscence therapy versus no treatment, Outcome 27 Mood-related
outcomes (anxiety) at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 27 Mood-related outcomes (anxiety) at follow-up
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 RAID (community)
Woods 2012a 154 -0.31 (7.12) 118 -0.27 (5.79) 72.7 % -0.01 [ -0.25, 0.23 ]
Subtotal (95% CI) 154 118 72.7 % -0.01 [ -0.25, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 HADS Anxiety (community)
Charlesworth 2016 83 -0.31 (4.8) 36 -0.54 (4.4) 27.3 % 0.05 [ -0.34, 0.44 ]
Subtotal (95% CI) 83 36 27.3 % 0.05 [ -0.34, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 237 154 100.0 % 0.01 [ -0.20, 0.21 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.81), I2 =0.0%
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Analysis 1.28. Comparison 1 Reminiscence therapy versus no treatment, Outcome 28 Carer outcomes
(stress related to caring) at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 28 Carer outcomes (stress related to caring) at follow-up
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Zarit Burden Interview Short Form (care home)
Azcurra 2012 44 -2.9 (4.81) 44 5 (9.21) 18.5 % -1.07 [ -1.51, -0.62 ]
Subtotal (95% CI) 44 44 18.5 % -1.07 [ -1.51, -0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.66 (P < 0.00001)
2 Zarit Burden Interview Short Form (community)
Sa¨rka¨mo¨ 2013 17 1.1 (10.99) 18 2.03 (12.41) 13.6 % -0.08 [ -0.74, 0.59 ]
Subtotal (95% CI) 17 18 13.6 % -0.08 [ -0.74, 0.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
3 Relatives Stress Scale (community)
Woods 2012a 192 1.43 (8.28) 135 1.97 (8.53) 24.0 % -0.06 [ -0.28, 0.16 ]
Subtotal (95% CI) 192 135 24.0 % -0.06 [ -0.28, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
4 NPI (community)
Charlesworth 2016 83 4.24 (32.29) 36 2.4 (27.35) 19.9 % 0.06 [ -0.33, 0.45 ]
Subtotal (95% CI) 83 36 19.9 % 0.06 [ -0.33, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
5 Zarit Burden Interview (community)
Amieva 2016 172 21.33 (32.96) 154 17.95 (32.34) 24.0 % 0.10 [ -0.11, 0.32 ]
Subtotal (95% CI) 172 154 24.0 % 0.10 [ -0.11, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 508 387 100.0 % -0.19 [ -0.54, 0.16 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 21.84, df = 4 (P = 0.00022); I2 =82%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 21.84, df = 4 (P = 0.00), I2 =82%
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Analysis 1.29. Comparison 1 Reminiscence therapy versus no treatment, Outcome 29 Carer outcomes
(depression) at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 29 Carer outcomes (depression) at follow-up
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HADS Depression (community)
Charlesworth 2016 83 0.58 (6.75) 36 -0.09 (6.02) 7.2 % 0.67 [ -1.77, 3.11 ]
Woods 2012a 201 0.77 (3.13) 144 0.88 (3.21) 92.8 % -0.11 [ -0.79, 0.57 ]
Total (95% CI) 284 180 100.0 % -0.05 [ -0.71, 0.60 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 1.30. Comparison 1 Reminiscence therapy versus no treatment, Outcome 30 Carer outcomes
(anxiety) at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 30 Carer outcomes (anxiety) at follow-up
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 HADS Anxiety (community)
Charlesworth 2016 83 1.39 (6.48) 36 -0.07 (6.83) 7.7 % 1.46 [ -1.17, 4.09 ]
Woods 2012a 201 0.67 (3.63) 144 0.18 (3.5) 92.3 % 0.49 [ -0.27, 1.25 ]
Total (95% CI) 284 180 100.0 % 0.56 [ -0.17, 1.30 ]
Heterogeneity: Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.31. Comparison 1 Reminiscence therapy versus no treatment, Outcome 31 Carer outcomes
(quality of life) at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 31 Carer outcomes (quality of life) at follow-up
Study or subgroup Reminiscence therapy No treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 GHQ-12 (community)
Sa¨rka¨mo¨ 2013 17 1 (7.36) 18 1.87 (7.83) 7.9 % -0.11 [ -0.78, 0.55 ]
Subtotal (95% CI) 17 18 7.9 % -0.11 [ -0.78, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
2 GHQ-28 (community)
Woods 2012a 177 1.69 (11.23) 136 0.91 (11.13) 69.5 % 0.07 [ -0.15, 0.29 ]
Subtotal (95% CI) 177 136 69.5 % 0.07 [ -0.15, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 SF Mental (community)
Charlesworth 2016 83 0.92 (11.05) 36 2.53 (9.82) 22.6 % -0.15 [ -0.54, 0.24 ]
Subtotal (95% CI) 83 36 22.6 % -0.15 [ -0.54, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 277 190 100.0 % 0.01 [ -0.18, 0.19 ]
Heterogeneity: Chi2 = 1.04, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 1.04, df = 2 (P = 0.60), I2 =0.0%
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Analysis 1.32. Comparison 1 Reminiscence therapy versus no treatment, Outcome 32 Carer outcomes
(quality of caring relationship) at follow-up.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 32 Carer outcomes (quality of caring relationship) at follow-up
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 QCPR Conflict (community)
Charlesworth 2016 83 0.29 (6.92) 83 0.83 (6.92) 16.9 % -0.54 [ -2.65, 1.57 ]
Woods 2012a 191 0.04 (4.32) 138 0.37 (4.35) 83.1 % -0.33 [ -1.28, 0.62 ]
Subtotal (95% CI) 274 221 100.0 % -0.37 [ -1.23, 0.50 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
2 QCPR Warmth (community)
Charlesworth 2016 83 0.28 (7.82) 36 1.13 (8.01) 9.0 % -0.85 [ -3.96, 2.26 ]
Woods 2012a 198 0.84 (4.92) 139 1.48 (4.2) 91.0 % -0.64 [ -1.62, 0.34 ]
Subtotal (95% CI) 281 175 100.0 % -0.66 [ -1.59, 0.27 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
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Analysis 1.33. Comparison 1 Reminiscence therapy versus no treatment, Outcome 33 Mood-related
outcomes (apathy) post-treatment.
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 33 Mood-related outcomes (apathy) post-treatment
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Apathy Index (carer rated) (community)
Amieva 2016 172 11.8 (13.1) 154 10.4 (11.8) 100.0 % 1.40 [ -1.30, 4.10 ]
Total (95% CI) 172 154 100.0 % 1.40 [ -1.30, 4.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 1.34. Comparison 1 Reminiscence therapy versus no treatment, Outcome 34 Mood-related
outcomes (apathy) at follow-up (community).
Review: Reminiscence therapy for dementia
Comparison: 1 Reminiscence therapy versus no treatment
Outcome: 34 Mood-related outcomes (apathy) at follow-up (community)
Study or subgroup Reminiscence therapy No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Apathy Index (carer rated) (community)
Amieva 2016 172 19.69 (14.5) 154 18.44 (14.4) 100.0 % 1.25 [ -1.89, 4.39 ]
Total (95% CI) 172 154 100.0 % 1.25 [ -1.89, 4.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Update searches: July 2011, October 2014, April 2015, April 2016, April 2017
Source (searched 31 July
2011, 2 October 2014, and
then 29 April 2015, 5 April
2016, 6 April 2017)
Search strategy Hits retrieved
1. ALOIS (www.medicine.ox.
ac.uk/alois)
[Date of most recent search: 6
April 2017]
Keyword search: reminiscence OR RT July 2011: 40
Oct 2014:
April 2015: 3
April 2016: 2
April 2017: 0
2. MEDLINE In-process and
other non-indexed citations
and MEDLINE 1946-present
(OvidSP)
[Date of most recent search: 6
April 2017]
1. reminisc*.ti,ab.
2. RT.mp. and (dement* or alzheimer* or lewy or VCI)
.ti,ab. [mp=protocol supplementary concept, rare disease
supplementary concept, title, original title, abstract, name
of substance word, subject heading word, unique identi-
fier]
3. 1 or 2
4. randomized controlled trial.pt.
5. controlled clinical trial.pt.
6. randomized.ab.
7. placebo.ab.
8. randomly.ab.
9. trial.ab.
10. groups.ab.
11. or/4-10
12. 3 and 11
13. (animals not (humans and animals)).sh.
14. 12 not 13
July 2011: 234
Oct 2014: 228
April 2015: 73
April 2016: 64
April 2017: 75
3. Embase 1980- 5 April 2017
(OvidSP)
[Date of most recent search: 6
April 2017]
1. reminisc*.ti,ab.
2. (RT and (dement* or alzheimer* or lewy or VCI or
“cognit* impair*”)).ti,ab
3. or/1-2
4. randomly.ab.
5. trial.ti,ab.
6. RCT.ti,ab.
July 2011: 221
Oct 2014: 354
April 2015: 158
April 2016: 115
April 2017: 98
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7. (“single-blind*” or “double-blind*”).ti,ab.
8. clinical trial/
9. groups.ab.
10. or/4-9
11. 3 and 10
12. limit 11 to human
4. PsycINFO 1806-April 2017
(OvidSP)
[Date of most recent search: 6
April 2017]
1. reminisc*.ti,ab.
2. (RT and (dement* or alzheimer* or lewy or VCI or
“cognit* impair*”)).ti,ab
3. or/1-2
4. randomly.ab.
5. groups.ab.
6. trial.ti,ab.
7. (“double-blind*” or “single-blind*”).ti,ab.
8. Clinical Trials/
9. RCT.ti,ab.
10. placebo.ab.
11. (randomised or randomized).ti,ab.
12. or/4-11
13. 3 and 12
July 2011: 183
Oct 2014: 123
April 2015: 43
April 2016: 41
April 2017: 39
5. CINAHL (EBSCOhost)
[Date of most recent search: 6
April 2017]
S1 (MH “Reminiscence Therapy”)
S2 TX reminisc*
S3 TX RT AND dement*
S4 TX RT AND alzheimer*
S5 TX RT AND lewy
S6 TX RT AND “cognit* impair*”
S7 S1 or S2 or S3 or S4 or S5 or S6
S8 TX random*
S9 TX RCT OR CCT
S10 (MH “Clinical Trials”)
S11 AB groups
S12 TX “double-blind*” OR “single-blind*”
S13 AB placebo*
S14 S8 or S9 or S10 or S11 or S12 or S13
S15 S7 and S14
S16 EM 2004
S17 EM 2005
S18 EM 2006
S19 EM 2007
S20 EM 2008
S21 EM 2009
S22 EM 2010
S23 EM 2011
S24 S16 or S17 or S18 or S19 or S20 or S21 or S22 or
S23
July 2011: 201
Oct 2014: 102
April 2015: 32
April 2016: 34
April 2017: 46
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S25 S15 and S24
6. ISI Web of Science - all
databases [includes: Web of
Science (1945-present); BIO-
SIS Previews (1926-present)
; MEDLINE (1950-present);
Journal Citation Reports]
[Date of most recent search: 6
April 2017]
Topic=(reminiscence therapy) AND Topic=(dementia*
OR alzheimer*) AND Year Published=(2004-2011) AND
Topic=(random* OR trial OR RCTOR groups OR “dou-
ble-blind*” OR “single-blind*”)
July 2011: 50
Oct 2014: 40
April 2015: 42
April 2016: 22
April 2017: 38
7. LILACS (BIREME)
[Date of most recent search: 6
April 2017]
Free form: reminiscence July 2011: 7
Oct 2014: 12
April 2015: 0
April 2016: 0
April 2017: 13
8. CENTRAL (The Cochrane
Library) (Issue 4 of 12, 2017)
[Date of most recent search: 6
April 2017]
#1 reminisc*
#2 RT AND (dement* OR AD OR alzheimer* OR lewy
OR “cognit* impair*”)
#3 (#1 OR #2), from 2004 to 2017
July 2011: 128
Oct 2014: 118
April 2015: 40
April 2016: 0
April 2017: 48
9. ClinicalTrials.gov (
www.clinicaltrials.gov)
[Date of most recent search: 6
April 2017]
Interventional Studies | reminiscence July 2011: 7
Oct 2014: 8
April 2015: 2
April 2016:
April 2017: 6
10. ICTRP Search Portal
(apps.who.int/trialsearch) [in-
cludes: AustralianNewZealand
Clinical Trials Registry; Clin-
icalTrilas.gov; ISRCTN; Chi-
nese Clinical Trial Registry;
Clinical Trials Registry - India;
Clinical Research Information
Service - Republic of Korea;
German Clinical Trials Regis-
ter; Iranian Registry of Clinical
Trials; Japan Primary Registries
Network; Pan African Clinical
Trial Registry; Sri Lanka Clini-
cal Trials Registry; The Nether-
lands National Trial Register]
[Date of most recent search: 6
April 2017]
Keyword search: reminiscence July 2011: 19
Oct 2014: 20
April 2015: 3
April 2016:
April 2017: 7
127Reminiscence therapy for dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
PsycBITE
[Date of most recent search: 6 April 2015]
Keyword: Reminiscence AND
Method: RCT
July 2011: 11
April 2015: 0
TOTAL before deduplication July 2011: 1101
Oct 2014: 1015
April 2015: 396
April 2016:
April 2017: 370
TOTAL after deduplication and first assessment by CDCIG information specialists July 2011:
Oct 2014: 102
April 2015: 21
April 2016: 279
April 2017: 37
WH A T ’ S N E W
Last assessed as up-to-date: 6 April 2017.
Date Event Description
6 April 2017 New search has been performed Top-up searches were performed for this review in July 2011,
October 2014, July 2015, April 2016 and April 2017. New
studies were identified for inclusion within the review
6 April 2017 New citation required and conclusions have changed New studies added and content extensively revised. Conclu-
sions changed. Additional authors brought in
H I S T O R Y
Protocol first published: Issue 2, 1998
Review first published: Issue 3, 1998
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Date Event Description
31 July 2011 New search has been performed An update search was performed for this review on 31
July 2011. New studies were identified for both inclu-
sion and exclusion within the review
6 November 2008 Amended Converted to new review format.
6 February 2005 New citation required and conclusions have changed The reviewhas been substantially updated and rewritten
following the publication of three new trials
C O N T R I B U T I O N S O F A U T H O R S
Original version and first update:
• AS: all correspondence; drafting of review versions; updating of review; selection of trials; extraction of data; interpretation of
data analyses.
• BW: drafting of review versions.
Update 2005:
• BW: all correspondence; drafting of review versions; updating of review; selection of trials; extraction of data; interpretation of
data analyses.
Update 2017:
• LOP and EF: all correspondence; drafting of review sections; selection of trials; extraction of data; preparation of tables and
figures.
• BW: data analyses and interpretation; drafting of review background, results and discussion.
• AS: comments on draft review.
D E C L A R A T I O N S O F I N T E R E S T
BW: None known
LOP: None known
EMF: None known
AES: None known
MO: None known
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S O U R C E S O F S U P P O R T
Internal sources
• Bangor University, Wales, UK.
External sources
• Centre for Ageing & Dementia Research, Health & Care Research Wales, UK.
• KESS 2 (European Social Fund), UK.
• NIHR, UK.
This update was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the
Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed herein are those of the authors and do not
necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Current review includes updated use of ’Risk of bias’ tool, use of GRADE approach, inclusion of ’Summary of findings’ tables, methods
to deal with data from cluster randomised controlled trials and subgroup analyses. In this review, unlike the previous versions, we were
able to exclude studies from meta-analyses on the grounds of quality.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Mental Recall; Dementia [∗therapy]; Orientation; Psychotherapy, Group [∗methods]; Randomized Controlled Trials as Topic; Reality
Therapy
MeSH check words
Aged; Humans; Middle Aged
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